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Abstract 
 
Hepatitis C virus (HCV) is the causative agent of hepatitis C, this virus infects 
approximately 170 million people worldwide, equivalent to more than half of 
the population of the USA, and approximately 600,000 deaths per year due to 
liver failure and hepatocellular carcinoma can be attributed to HCV. Directly 
acting antivirals, first introduced in 2011, have revolutionised treatment of the 
disease, the most contemporary multi-drug combination therapies are curative 
in >90% of treatment naïve patients in real-world scenarios. However, patient 
cohorts such as difficult to treat genotypes of HCV in combination with 
advanced liver cirrhosis and previous treatment failures, as well as HIV/HCV 
co-infected patients, respond relatively poorly. 
 
To address the therapeutic need of these niche patient cohorts, candidates that 
target the entry and assembly stages, and host factors of the HCV life cycle 
were chosen specifically to develop, as combination of these therapeutics with 
the current replication stage inhibitors will reduce the probability of viral 
resistant mutations as an intrinsic pharmacodynamic property of the therapies, 
as well as reducing treatment duration, and importantly treatment cost. 
 
To this end, three separate arms of research have been undertaken. 
Mechanistic parameters of asymmetric transfer hydrogenation of ketones were 
developed, allowing a short, modular and enantioselective synthesis of 
MeBmt, a component of the host-targeting HCV agent cyclosporin A, by 
dynamic kinetic resolution. 
 
A novel assembly inhibitor of HCV, CT3, was optimised resulting in a lead 
compound 372 which boasts approximately fifteen fold increase in efficacy 
against HCV, more than ten fold increase in metabolic half life and an 
increase in other molecular efficiency metrics as compared to the original hit, 
which culminated in an in-vivo PK study in mice. 
 
Lastly, a synthesis of a potent photoaffinity probe was designed and 
successfully implemented, designed around the framework of a novel inhibitor 
of HCV entry – chlorcyclizine. The probe is being utilized in biological 
experiments to understand molecular mechanism of action of chlorcyclizine 
against HCV, which may, perhaps, uncover biological mechanisms related to 
HCV entry. 
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Introduction to Hepatitis C 
 
1.1 Hepatitis C  
Hepatitis C virus (HCV) is the causative agent of hepatitis C. HCV is a small, 
single stranded, positive sense RNA virus that is transmitted by direct blood-
to-blood or other percutaneous contact, with a significant proportion of the 
infected population unaware of their infection status due to the often 
asymptomatic onset. Persistent infection of HCV results in chronic hepatitis 
and liver disease, which may progress to a cirrhotic state, causally increasing 
the incidence of hepatocellular carcinoma and liver failure. Late stage 
progression of hepatitis ultimately may call for a liver transplant with 
universal graft re-infection. HCV infects approximately 170 million people 
worldwide and approximately 600,000 deaths per year due to liver failure and 
hepatocellular carcinoma can be attributed to HCV. Directly acting anti-virals 
have greatly improved the prognosis with the current state of the art delivering 
>90% sustained virologic response (SVR) across all genotypes in treatment 
naïve patients, however the global disease burden is not expected to peak until 
2020.  
 
1.2 Taxonomy, origin and epidemiological development of HCV 
Hepatitis C virus (HCV) is the type species of the genus Hepacivirus other 
members include canine hepacivirus (CHV) and non-primate hepacivirus 
(NPHV), in turn classified as a part of the Flaviviridae family. Other members 
of this family include Zika virus, West Nile virus and Dengue virus.10 HCV 
comprises a diverse set of virus subtypes, which can be categorized into seven 
1 
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phylogenetic clades based on geographical location or origin. Of these 
subtypes, the most commonly encountered subtypes in western countries are 
1a, 1b, 2a, 2b, 3a, 4a and 6a, of which 1a and 1b comprise 60% of all 
infections11. These HCV subtypes are genotypically and phenotypically 
distinct viruses and pertain to different and discrete subsets of the infected 
population epidemiologically10.  
The true origins of HCV in terms of virus evolution still remain 
unclear, leading hypotheses include a model of a non-human primate original 
host for HCV, with humans acquiring a stable infection variant zoonotically12 
in close analogy with Simian Immunodeficiency Virus (SIV) to Human 
Immunodeficiency Virus (HIV) 13. This scenario is supported more in terms of 
epidemiology than by some genotypic classification – common and diverse 
HCV infections can be seen in areas of the world where human, ape and other 
monkey populations overlap, before the development of the ability of long 
range travels in these human populations, continued transmission and 
replication of HCV in geographically distinct locations accounts for the 
phylogenetic clade distribution of the HCV genotypes and subtypes. 
 Despite this, to date HCV or homologues have not been observed in 
any ape or monkey species other than humans. Recently however, an RNA 
virus (termed Canine Hepacivirus, CHV) was discovered in dogs that 
possesses similar sequence homology to HCV14, though in this case the virus 
is largely localized in respiratory samples, with a presumed respiratory route 
of transmission, which has not been observed for HCV. Similarly, Non-
Primate Hepacivirus (NPHV) has been observed in horses. Each of these 
hepaciviruses may be adapted completely to one particular species, with subtle 
species-dependent factors in replication being responsible for the lack of 
propensity for zoonotic transfer. It has been postulated therefore, in opposition 
to relatively recent virus transfer originating from another mammal, that HCV 
has simply always infected humans and their evolutionary ancestors, and that 
the virus has evolved to maintain infection along with us. It is possible the 
medical advances of the modern era - pushing the boundaries of the human 
lifespan, combined with systematic advances in understanding of the human 
body and an increase in opportunity for transmission have shone the light on 
this virus in terms of allowing the pathogenicity of HCV to reveal itself 
clinically, modern methods of detection notwithstanding.12 
 Recent phylogeographic analysis has shown that the current epidemic 
of HCV subtypes 1a and 1b in the developed world began as recently as 1940 
as opposed to a more gradual increase across the 20th century as has been 
previously suggested11. The specificities of the time frames uncovered by this 
study suggest that the current HCV pandemic has causal roots in an increased 
number of parenteral iatrogenic procedures during and after World War II 
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(1939-1945) using contaminated blood for transfusions, the incorporation of 
plasma pooling and contamination during non-sterile procedures. Lyophilized, 
pooled plasma remains infectious for long periods of time. The increase in 
number of HCV genotype 1a infections also specifically coincides with peak 
intravenous drug use (late 1960’s) before the public became aware of the 
dangers associated with non-A non-B hepatitis which would eventually come 
to be designated as hepatitis C.11 In spite of this, intravenous drug use 
continues to be one of the highest risk factors for acquiring HCV, being 
responsible for approximately 90% of new cases worldwide15.  
 Finally, HCV was officially discovered and classified in 198916  as a 
result of ongoing investigations into the causes of the aforementioned non-A, 
non-B hepatitis that had become associated with blood transfusions and 
intravenous drug use. Further development of diagnostic tests revealed the true 
extent of HCV pandemic, it is currently estimated that 170-20017 million 
people are infected with HCV, approximately 2.7-3% of the worlds 
population.  
 
 
1.3 Hepatitis C Virus life cycle, protein structure and function 
HCV particles primarily infect and replicate in hepatocytes, but they may also 
infect peripheral blood mononuclear cells such as erythrocytes and monocytes, 
although they do not replicate in these cells. Evidenced by the low buoyant 
density of HCV compared to other viruses, it is proposed that circulating HCV 
is associated with human serum lipoviral particles (LVP), with HCV and the 
LVP sharing an external plasma membrane.18 
 
Virions come into contact with hepatocytes in the space of Disse following 
diffusion across the fenestrated endothelium of the liver sinusoids, wherein 
they may bind with low affinity (initially) to cell surface receptors on 
hepatocytes19. In the liver biopsy samples of patients however, infected cells 
occur in clusters, pointing to a cell-to-cell spread as the predominant mode of 
HCV transmission20,21 
These initial binding events with low-density lipoprotein receptor (LDLR), 
glycosaminoglycans (GAGs) facilitate stronger post binding interactions with 
HCV associated entry factors that trigger cellular entry, such as CD81, SRB1, 
claudin 1 (CLDN1) occludin (OCLN) and Niemann-Pick C1-like 1 receptor 
(NPC1L1). These factors interact with the HCV membrane and associated 
lipoproteins and facilitate migration to tight junctions ultimately resulting in 
clathrin-mediated vesiculation and endocytosis of the entire viral particle22, as 
opposed to fusion with the cell membrane and injection of the viral machinery 
into the cytosol. The HCV particle enclosed in the endosomal vesicle matures 
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to an early endosome as part of the internalization process.23 HCV evades 
lysosomal degradation and the viral genetic material is delivered to their 
cytoplasmic site of replication on the ER following HCV-endosomal fusion 
triggered by endosomal acidification (~pH5) - this consequently renders the 
HCV infection susceptible to lysosomotropic reagents such as bafliomycin and 
chloroquine that effect atypical pH changes in lysosomes24.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1: Representation of the coding region of the HCV genome partitioned to display 
polyprotein cleavage products. 
 
The HCV Core protein forms the viral nucleocapsid and is involved in the localization of 
the HCV replication complex on the ER.1 Multifunctional envelope glycoproteins E1 and E2 
are essential for assembly and infectivity of the HC virion, E1 and E2 form heterodimers 
that are presented on the virus surface and interact with HSPG on the surface of hepatocytes.  
The p7 viroporin self-assembles into hexamers that may insert themselves into membranes 
and function as ion channels, it is observed to facilitate virus production and is found to be 
vital for infectivity in vivo3 however the precise mechanisms remain unclear. p7 has been 
proposed to act as a low pH activated ion channel equilibrating pH of acidic compartments 
which is necessary in the later stages of HCV virion assembly4, this function has been 
investigated by mutagenesis studies5. NS2, a cysteine protease liberates fully functional 
NS3/4A from the polyprotein promoting replication. The multifunctional serine 
protease/RNA helicase NS3/4A cleaves the HCV polyprotein at the NS3/4A, NS4A/4B, 
NS4B/ 5A, and NS5A/5B junctions once it has liberated itself from NS2,6 it is also involved 
in evading the host innate immune response7 The active site of NS3 is largely flat, with 
substrate recognition really being a result of molecular interactions over a large area of the 
protease more akin to protein-protein interactions, giving rise to high specificity3. NS4B 
lacks a discrete singular enzymatic function compared to, for example, a protease or an RNA 
polymerase and as such the structure and function of NS4B was relatively poorly 
characterized, however developing knowledge regarding interaction between the HCV 
proteins reveals that NS4B has been implicated in the modulation of the RNA-dependent 
RNA polymerase (RdRp) NS5B8, and also as playing a crucial role in the induction and 
development of the membranous web that serves as a scaffold for the HCV replication 
compex.3 The phosphoprotein NS5A is another multi-functional peptide that is involved in 
several different undertakings in proliferating HCV by its interaction with other proteins. 
NS5A is implicated in the modulation of the RdRp NS5B as well as alterations to the 
cellular environment increasing amenability for HCV replication9 3. Finally, NS5B, the RNA 
dependent RNA polymerase (RdRp) conducts the replication of HCV RNA via the synthesis 
of a complimentary negative strand of RNA and the subsequent synthesis of excess amounts 
of the positive stranded RNA from this template.3  
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The cellular machinery of the hepatocyte is directly recruited to begin 
initial translation of the HCV genome from the positive stranded RNA directly 
to the unprocessed polypeptide25 (in analogy to mRNA). The HCV is 
constructed of one open reading frame of ~9600 nucleotides flanked on the 3’ 
end by an untranslated region (UTR) and on the 5’ end by an internal 
ribosomal entry site (IRES) responsible for the initiation of translation.  
The polypeptide is cleaved into 10 functional proteins by the cellular 
peptidases and viral proteases: structural proteins Core, E1, E2, p7 and non-
structural proteins, NS2, NS3, NS4A, NS5A and NS5B (fig 1.1) and the 
proteins are localized on endoplasmic reticulum (ER) derived membranes. In 
terms of functionality, the genome can be divided into an assembly module – 
C, E1, E2, p7 and NS2; and a replication module NS3-NS5B however many 
of the proteins have multiple functions facilitating both viral replication and 
assembly.3 Membrane alterations in the ER of the hepatocyte driven by NS4B 
and others result in the formation of a “membranous web” as a site for 
continued replication. The membranous web and other ER substructures such 
as double or multi-membrane vesicles (DMV, MMV) serves to protect the 
viral RNA from potential host defences, as well as to compartmentalize and 
increase local concentrations of specific viral products, while providing 
physical support for the viral replication complex.26 Viral replication 
continues with assistance from various host factors.  
Assembly of the HCV virion is a complex effort involving the cellular 
localization of the HCV structural proteins in different compartments in the 
cell. The HCV core proteins form dimers and polymers that undergo 
trafficking to the surface of cytosolic lipid droplets. The Core proteins are then 
recruited along with E1 and E2 dimers to package HCV RNA, which 
undergoes budding into the ER, all in a concerted process. 27,28 During 
secretion and trafficking through the Golgi, the E1 and E2 are post-
translationally modified, the virions interact with apoE-containing VLDL and 
HDL particles, acquiring their characteristic low buoyant density and the 
virions are released from the cells via a secretory pathway.18 
Despite the intricate and extremely complicated nature of this process, 
an established HCV infection will result in the production of some 1012 virions 
per day in an infected individual.29 
 
 
1.4 Treatment of Hepatitis C Virus 
Great progress in terms of understanding HCV has been made since the 
discovery of the virus in 198916 - elucidation of the viral lifecycle and viral 
genome, with protein structure and function along with cell culture systems 
and animal models. Improved understanding of the virus inevitably translates 
 
 
 
 
 
 
7 
into improved therapeutic strategies as is evidenced by the classes of drugs 
that have been historically used to treat HCV, moving from broad spectrum 
anti-virals such as interferon and ribavirin where our knowledge and 
comprehension of HCV was minimal, to directly-acting and host-acting anti-
virals, to target specific singular viral and host proteins, with distinct clinical 
end-points, as knowledge of HCV increases.  
 
1.4.1 Interferon and Ribavirin  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interferons (IFN) (fig. 1.2A) are cytokines that are critical mediators in the 
mounting of an immune response against viruses and are also the first class of 
therapeutic interventions that were used against HCV, along with the broad-
spectrum anti-viral ribavirin, a ribonucleoside analogue30-32. IFN-α of the class 
IFN-type 1, suppresses HCV replication by the induction of eponymous IFN-
stimulated genes (ISG’s) through phosphorylation of the STAT1/2 complex 
mediated Jak1 and Tyk2 kinases. ISG expression acts to establish an anti-viral 
state within the cell, hundreds of genes are induced33 which precipitates in 
changes to protein expression immune modulation and lipid metabolism in the 
cell population to name a few, that act to resist the proliferation of HCV.  
Ribavirin (fig. 1.2B, 101) is a broad spectrum anti-viral drug, that, 
when given in mono-therapy is not effective against HCV, but in combination 
therapy with IFN and other therapies, has been demonstrated to yield 
improvements in sustained virologic response (SVR48 IFN-16%, SVR48 
IFN+ribavirin – 40%34). It is tempting to assume that ribavirin acts via chain 
termination of viral RNA replication via incorporation into viral RNA, 
analogous to other ribonucleoside analogues, however at clinically suitable 
concentrations, incorporation into RNA is too low.35  
Figure 1.2 Graphical render of interferon-α and structure of Ribavirin 
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It is possible that incorporation into HCV RNA increases the error rate in 
HCV replication just enough to render the virus particle non-viable as an 
infectious agent. Only a very modest increase is required for this “error 
catastrophe” as HCV, akin to other RNA viruses, has no proofreading/error 
checking capabilities of it’s own replication and as a result is very error prone 
regardless.36 Ribavirin has also been observed to up-regulate specific IFN 
stimulated genes (ISG’s), and when used in conjunction with IFN-α the effect 
was synergistic when compared with either drug applied separately due to the 
use of separate pathways to achieve these means.37 Considering ribavirin 
given in monotherapy does not display any anti-HCV effect, it is likely that 
the IFN potentiating effect of ribavirin is the principal mechanism of action. 
Pegylated IFN-α in combination with ribavirin is generally poorly 
tolerated with regards to numerous side effects, hence it is contraindicated for 
a large cohort of patients, and response rates to the treatment, at best, are 54-
56% SVR31. Nonetheless without suitable alternatives, IFN/ribavirin remained 
the mainstay for HCV treatment until 2011.  
  
 
1.4.2 Directly acting anti-virals (DAA)  
To address this therapeutic need, a worldwide effort on behalf of academic 
institutions and pharmaceutical companies is currently underway to produce 
drugs that act directly on HCV proteins. Direct acting anti-virals (DAA’s) 
have the potential to be efficacious while avoiding the side effects and other 
limitations that are associated with IFN-α and ribavirin through leveraging 
specificity. 
Boceprevir and Telaprevir (fig. 1.3. 102, 103 respectively) were the 
first of the new cohort of DAA’s to gain approval in mid-2011 on the back of 
successful phase 3 clinical trials (Boceprevir38,39, Telaprevir40,41). They are 
first generation reversible covalent inhibitors of the HCV NS3/4A protease, 
possessing an α-keto amide functional group that allows reversible formation 
of a hemiacetal moiety, preventing dissociation (koff) from the binding pocket. 
Boceprevir and Telaprevir bind to the active site of the protease, interrupting 
HCV polypeptide processing in a competitive manner (fig. 1.3.)42 
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Second-generation NS3/4A inhibitors such as Grazoprevir (fig 1.3, 104) a 
component of a contemporary two-drug combination Zepatier, are non-
covalent inhibitors, possess pan-genotypic activity and improved resistance 
profiles.43  
Following the successful introduction of Boceprevir and Telaprevir, 
Sofosbuvir (fig 1.3A, 105) was the first NS5B inhibitor to be approved for use 
alone or in combination with other anti-HCV treatments in multi-drug 
regimens. Sofosbuvir is a nucleoside analogue whose incorporation into viral 
RNA by NS5B causes chain termination of RNA synthesis with a low 
nanomolar EC50 and pan-genotypic activity. Sofosbuvir in combination with 
Ribavirin in a 12 week treatment course resulted in sustained virologic 
response after 12 weeks (SVR12) in >90% of patients.44 Sofosbuvir as a 
component triple therapy (SOF/RBV/IFN) affords excellent SVR rates in null-
responders who are traditionally resistant to other forms of DAA triple 
therapy.45  
The most recent class of DAA’s to gain FDA approval, the NS5A 
inhibitors, also have found successful use in combination therapies. NS5A 
inhibitor Daclatasvir 100, is a palindromic inhibitor of NS5A with a low 
picomolar EC50 Ledipasvir 107 is a component of the infamously expensive 
but efficacious Harvoni46, a dual combination of Sofosbuvir and Ledipasvir47 
($94,000/12 week course).  
 
 
 
Figure 1.3 Structures of Boceprevir 102, Telaprevir, 103 and Grazoprevir, 104. Binding of 
Boceprevir to the NS3 active site – reversible covalent inhibition. 
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Modern treatment regimens such as Harvoni, VIEKRA PAK, Technivie and 
Zepatier consist of all oral combinations, either double or triple therapy of 
NS3/4A, NS5A and NS5B inhibitors without ribavirin and interferon48.  
 
 
1.4.3 Host-targeting anti-virals 
 
Host targeting anti-virals (HTA’s), as opposed to targeting viral proteins 
directly, target host proteins that are implicated in the life cycle of HCV. The 
categorization of the drugs by target is appropriate as a result of the divergent 
pharmacodynamic implications of the drug class as a whole. The main 
advantages of using HTA’s is that, in targeting a host factor in replication, the 
drugs are often intrinsically pan-genotypic. Furthermore, the virus cannot 
simply acquire resistance through a point mutation to prevent a ligand binding 
and often multiple changes are required to reduce or circumvent the 
dependence of the virus on the host factor in question. These changes often 
result in a loss of replicative fitness for the virus and present a high barrier for 
resistance. The immediate disadvantage of this therapeutic class is that in 
specifically targeting a host factor, consideration must be taken to avoid 
possible toxicity from compromising the endogenous role of the target.49  
 
1.4.3.1 Entry inhibitors 
There are several possible host-derived targets to block entry of HCV into the 
hepatocytes, with some potential treatments in the early stages of 
development. Discussion here is limited to treatments that have progressed 
into and beyond proof-of-principle experiments in mice.50 Small molecule and 
antibody inhibitors of entry factors on the cell surface membranes have been 
shown to significantly reduce the kinetics of HCV infection in the uPA-SCID 
mouse model such as NPC1L1 small molecule inhibitor ezetimibe and EGFR 
inhibitor erlotinib49 – these compounds act by preventing HCV association 
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Figure 1.4 Structures of HCV inhibitors Sofosbuvir 105, Daclatasvir 106 and Ledipasvir 
107. 
 
 
 
 
 
 
11 
with its entry factors. Monoclonal antibody inhibitors of CD81 and SRBI were 
found to completely protect mice from establishing HCV infection in a 
prophylactic manner. Several of the targets implicated in HCV entry also play 
a role in transmission from cell to cell.  
 
1.4.3.2 Cyclophilin inhibitors 
Cyclophilin A (CyPA) is an endogenous proline cis-trans isomerase that has 
been shown to be a critical component to HCV replication. Cyclophilin 
antagonists are potent inhibitors of HCV replication and are discussed at 
length in Chapter 2. 
 
1.4.3.3 miR-122 antagonists 
MicroRNA-122 (miR-122) is an endogenous microRNA found most 
frequently in the liver and is involved in regulation of liver metabolic 
processes; miR-122 is also implicated in HCV pathogenesis. MiR-122 binds to 
HCV in the 5’UTR region and has a positive effect on virus translation, 
replication, and the production of infectious virions.51 Miravirsen is a single 
stranded RNA (15 nucleotides, MW 4897Da) that is the complimentary 
antisense sequence to miR-122, Miravirsen and binds miR-122 in a 
heteroduplex conformation, arresting HCV replication.52 In a phase 2a clinical 
trial, Miravirsen dosed at up to 7mg/kg of bodyweight, with weekly injections 
for five weeks, resulted in a 3-log-drop in HCV viral load: the HCV viral load 
in four out of nine patients dosed at 7mg/kg became undetectable.   
MiR-122 knockout mice have been shown to rapidly develop 
hepatocellular carcinoma and the sequestration of significant amounts of miR-
122 by HCV is thought to contribute to this. 53 However sequestration in the 
short term using a therapeutic “miR-122 sponge” such as Miravirsen does not 
appear to contribute to this effect.54 
 
1.5 Phase 4 analyses of DAAs 
Post market surveillance, so called Phase 4 analysis, of modern anti-HCV 
treatments has shown that, in general, real-world scenarios of all-oral 
combination DAA regimens are, in terms of response rates, in-line with what 
has been reported in clinical trials.55 Most treatment failures are as a result of a 
lack of patient compliance. The treatment effectiveness can be rescued by 
extending the length of therapy, or with the addition of Ribavirin or DAAs 
from other drug classes.56 
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HTA’s by their nature, possess promising therapeutic potential for 
pharmacological development in the fight against HCV. Currently approved 
DAA’s and compounds in late stage development will be sufficient to treat the 
vast majority of patient cohorts regardless of HCV genotype.  
 
Continuing research in this area should be focused on further enhancing the 
response rate and shortening treatment duration for the most at-risk, niche 
patient cohorts such as difficult to treat genotypes of HCV in combination 
with advanced liver cirrhosis and previous treatment failures, as well as 
HIV/HCV co-infected patients57, for which drug-drug interactions may be an 
issue.  
 
In the light of this, the specific, intrinsic properties of HTAs indicates that 
these therapeutics would be ideal incorporations into DAA combinations to 
treat the most difficult cases of HCV in terms of efficacy, probability of 
escape mutant production, tolerability and importantly treatment cost58. Truly 
efficacious treatment of HCV began with DAA/HTA combinations for good 
reason, perhaps it will end with them too.59 
 
1.6 Target- and phenotype-based drug discovery 
 
There are two different conceptual models in drug discovery and optimisation, 
the target-based approach and the phenotype-based approach. The conceptual 
differences between these two classes can be thought of simply as the breadth 
of the disease phenotype that is considered. 
 
Target-based drug discovery is a reductionist, mechanism based approach, 
focusing on the modulation of the activity of one particular validated target 
wherein the modification of this target is correlated causally with the treatment 
of a disease state. An example of this would be a high-throughput screen of 
small molecules in an in-vitro biochemical assay, targeted towards a specific 
viral protease60.  
 
Target-based approaches require prior understanding of the mechanistic 
underpinnings of a disease before an assay can be developed. When targeting 
specific proteins often crystal structures are available to help guide structure-
based drug design. After a molecular target of therapeutic interest has been 
identified, target validation must be performed to guarantee that modulation of 
the target (receptor, enzyme, transporter, DNA etc.) in a physiological 
environment will result in a modification of the disease phenotype, here the 
specific molecular mechanism of action will play a role (types of 
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agonism/antagonism, receptor residence time, competitive/non-competitive, 
covalent/non-covalent, reversibility, allostery etc.) and in this manner the drug 
can be more finely tuned to the disease state it is intended to target61. 
 
Phenotypic drug discovery is different from target based approaches in that 
screens for target identification and development will take place in a 
phenotypic model for the disease state, and will focus on modulation of the 
whole disease state. Phenotypic approaches are holistic as opposed to 
reductionist, and as such do not require such extensive target validation. 
Phenotypic assays used in high-throughput screens have the potential to give 
rise to a large array of potential leads with varied mechanisms of action. 
Phenotypic drug discovery is the oldest form of drug discovery, and in its 
crudest sense has been practiced for several thousand years by way of chewing 
or stewing roots, herbs, berries and barks for their medicinal properties.62 
Modern examples move away from animal models and instead usually focus 
on a model of the disease in a physiologically relevant cell line. A prudent 
example of a phenotypic screen is a quantitative high-throughput cell based 
screen that was recently performed in our group against HCV63 where the 
reduction of HCV virus load was the determinant of efficacy as opposed to 
some modulation of a specific receptor. Screens such as this are non-
discriminatory in terms of the mechanisms of action that the leads may then 
possess, and as such many first-in-class approved drugs are now discovered 
using phenotypic screens61. Most ‘follower’ drugs however are discovered 
through target-based approaches once the target of the phenotype-based drug 
is identified. 
 
In the specific case of HCV, target-based approaches should be leveraged 
towards better improvements of treatments with particularly strong biological 
mechanisms, that is, efficacious treatments with intrinsically high barriers to 
resistance. Alternatively it could be argued that phenotypic based approaches 
would find more utility in the discovery of novel HCV inhibitors with 
mechanisms of action that do not directly overlap with currently marketed 
drugs or even therapeutics that are in development. 
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1.7 This work 
 
The following work is concerned with development of three inhibitors of HCV 
with mechanisms of action that do not coincide with currently approved drugs. 
 
Chapter 2 describes the development of synthetic methodology with 
applications primarily directed towards the synthesis of MeBmt, a component 
of cyclosporin A (CsA) - a host-targeted replication stage inhibitor. The 
development of mechanistic parameters of dynamic kinetic resolution by 
asymmetric transfer hydrogenation of β-keto α-amido carbonyl derivatives is 
described,. And their subsequent use in the synthesis of MeBmt. The 
mechanism of action of cyclosporin A necessarily gives the compound a high 
barrier to resistance when being used as an anti-HCV compound. A target-
based approach towards optimisation of CsA permits rational design through 
specific modifications guided by in silico docking experiments, as well as 
specific modifications to improve the pharmacokinetic profile of the molecule. 
It is anticipated that this chemistry will ultimately facilitate the production of 
analogues of CsA that have been optimised specifically towards HCV 
infection. 
 
Chapter 3 describes the chemical optimisation of a late stage inhibitor of 
HCV derived from a phenotypic high-throughput screen. In lieu of a defined 
binding site and crystal structure, optimisation is iterative and is guided based 
on efficacy and toxicity feedback from cell-based biological assays as well as 
in-vitro measurements of ADME properties, working towards proof of 
principle experiments in a suitable rodent model. 
 
Chapter 4 discusses the mechanism of action and attempted target 
deconvolution of chlorcyclizine – an HCV entry inhibitor, again derived from 
a phenotypic high throughput screen. Deciphering the mechanism of action 
and binding partner of chlorcyclizine can permit optimisation in a target based 
manner, in the same approach as is used for cyclosporin A. 
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Target-based drug discovery: Developing 
synthetic methodology towards derivatives of 
Cyclosporin A.  
 
2.1 Introduction 
 
Cyclosporin A (CsA, fig. 2.1, 201), a complex cyclic peptide, containing 11 
amino acid residues, was originally isolated from the fungus Tolypocladium 
inflatum in 196964 and is a constituent of the Model List of Essential 
Medicines as determined by the World Health Organization. CsA is notable 
for being a potent immunosuppressive agent and is used to circumvent 
immunological graft rejection following transplantation, but is also known to 
be a potent, host-directed inhibitor of HCV replication.57 
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Figure 2.1 Structure of cyclosporin A and it’s constituent amino acid MeBmt 
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CsA is composed of eleven amino acids, two of which are non proteinogenic 
(D-Ala and MeBmt) and seven are N-methylated65. Besides its biological 
profile, the compound possesses interesting physical properties. Especially the 
amino acid profile (mostly non-polar, lipophilic, branched) and their 
subsequent N-methylation make the compound quite unusually lipophilic for a 
peptide (clogP 3.6 at physiological pH). Owing to its lipophilicity, CsA is 
poorly soluble in water and is administered as an emulsion66: also the 
solubility of CsA in water decreases as the temperature of the aqueous 
solution increases67. Much of the biological profile of CsA, including the anti-
HCV activity, is a result of interference with signalling cascades beginning 
with the interaction of CsA with the endogenous peptidyl-prolyl isomerase 
CypA68 as mentioned in Chapter 1. 
 
2.1.1 Cyclosporin A as an immunomodulatory agent 
Foreign pathogens recognised by T-cells will have the eventual effect 
of activating the protein phosphatase calcineurin, via the calcium-sensitive 
messenger protein calmodulin. Calcineurin (CN) exerts its effect via 
dephosphorylation of the transcription factor – Nuclear Factor of Activated T-
cells (NFATc). Once dephosphorylated, NFATc then increases the 
transcription and translation of interleukins in T-cells, thereby potentiating the 
immune response. Cyclosporin A also binds to CypA (fig 2.2-B), then this 
binary complex may bind to and sequester CN via a protein-protein 
interaction, greatly reducing the T-cells’ ability to elicit an immune 
response.69-72 The presence of cyclosporin A imparts stability to the (CN-
CyPA) protein-protein interaction; in the crystal structure it can be seen at the 
interface of the protein complex (fig 2.2-A). Modifications to CsA have been 
shown to alter the immunosuppressive effect, whether by decreased binding 
affinity to CypA, or CN or both73,74 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 2.2. A – Ternary complex between CypA (lilac), CsA (stick model) and calcineurin 
(pink). B Crystal structure of cyclosporin A bound in the isomerase site of CsA 
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2.1.2 Cyclosporin as an anti-HCV agent 
Cyclophilins, in particular CypA and CypB, have also been shown to 
be critical components to HCV replication. Investigations into the 
involvement of CsA and CypA, and as to their mechanistic involvement in 
HCV replication, began due to the observation that CsA inhibited proliferation 
of non-A non-B hepatitis following daily dosing. Huh7-Lunet cells transduced 
with a vector for silencing the expressions of CypA or CypB selectively 
showed that HCV replication is drastically inhibited under CypA knockdown 
but that knockdown of CypB had no effect. Inhibition of replication was 
rescued by overexpression of wild-type CypA, but importantly not by a CypA 
mutant lacking isomerase activity, demonstrating the necessity of the innate 
activity of the enzyme in HCV replication75. Further investigations into the 
involvement of CypA demonstrate the formation of stable complexes between 
CypA and proline rich regions of HCV non-structural protein NS5A – 
potentiating HCV replication76,77. CsA binds to the isomerase pocket of CypA, 
preventing the interaction with NS5A, inhibiting HCV proliferation78 via a 
host-targeting mechanism. 
 
2.1.3 Analogues of Cyclosporin A 
 Resistance to CsA and analogues is difficult to develop due to its host-
acting mechanism. Since it acts on host CypA, the virus cannot simply 
develop a point mutation, and must circumvent the need for human CypA 
entirely, this is borne out in numerous in-vitro studies79-81. Due to its potency, 
attractive resistance profile, and the fact that it is already an approved drug, 
CsA is an attractive candidate for medicinal chemistry development and 
repurposing towards an anti-HCV drug. CsA binds to CyPA through 6 amino 
acids: Sar, Abu, MeBmt, MeVal MeLeu, MeLeu, shown in lilac, fig. 2.3, 201, 
the CN binding domain is also shown in pink - compare to fig 2.2A/B. 
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The bioactive structure of CsA analogues bound to CypA has been calculated 
to be structurally very similar to the solution average conformer of CsA in 
water due to the intramolecular hydrogen bonding structure across the face of 
the cyclic peptide ring, fig 2.3, 204.82,83 MeBmt lies directly in the centre of 
the CypA binding domain: even small chemical alterations in MeBmt 
drastically affect the CyPA/CN binding and anti-HCV activity. The SAR is 
stringent: in general existing modifications have so far tended to reduce 
potency, but a few inspired modifications have been made, for example, as 
seen with Me2Bmt-CsA84. Me2Bmt-CsA (4-Dimethyl MeBmt) binds to CyPA 
with an affinity of 1% that of CsA: however, its immunosuppressive effect 
was reported to be 30% that of CsA. It has been proposed that the differences 
in efficacy are related to the equilibration between the CypA bound 
conformation and a non-binding conformation under physiological 
conditions84. The only modification that was found to improve the potency 
was the incorporation of an α methyl-thio substituent in place of the double 
bond. A summary is given below, fig 2.4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N-Methylation is favoured over N-H, however other N-alkyl derivatives have 
not been explored. The effect of stereochemistry at the α and β positions has 
not been addressed, but at the γ position the R configuration is favoured. 
Several analogues in the side chain have been tested against HCV: however, 
only the thioether derivative, fig 2.4, has been shown to be more active than 
CsA itself.74 
 
 
 
Figure 2.4 Summary of potency in CyP binding for MeBmt derivatives as part of CsA2 
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CsA analogues in the 1-position synthesised by Aebi et al universally 
decreased the immunosuppressive activity of CsA – replacement of the double 
bond with a triple bond or removing the methyl group at position 4 decreases 
activity by 90%, illustrating its occupation of the binding pocket. It was also 
noted, however, that the substitutions at MeBmt did not change the overall 
structure of the CsA molecule in any major way; the same hydrogen bonding 
patterns were retained. This is important when considering structural 
alterations – CsA has the potential to act as a rigid platform from which to 
build modifications in a rational manner.  
 
2.1.3.1 Alisporivir, SCY635 and NIM811 
Several analogues of CsA have entered clinical trials as antivirals, all more 
potent than the parent compound with reduced immunosuppressive effects (fig 
2.5) establishing clinical proof of concept. However none have emerged to 
become approved drugs for use as anti-HCV drugs (fig 2.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 CsA derivatives that have entered clinical trials, structural differences 
highlighted. 
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DEBIO-025 (Alisporivir) 
DEBIO-025 (Alisporivir) is a non-immunosuppressive cyclosporin analogue 
that has proved to be a much more potent inhibitor of HCV replication with 
approximately 10-fold potency increase in potency over CsA observed in the 
HCV subgenomic replicon assay, EC50 9.8-28.9nM, depending on HCV 
genotype57. The structural modifications present in Alisporivir are located on 
the boundary of the CyP/CN binding domain resulting in low affinity for 
calcineurin; the MeLeu-Sar sequence is substituted with EtVal-MeAla. As a 
consequence Alisporivir lacks an immunosuppressive effect. DEBIO-025 was 
found to be 7000 fold less active than CsA at inhibiting IL-2 production.57 
Phase II clinical trials show that DEBIO-025 is generally well tolerated. 
ESSENTIAL85 and VITAL-185 trials reported common side effects of 
reversible hyperbilirubinemia. SVR is achieved in 76% of patients receiving 
Alisporivir in combination with ribavirin and IFNα, with no null-responders, 
in comparison to ribavirin and interferon alone wherein 55% of patients 
achieved SVR. Alisporivir in monotherapy was shown to be nearly as 
effective as interferon and ribavirin with 53% SVR.  
 
SCY-635 
SCY-635 is an analogue of CsA possessing a dimethylamino-ethylthio 
substituent at the Sar3 α carbon atom and a hydroxyl substituent at the gamma 
carbon of the MeLeu4 residue. SCY-635 has an EC50 for HCV replication 
inhibition of 100nM and an EC50 for IL-2 inhibition of 4209nM whereas the 
respective EC50 values for CsA are 370/6.7nM.86 The binary complex, 
CyP/SCY-635 exhibits a low binding affinity for CN 87. 
  
NIM811 
NIM811, originally isolated as a side-product of CsA biosynthesis is another 
potent inhibitor of CypA that does not possess any CN affinity and therefore 
has no immunosuppressive activity88,89 A study to determine the antiviral 
efficacy of NIM811 in patients that had already experienced IFN/Rib based 
treatment failure, show a 2.85 (± 1.02) log10 fold drop in viral load. Clinical 
development of NIM811 has been discontinued due to a lack of efficacy when 
compared to Alisporivir.89 
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2.1.4 Derivatization of the MeBmt residue 
Despite the on-going research into CsA structure-activity relationships, there 
are very few analogues of CsA incorporating different MeBmt derivatives and 
most have already been mentioned. MeBmt is a complex N-methylated amino 
acid possessing three contiguous stereocenters, as well as a trans double bond. 
There are many published routes towards MeBmt83,90-115 having distinct 
strategies for tackling the aforementioned structural features. To thoroughly 
explore the SAR of cyclosporin A and derivatives for medicinal purposes, a 
totally flexible synthesis of MeBmt is fundamentally necessary. 
 
2.2 Synthetic Chemistry of MeBmt  
 
Immanently, the MeBmt side chain is constructed via the acetate pathway, 
analogous to other polyketides.116 The natural biosynthetic pathways and the 
reported artificial synthetic routes share similarities in strategy, many reported 
routes are based on stereoselective aldol and Claisen chemistry, and these 
features and manners of bond forming processes are present in the 
biosynthetic pathway (fig 2.6) 
 
 
 
 
 
 
 
 
 
The olefinic side chain has previously been installed via regioselective alkyne 
reduction108, fig 2.7A, regiocontrolled Wittig chemistry91 2.7B, or commonly 
through the synthesis of the aldehyde (2R,4E)-2-methyl-4-hexenal 205 which 
is a key synthetic intermediate in a number of synthetic routes to MeBmt. This 
in turn is derived from 3-buten-2-ol utilizing a Johnson-Claisen orthoester 
rearrangement as shown, 2.7C with subsequent reduction/oxidation 
conversions.95 Aldehyde 205 is volatile as well as being prone to racemization, 
limiting the effectiveness of routes utilising this material as an intermediate. 
 
 
 
Figure 2.6 MeBmt biosynthetic pathway involves Claisen-like chain extensions, enantio- 
and chemoselective reductions, and has separate steps for N-methylation. 
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The stereochemistry at the 1 and 2 position of the amino acid has been 
established previously via chiral pool synthesis, Sharpless asymmetric 
epoxidation followed by ring opening, as well as asymmetric glycine aldol 
reactions90 with either chiral auxiliaries or chelating metals, fig 2.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
As described, published routes for MeBmt contain many steps, are often low 
yielding, linear, and the stereoselective transformations are often inflexible in 
terms of stereochemistry and side chain tolerance, and many require separate 
N-methylation steps. Allowance must be made in the synthetic routes for these 
features. In short, they are not suited for optimisation of the MeBmt residue in 
terms of CyP binding.  
Figure 2.7 Some reported methods for installation of MeBmt trans double bond moiety 
involving regioselective reductions, or rearrangement reactions. 
Figure 2.8 Sample of reported methods for installation of MeBmt 1,2-vicinal stereocenters 
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The synthetic route should ideally be short and modular with late 
incorporation of the side chain to facilitate analogue production, and 
stereodivergent in terms of position 1 and 2, with prior incorporation of N-
methylation.  
 
2.2.1 Proposed Strategy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The proposed synthetic route fig 2.9, involves two key transformations: firstly 
a crossed Claisen condensation117 of the previously reported95 acid 206 to an 
appropriately protected sarcosine derivative 207 to yield the MeBmt scaffold 
208 as a β-keto carbonyl analogue. Dynamic kinetic resolution (DKR) of 208 
has the potential to selectively yield any one of four potential stereoisomers to 
investigate how the stereochemistry at these positions affects the biological 
profile of the molecule. The protecting groups that facilitate the crossed 
Claisen and direct the enantioselective reduction are ideally cleaved 
hydrolytically (esters, carbamates, amides) from 209 in a single step. The 
proposed route eliminates the need for stepwise chemoselective methylation of 
each target, benefits from late-stage incorporation of the side chain, is 
divergent in stereochemistry and avoids the problematic usage of aldehyde 
205. 
 
2.2.2 Synthesis of β-hydroxy α-amino acids by dynamic kinetic resolution 
Noyori118 and Genet119 describe the DKR by asymmetric hydrogenation (AH) 
of prochiral substrates, the stereochemical configurations of the product are 
dependent on both the structure of the catalyst, and that of the substrate. 
Hydrogenation of β-keto α-amido ester derivatives with the Ruthenium 
BINAP catalyst system under an atmosphere of hydrogen gives preferential 
syn stereochemistry, fig 2.10.  
Figure 2.9 Proposed synthetic route towards MeBmt 
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The absolute stereochemistry of the products is derived from facial 
discrimination via the atropisomeric catalyst structure, and the stereocenter at 
the 2-position is set relative to this. 
 
 
 
 
 
 
 
 
 
 
 
 
Very high enantiomeric excess (ee) and diastereomeric excess (de) can be 
achieved using these systems, provided that the rate of equilibration between 
the two isomers of the ketone substrate (210a/b) is arbitrarily fast (keq) in 
comparison to the rate of reduction of the product (k1, k2) – the catalyst should 
be discriminating in an effective 1:1 distribution of substrate enantiomers as 
much as possible. Though syn-hydrogenation by this method would in theory 
give the desired (2S,3R) configuration of MeBmt, the high pressures of 
hydrogen required renders the method unsuitable, due to potential reduction of 
the olefinic side chain, experimental inconveniencies of using very high-
pressure apparatus notwithstanding.  
The technology has been expanded upon and has since been extended 
to asymmetric transfer hydrogenation (ATH) in which the reagent is not 
hydrogen gas, but another hydrogen source such as isopropanol120, formic 
acid121 and formate salts122. These conditions do not require specialist 
apparatus for high pressures, as such they are safer, have a broader substrate 
scope, and the catalysts are generally less sensitive. DKR via ATH has been 
shown to give both anti or syn products selectively depending on the structure 
of the substrate. 123 
 
α-amido ester substrates have been demonstrated to give anti products 
selectively under transfer hydrogenation conditions as demonstrated by 
Seashore-Ludlow et al122. It is postulated that this selectivity, shown in fig 
2.11A, is primarily due to intramolecular hydrogen bonding in the substrate as 
illustrated in fig 2.12. 
 
 
Figure 2.10 Asymmetric hydrogenation of α-amido β-keto esters 
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The ketone is reduced stereoselectively with facial preference based on the 
structure of the catalyst, whereas the diastereoselectivity is a substrate-
controlled factor, due to steric crowding (CO2Me vs. H) in a transition state 
that is restrained by hydrogen bonding (fig 2.12). If the approach of the 
catalyst to the ketone is sterically impaired then reduction may not occur.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
If this intramolecular hydrogen bonding is interrupted, for example by 
substitution on the nitrogen, then syn configuration dominates, rationalized by 
a Felkin-Anh induction model: the configuration of the α carbon is constantly 
being racemised due to the facile tautomerism under the reaction conditions. 
Several substrates in the literature have been reduced that do not possess the 
capacity for intramolecular hydrogen bonding 120-122,124,125, all favouring syn 
reduction (ex fig 2.11B).  
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Figure 2.12 A working model of asymmetric induction in the ATH DKR of α-amido β-keto 
esters 
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Considering reduction of substrates containing fully substituted amides tends 
towards syn products, and that reduction of alkyl substituents has been 
previously demonstrated, we commenced a program to develop a short 
synthetic route towards MeBmt and derivatives by asymmetric transfer 
hydrogenation in order to modify the amino acid, allowing incorporation into 
CsA and study the modulation of biological activity. 
 
2.3 Formal synthesis of MeBmt by ATH DKR via C3 inversion  
As a model system to develop the reaction conditions before using the 
synthetically valuable MeBmt side chain, we employed an isobutyric side 
chain as opposed to (R,E)-2-methylhex-4-enoic acid. Following the synthetic 
strategy to the end of the synthetic route would yield N-methyl (2S, 3R) 3-
hydroxyleucine, 211 (fig 2.13). 
 
 
 
 
 
 
 
 
 
Crossed-Claisen condensation of isobutyryl chloride with Z-Sar-OMe, 208 
following the protocol of Misaki et al117 gave the crossed product 209, in 
disappointing 28% yield. The efficiency of this condensation reaction could 
not be improved by using longer reaction times, by altering the order of 
addition of reagents, or using 2 equivalents of 208. Product 209 was 
unexpectedly isolated entirely as the enol tautomer 212 (>99% enol as judged 
by analysis using 1H NMR in CDCl3) as opposed to the keto form, and could 
not be reduced by ATH DKR to give 210 using the conditions employed by 
Ludlow et al122.(as judged by TLC) 
 
 
 
 
 
 
 
We suspected that the cause of the failure to convert 209 into 210 resided in 
the position of the keto:enol equilibrium, and numerous different reaction 
conditions were employed in an attempt to circumvent this. There are several 
Figure 2.13 A pilot synthesis of N-Methyl (2S, 3R) 3-hydroxyleucine 
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27 
published methods for the ATH of beta keto carbonyl derivatives123 utilizing 
different hydrogen sources (HCO2H, HCO2H/NEt3, HCO2Na/H2O, iPrOH), 
catalysts (213-215, fig 2.15), solvents (DCM, THF, iPrOH, DMF, DCM/H2O 
emulsion), temperatures (-5°C to 40°C). Hence a screen of reaction conditions 
was established to find an appropriate combination of conditions to reduce the 
challenging substrates 212:209. A variety of solvents were examined, varying 
in degrees of polarity and capacity for hydrogen bonding in an attempt to 
preferentially stabilize the keto tautomer or by other means facilitate the 
reduction. By TLC no reduction was observed in H2O (aggregation of starting 
materials), DMF126, DCM/HCO2Na(aq), iPrOH120, DCM, a 5:2 HCO2H/NEt3 
azeotrope or toluene. Catalyst loading could be increased up to 10% and the 
reaction run at 50°C with no trace of the desired product. Preforming the 
active 16 electron catalyst species is necessary for some reductions that are 
deemed particularly challenging120 however reduction was again unsuccessful 
even with the more active tethered catalyst 213 (fig 2.15). Finally, ZnCl2 was 
introduced into the reaction wherein it was intended to function as a Lewis 
acid – stabilizing the di-keto arrangement, but conversion to the reduced 
product was not observed (fig 2.15B). 
 
Despite surveying a wide variety of reaction conditions, the starting material 
could not be reduced and was often recovered almost quantitatively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Following this investigation of reaction conditions, and varying the nitrogen 
protecting groups (CBz, Bz), it was concluded that the lack of reduction was 
directly due to a lack of keto tautomer at equilibrium, even though inter-
conversion may take place to some extent.  
Figure 2.15 Catalysts employed in failed ATH DKR attempts 
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The successful reduction of γ-alkyl β-keto α-amido esters has previously been 
reported122, which were isolated primarily as ketones, as well as the separate 
reduction of γ-aryl N-methylated substrates124. The γ-alkyl substrates 
however, universally contained hydrogen on the amine in the alpha position 
for participation in intramolecular hydrogen bonding, or harboured an aryl 
group in the γ-position (fig 2.11A, B). Both of these features stabilise the keto 
tautomer preferentially, compared to the enol tautomer. 
 
To emphasize the vital importance of intramolecular H-bonding, a synthesis of 
N-methyl (2S, 3R) 3-hydroxyleucine was carried out, fig 2.16A as well as a 
formal synthesis of MeBmt starting from 3-buten-2-ol, fig 2.16B. Both 
syntheses required stepwise N-methylation and stereochemical inversion at the 
3-position of the resolved alcohols 217 and 220. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16 A synthesis of (2S,3R)-3-OH MeLeu and a formal synthesis of MeBmt starting 
from 3-buten-2-ol.  
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In the synthesis of N-Me leucine, fig 2.16A, isobutyryl chloride undergoes a 
titanium chloride catalysed crossed Claisen condensation with a benzoyl 
protected glycine methyl ester, yielding ATH DKR substrate 216 in 54% 
yield. DKR as described by Somfai et al employing sodium formate and Ru(p-
cymene) (R,R) Ts-DPEN gives β-hydroxy α-amino derivative 217 with good 
diastereo- and enantioselection. Cyclisation to the oxazolidinone 218 with 
inversion at C2 proceeded smoothly, yielding 218 in 89% isolated yield, 
analysis of coupling constants at this stage reveals a trans relationship 
between the ring protons, corresponding to an ‘anti’ configuration in the 
starting material 217 as depicted in fig 2.16A. Methylation with methyl triflate 
and subsequent hydrolysis affords (2S,3R)-3-OH N-Me Leu. 
 
The formal synthesis of MeBmt outlined in fig 2.16B commences with the 
synthesis of (R,E)-2-methylhex-4-enoic acid 206, followed by elaboration to 
the amino acid derivative analogous to fig 2.16A. Although the synthesis of 
chirally pure 206 is reported via the diastereomeric separation shown, we 
sought to improve upon this by means of a direct synthesis of 206 utilizing an 
Ireland-Claisen rearrangement, which was contingent on the synthesis of 
enantiopure (S)-3-buten-2-ol. It was proposed that the stereochemical 
information present in the kinetically resolved (S)-3- buten-2-ol would be 
retained when subjected to an Ireland Claisen rearrangement 127,128, this 
sequence is described in fig 2.17.  
 
 
 
 
 
 
 
 
 
 
 
It can be seen how a 1-4 chirality transfer leads to retention of stereochemical 
information through the chair-like transition state, owing to the 
conformational bias of the equatorial methyl group (fig 2.17B) after 
regioselective enolate formation. However, after a screen of ten commercially 
available lipases solvents and acyl donors, the maximum ee obtainable in the 
enzymatic kinetic resolution of (S)-3-buten-2-ol was 72%, with low yield 
resulting from difficult isolation of the volatile product. Further depletion of 
ee was observed in the Ireland-Claisen rearrangement step. 
Figure 2.17 A synthesis of (R,E)-2-methylhex-4-enoic acid 206 from 3-buten-2-ol. 
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It was decided therefore, to move forward with the literature-established 
method for the synthesis and isolation of 206 previously discussed, fig 2.15. 
Racemic (E)-2-methylhex-4-enoic acid was synthesized by a Claisen 
orthoester rearrangement of 3-buten-2-ol and triethyl orthopropionate. The 
acid was coupled to phenylglycinol utilizing HATU as a coupling reagent in 
DCM improving upon the literature yield. Complete chromatographic 
separation and acid catalyzed hydrolysis afforded the enantiopure acid 206. 
Crossed Claisen condensation in a disappointing 22% yield furnished the β-
keto derivative 219, which was subsequently reduced to the anti- β-hydroxy α-
amino precursor to MeBmt, 220. The synthesis of MeBmt from intermediate 
220 has been previously demonstrated112 thus this constitutes a novel formal 
synthesis of MeBmt using ATH DKR as a key step. 
 
2.4 Direct synthesis of MeBmt by syn-ATH DKR of β-keto amides  
 It has been noted that intramolecular hydrogen bonding is responsible for the 
anti-selectivity of reduction (fig 2.11), however what has not been reported, as 
we have discovered, is that the hydrogen bonding appears to be responsible for 
the tautomer distribution and reactivity of this compound class in general.  
On this basis it was postulated that a 6-membered ring intramolecular 
hydrogen bond could be introduced via replacement of the terminal ester 
moiety by an amide (fig. 2.18 B). β-Keto amides have been previously utilized 
as ATH DKR substrates, though not for the synthesis of amino acids. It was 
hypothesized that intramolecular hydrogen bonding as described should 
provide the opportunity for stabilization via 6-membered ring hydrogen 
bonding leading to a substantial percentage of the keto tautomer and 
consequent syn reduction despite N-methylation. 
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The Ti catalysed crossed-Claisen condensation proved unsuitable for the 
synthesis of N-methyl-β-keto precursors in the manner that we would desire. 
The alpha proton of was not acidic enough to be conveniently removed with 
the combination of TiCl4 and Hunig’s base; moreover the use of stronger 
bases such as LDA or LiHMDS is likely to lead to the racemisation of the α-
position of the acid 206, which would be untenable. 
 
An excellent alternative proved to be a thioesters Claisen condensation. An 
optimized biomimetic crossed-Claisen condensation utilizing ‘soft 
enolization’ (Lewis acid assisted) of thioesters and N-acyl benzotriazoles 
gives reliable, high yielding gram-scale access to N-methyl-β-keto thioesters, 
which can be quantitatively transformed into the analogous β-keto amides in 
one step utilizing a thiophilic Lewis acid, silver trifluoroacetate, and an 
appropriate amine nucleophile129 (fig 2.19).  
 
The efficiency of the Claisen condensation of thioesters is thought to be a 
consequence of the electronic structure of the sulphur atom. Due to the 
valence electrons of sulphur residing in the third shell the C-S bonds are 
longer in thioesters than the corresponding oxoester or amides. As a result 
there is less contribution to resonance stabilization caused by decreased O-S 
Figure 2.18 Comparative proposed intramolecular H-Bonding patterns in ATH DKR model 
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32 
orbital overlap. This raises the acidity of the protons on the neighbouring 
alpha carbon because the conjugate base can be appropriately stabilized as the 
enolate, thioesters therefore behave more like ketones than esters with regard 
to reactivity, which might not be expected considering S and O are both group 
16 elements - and so the Claisen condensations are facile. The ubiquity of 
thioesters in biological systems for regioselective aldol reactions is testament 
to this. 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.1 Optimisation of syn-ATH DKR reaction  
The reactivities and properties of these compounds are delineated in Table 2.1. 
The 1H NMR spectra of the N-methyl-β-keto amides (CDCl3) are mixtures of 
keto and enol tautomers with substantial amounts of both, as opposed to the 
N-methyl esters, which exist entirely as the enol tautomers. The distinct proton 
environments (confirmed by analysis of HMBC spectra) can be discerned in 
the 1H NMR of the beta keto amide substrates, which lends support to the 
hypothesis of fig 2.18B, namely the intramolecular hydrogen bonding shifts 
the proton environments noticably downfield (Hb, Hc, fig 2.20).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.19 Synthesis of α-amido β-keto amides and α-amido β-hydroxy amides 
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FMOC, CBz and Bz were investigated as N-protecting groups for reduction - 
all three displayed susbtantial amounts of the keto tautomer at equilibrium as 
the N-Methyl-β-keto anilides.  
 
To recapitulate, the N-Me methyl ester series exemplified by 209 is 
completely unreactive towards reduction, however under the same conditions 
successful reduction was observed for all three derivatives, entries 9, 10 and 
11 which proceed with very high enantio- and diastereoselectivity, albeit in 
poor overall yield. Although the Fmoc derivative gave the highest 
conversions, the CBz protecting group was chosen for optimization due to the 
substantially higher yields in the preceding reactions. Furthermore the Fmoc 
derivative decomposes under NEt3/HCO2H conditions, due to base-catalysed 
Fmoc deprotection (Table 2.1 i ).  
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Figure 2.20 Analysis of intramolecular hydrogen bonding by NMR 
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A screen of five commercial catalysts (structures shown in Table 2.2) reveals 
the tethered catalyst D, (R,R)-Ru Teth-TsDPEN (as pioneered by Wills129 and 
coworkers) and to give the highest conversion, and isolated yield with almost 
complete stereocontrol, at 5% catalyst loading.  
 
It was noted that the more contemporary tethered catalysts gave higher 
isolated yields than the non-tethered derivatives, (entries 1-6) perhaps due to 
increased stability under the reaction conditions. Critically, an isolated yield 
above 50% demonstrates that the α-carbon is being racemised under the 
reaction conditions through tautomerism. In an attempt to increase the yield, 
the reaction time was increased to 120 hours, which resulted in no isolation of 
the product due to decomposition of the reaction materials. 
 
 
 
 
 
 
Entry R1 R2 R3 Keto:Enola Isolated Yield (%) drc erd 
 1 H Bze OMe >99:1 26 15:85 50:50 
 2 H CBz OMe >99:1 84 92:8 98:2 
 3 Me Bz OMe >1:99  NDl ND ND 
 4 Me CBz OMe >1:99 NR ND ND 
  5g Me CBz NHPh 30:70 ND ND ND 
  6h Me CBz NHPh 30:70 ND ND ND 
 7i Me CBz NHPh 30:70 ND ND ND 
 8j Me CBz NHPh 30:70 13 >95:5 >99:1 
 9j Me FMOC NHPh 25:75 18 >95:5 >99:1 
 10j Me Bz NHPh 28:72 4 >95:5 ND 
        
         
         
         
         
 a Keto:enol tautomers 1H NMR, CDCl3. b 1H NMR of crude reaction material, c syn:anti  
ratio 1H NMR of crude reaction mixture. d 3S:3R in major diastereomer. e Reduction with 
NaBH4. f Product detected by LCMS but not in isolable amounts. g iPrOH, K2CO3. h 
HCO2H:NEt3 5:2, neat iDCM/HCO2H/NEt3.  jDCM/HCO2Na emulsion. kND – Not 
Determined. lNR – No Reaction 
Table 2.1 DKR via ATH of α-amido β-keto amides 
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Entry Catalyst Cat. loading (%) Solvent System t (h) Yield %a drb erc 
1 A 5 H2O/DCM 40 36 >95:5 >99:1 
2 B 5 H2O/DCM 40 34 >95:5 96:4 
3 C 5 H2O/DCM 40 36 >95:5 97:3 
4 D 5 H2O/DCM 40 64 >95:5 >99:1 
5 E 5 H2O/DCM 40 40 >95:5 98:2 
6 F 5 H2O/DCM 40 42 >95:5 96:4 
7 D 5 H2O/DCM 120 ND ND ND 
9 D 10 H2O/DCM 40 (>99) 64 >95:5 >99:1 
(R)
(R) N
H
N
SO O
Ru
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(R)
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(R) N
N
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Me
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 a Isolated yield following column chromatography (conversion in parentheses). b syn:anti 
ratio in H1 NMR of crude reaction mixture. c 3S:3R ratio in major diastereomer – chiral 
HPLC.  
Table 2.2 Optimisation of syn ATH DKR 
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2.4.2 Crystal Structure  
The isolated virtually enantiopure product from entry 4, Table 2.2 was 
recrystallized from a solvent system of hexane and Et2O overnight to form 
fine, white needles, which were imaged using light-microscopy at various 
magnifications, shown in fig 2.21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The translucent crystals were analysed by Dr. Curtis Moore at the University 
of California – San Diego X-ray crystallography facility and the crystal 
structure thus obtained is shown below – fig 2.20. 
 
 
 
 
 
 
 
 
Figure 2.21 Microscopic images of re-crystallized ATH DKR product – entry 4, Table 2.2 
4x 4x 
10x 20x 
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The structure is confirmed, unambiguously, to be (2S,3R) – 221, as anticipated 
by rationalisation of catalyst approach. Stereocontrol is established through 
catalyst-selected Re/Si face attack, which occurs under the pre-requisite that 
this face is not blocked by the larger N-methyl-CBz substituent, this concept is 
illustrated in fig 2.21126. 
 
 
 
 
 
 
 
 
 
 
Figure 2.21 Crystal structure confirmation of bond connectivity and absolute 
stereochemistry - confirms syn (2S, 3R) - 221 as the major product of ATH DKR when 
using (R,R)-Ru Teth-TsDPEN, as predicted, Fig 2.15 Tables 2.1, 2.2. 
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Figure 2.22 Proposed catalytic cycle of (R,R)-Ru Teth-TsDPEN in the synthesis of 221 by 
DKR/ATH. 
Ru
N
N
Ts
Ph
Ph H
Cl Ru
N
N
Ts
Ph
Ph
KOH(aq)
18 e- complex
Precatalyst
16e-complex
HCO2Na(aq)
Ru
N
N
Ts
Ph
Ph
O
O
H
Ru
N
N
Ts
Ph
Ph
H
H
(S)
O
NMeCBz
O
NHPh (R)
O
NMeCBz
O
NHPh
Ru
NN
Ts
H
H
O iPr
NMeCBz
CONHPh(R)
OH
(S)
NMeCBz
O
NHPh
221
X-Ray
Racemisation via tautomerism
CO2
Ru-formato
species225
226
227
228
S-229
Ru-hydride
H
Ru
NN
Ts
H
H
O iPr
NMeCBz
CONHPh
Ru
NN
Ts
H
H
O
iPr
CONHPh
NMeCBz
Ru
NN
Ts
H
H
O iPr
CONHPhR2N
R-229
R-229 Si-face approach
R-229 Re-face approachS-229 Re face approach
Ru
NN
Ts
H
H
S-229 Si-face approach
O
iPr
CONHPh
R2N
S-229 Re face approach
 
 
 
 
 
 
38 
2.4.3. Synthesis of MeBmt by syn-ATH DKR 
 
The above, optimised, synthetic protocol was applied to (R)-206. Formation of 
the benzotriazolyl electrophile 230 by nucleophilic substitution, followed by 
crossed-Claisen condensation gives thioester 231 in 63% overall yield from 
206. Displacement of thioester with aniline and subsequent reduction of amide 
232 by syn-ATH DKR affords N-methyl-β-keto amide 223, which 
subsequently undergoes basic hydrolysis to MeBmt, 202. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.23 Synthesis of MeBmt via syn-ATH DKR 
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2.5 Summary, conclusions, and future work 
We carried out a research programme to develop a synthetic route towards 
MeBmt, the unnatural constituent amino acid of CsA. The synthetic route thus 
developed is short, modular and stereodivergent, and will hopefully prove to 
be flexible in terms of alkyl side chain incorporation, which will enable the 
construction of CsA analogues that would not have been able to be 
synthesised by any other means. During the course of the programme, several 
key developments were made in understanding of the substrates for ATH 
DKR. Prediction and control of intramolecular hydrogen bonding has been 
proven to be pivotal in relation to predicting both the reactivity of the 
substrates, prediction of the 3 dimensional structures of reactive intermediates 
and stereoselection of the reaction. Rationalisation of the structure of stable 
reactive intermediates can be used to predict the syn/anti outcome of the 
reaction, the absolute configuration of which can be controlled by catalyst 
structure. In a medicinal aspect, future work in this area will concentrate 
foremost on synthesis of CsA analogues modified in the MeBmt position 
guided by molecular modelling.  In terms of chemistry and methodology 
development, future work will focus on the use of protecting groups to direct 
the reaction, that are orthogonal in their deprotection procedure, to enable the 
synthesis of FMOC-protected derivatives directly. It is hoped that the 
methodology developed herein can be used to facilitate the synthesis of CsA 
analogues, specifically by solid phase peptide synthesis, with the goal of 
optimising the systematically optimising the properties of CsA for use in the 
treatment of HCV. 
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Phenotype based drug discovery: 
Pharmacological development of ‘Chemotype 
3’ as an inhibitor of HCV assembly. 
 
3.1  Introduction 
As previously outlined, recent advances in HCV therapy since 2011 
transformed frontline therapies with the introduction of DAA’s and 
combination therapies of these treatments. End-game treatment of HCV will 
involve highly efficacious pan-genotypic multi-drug regimens. The individual 
drug components will likely exert their effect through different mechanisms of 
action to reduce the possibility of viral adaptive mutations and resistance. The 
regimens will be simple to administer to ensure patient compliance, as well as 
affordable by all patient populations.  
While the current treatments are effective at clearing HCV, what 
cannot be accounted for is the build up of drug-resistant viral mutants in the 
exceptionally large treatment populations as seen with HCV (150-170 million 
infected individuals) particularly towards NS5A inhibitors. They are also 
notoriously expensive. The fact remains that the sheer scale of the HCV 
pandemic is such that if 100% of infected individuals, at a conservative 
estimate 150 million, could be instantly diagnosed, and following this, the 
current state of the art treatment with SVR~90%15 is administered at a cost of 
12 trillion USD, (Harvoni or VIEKRA PAK $86-88k/treatment course) then 
there would remain a cohort of 15 million people harbouring infectious, 
3 
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presumably drug resistant HCV, with no treatment options - approximately 
equivalent to the entire population of Guatemala.  
Therefore, in addition to the newer therapies that have emerged, it is 
still necessary to pursue the development of new therapeutics that can be used 
in combination with existing drugs, which possess novel mechanism of action 
against HCV. Cell based high throughput screens are an ideal platform for the 
discovery of such therapeutic agents because the suppression of viral 
proliferation (the phenotype) is not tied to the strength of interaction of a drug 
with one particular viral or host protein, but is tied simply to the decrease in 
viral load, for example by fluorescence output or viral protein staining 
quantification.63  
 
3.2  Discovery of inhibitors of HCV through a phenotypic high-
throughput screen 
 Previously in our group an assay platform with a cell-based HCV 
infection system was developed. The assay was successfully miniaturized to a 
1536-well plate format that would be suitable for quantitative high-throughput 
screening of large chemical libraries to establish novel inhibitors of HCV63. A 
screen of the NIH molecular libraries small molecule repository (MLSMR, 
>340k small molecules130) was performed generating 4-point dose-response 
curves for every compound, resulting in approximately 3000 primary hits, that 
appeared to completely reduce HCV replication in the assay131.  
To ensure high quality hits further pruning of the data set was performed in 
terms of removing promiscuous binders and structural clustering analysis, 
resulting in a secondary set of 650 compounds. The 650 compound set were 
subject again to the initial efficacy test though this time developing an 11 
point dose response curve, and also a cytotoxicity assay was carried out to 
remove any hits that were reducing HCV load by means of cytotoxicity. 
Following this an orthogonal HCV core staining efficacy assay was used to 
directly quantify the reduction in HCV proteins, confirming the specific action 
towards HCV. Using this system, more than 340k small molecules in the MLS 
library yielded 158 selective inhibitors of HCV for further investigation and 
development.  
The 158 hits from the screen were further categorized by their structure, and 
the stage of the HCV life cycle they inhibited was deduced from a 
combination of cell-based infection assays. 
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3.2.1 Separation of hits by mechanism class 
HCV pseudoparticles (HCVpp): These are defective retroviral particles which 
display HCV envelope glycoproteins, these virus particles may enter the cells 
but do not undergo replication. Culturing these viral particles with a drug 
candidate in hepatocytes, followed by isolation of intercellular HCV particles, 
and comparison with a control, allows us to ascertain whether there is an 
inhibitory effect on viral entry.132,133 
HCV replicon assay: The HCV replicon assay is an older assay that utilizes 
integrated HCV RNA only, and is used to measure the effect that a particle 
may have specifically on the replication stages of HCV133 
HCV single cycle assay (HCVsc): HCVsc infect cells in vitro and replicate but 
cannot assemble to form new virions, permitting study of inhibitory effects 
that would occur throughout the entire viral life cycle prior to assembly. 
HCV cell culture (HCVcc): The isolation of the JF1 strain of HCV genotype 
2a permitted the development of a cell culture assay in which HCV can infect, 
replicate and secrete from Huh-7 cells to form infectious HCV virions. This 
assay allows us to study the entire HCV replication cycle and was used as the 
primary assay in the high-throughput screen.  
Using these assays, the 158 screen hits could be separated by class i.e. which 
stage of the HCV life cycle they act upon.  
158 Candidates: 
• 39 Entry inhibitors 
• 14 Replication inhibitors 
• 18 Entry/replication  
• 37 Trafficking inhibitors 
• 47 Assembly/secretion inhibitors 
• 3 Not determined 
Based on these classes, and on the structural properties of the compounds, 
several hits were selected for lead optimization, chemical and pharmacological 
development.  
With regards to ranking of assay hits in terms of favourable structures, the 
principle that the physicochemical properties of a molecule can be used to 
broadly predict aspects of its biological function, Lipinski’s rule of 5134 and its 
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more modern derivatives in QSAR analysis (polar surface area, rotatable 
bonds, various ligand efficiency metrics etc.) are useful tools for 
approximating the “drug-likeness” of a small molecule. 
3.2 Drug interactions and resistance  
Drugs that are used in combination have the capacity to modulate the potency 
of other drugs in a physiological setting. The effects can be antagonistic, sub-
additive, additive or synergistic. Because the enzyme and receptor inhibition 
kinetics by a drug are hyperbolic in nature, complete suppression of viral 
replication can be more readily achieved in a physiological setting by 
inhibiting more than one enzyme that the virus is dependant on 
simultaneously. Using drugs in this manner is termed drug synergism. 
Strategies for drug synergy include: blocking multiple enzymes in the same 
pathway, blocking targets in different pathways that the target has in common, 
or the use of multiple drugs for the same target. As well as comprising 
extremely efficacious therapies, these strategies also make the development of 
resistant escape mutants much more unlikely. Highly active anti-retroviral 
therapy (HAART135) towards HIV is a relevant example of the benefits found 
from exploiting drug synergism, viral resistance can be avoided while still 
maintaining efficacy, and allows reducing the effective dose for each drug to 
minimise potential side effects. Direct acting anti-virals will always have the 
potential to create resistant strains through selection for viral mutants by point 
mutation among other possibilities. 
Considering that most currently marketed drugs for HCV directly target the 
replication stages of the virus, the most attractive candidates in terms of 
looking towards a new synergistic therapy may reside in the less explored 
entry and assembly inhibitor classes of drugs. 
3.3.1 Assembly inhibitors of HCV 
There are several identified small molecule inhibitors of HCV that have their 
effects on the assembly stage of the virus136-141  
Late stage trafficking of core proteins to the site of replication in lipid droplets 
requires the function of the diacylglycerol acyltransferase-1 (DGAT1)142. 
There are several known small molecule inhibitors of DGAT1143 and 
inhibition of DGAT1 has been shown to severely impair infectious HCV 
virion production in-vitro, however a study attempting to determine the 
efficacy of DGAT1 inhibitors in treating HCV was terminated prematurely 
due to a lack of an antiviral effect.144 
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The grapefruit derived flavonoid Naringenin (fig 3.1) has been demonstrated 
to inhibit HCV assembly137,145. Naringenin specifically blocks the assembly of 
viral particles - the proposed mechanisms are related to fatty acid synthesis, 
on which HCV is dependant for infectious particle production. Naringenin 
acts as a peroxisome proliferator-activated receptor α (PPARα) agonist 
leading to a decrease in VLDL production, which is required for effective 
HCV assembly and propagation of infectious particles. It has also been 
established that Naringenin inhibits the activity of microsomal triglyceride 
transfer protein (MTP), which in turn acts to inhibit ApoB mediated cellular 
egress of HCV. 
Another inhibitor of the aforementioned transfer protein MTP is the 
antiarrhythmic compound Amiodarone, (fig 3.2) which is found to inhibit both 
the assembly and secretion steps of the HCV life-cycle independent of 
genotype. Activity at the entry stage was attributed to down-regulation of 
CD81 receptors.139 
Imino-sugar PBDNJ0804 was identified as an inhibitor of alpha glucosidases 
that are required for efficient folding and processing of HCV envelope 
glycoprotein E2, precluding HCV assembly and secretion.138 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Previously identified small molecule inhibitors of HCV assembly 
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3.3  ‘Chemotype 3’ as an inhibitor of Hepatitis C Virus assembly 
From the assembly/inhibitor class, the candidate chosen for chemical 
optimization was N-benzyl-1-(2,4-dimethoxybenzyl)-N-phenethylpiperidin-4-
amine, named Chemotype 3 (CT3), fig 3.2. 
 
 
 
 
 
 
 
 
CT3 is a potent inhibitor of HCV production acting on the assembly/secretion 
stage of the virus life cycle with an EC50 in the low single digit µM range, 
with an acceptable therapeutic index in vitro. CT3 displays no significant 
inhibition of replication in either the HCVpp, HCVsc or HCV replicon assays 
at a concentration of 10µM, however in the HCVcc assay CT3 displays >90% 
inhibition of viral replication at these concentrations. This demonstrates that 
CT3 must primarily act to inhibit HCV at a stage after viral RNA replication, 
for example viral capsid assembly in lipid droplets, trafficking to the cell 
surface, secretion into the extracellular environment or migration between 
cells.  
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Screening: IC50 = 4.67uM, CC50 52.4uM
Commercial: IC50 = 1uM, CC50 = 11.5uM
Resynthesis: IC50 2.03uM, CC50 75.7uM
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Figure 3.2 Structure and pharmacological properties of CT3 
Figure 3.3 Analysis of differences between intra- and extracellular RNA upon treatment 
with CT3 
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Upon treatment of HCV in vitro with CT3, intra and extracellular viral RNA 
concentrations are measured. As the concentration of CT3 increases, both 
intracellular and extracellular RNA decreases. Cyclosporin A, affecting the 
replication stage of the HCV life cycle caused approximately 4-log fold 
reduction in intracellular RNA copies, while the extracellular level reduced 
less than 3-log fold. Conversely, CT3 leads to only about 1-log fold decrease 
in intracellular RNA copies when causing 3-log fold reduction in extracellular 
RNA level over the concentration ranges shown. When extracellular medium 
is used to re-infect naïve Huh 7.5.1 cells, CT3 is shown to cause a dose-
dependent reduction in TCID50 values, an orthogonal confirmation of its 
effect on extracellular RNA copies, fig 3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DAPI! HCV Core! Lipid Droplets! Overlay!
2.5μM CT3
1.25μM CT3
No Treatment
5μM CT3
10μM CT3
Figure 3.4 Immunostaining demonstrates CT3 specifically affects HCV assembly stages 
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Monitoring the co-localisation of HCV and cellular constructs allows us to 
discriminate between effects on viral assembly and viral secretion. HCV is 
known to assemble in lipid droplets, and as such HCV core proteins will co-
localise with lipid droplets during viral assembly – fig. 3.4. Upon treatment 
with CT3, co-localisation of HCV core proteins and lipid droplets (shown as 
yellow in overlay) decreases with increasing concentrations of CT3, indicating 
that assembly is inhibited, if CT3 did act on secretion we would still observe 
assembly in lipid droplets. In summary, CT3 inhibits HCV production but acts 
in such a way to stop the viral assembly in lipid droplets, as opposed to 
stopping its replication or secretion of virus particles. CT3 appears to have 
little affect on the stages of the HCV life cycle before virus assembly.  
CT3 comfortably meets the Lipinski parameters for hydrogen bond 
donors and acceptors, having two hydrogen bond donors (at physiological pH) 
and four hydrogen bond acceptors; it is a reasonably low molecular weight 
compound at 444.6 Da. Though the cLogP is high as drawn above, CT3 would 
exist as a salt at physiological pH facilitating water solubility. A medicinal 
chemistry based optimization program on this compound class was undertaken 
that was guided by in vitro cell based assays for efficacy and toxicity, as well 
as in vitro ADME consisting of metabolic stability in cultured human 
microsomes, measurement of solubility in water, and membrane permeability. 
The overarching goals of the program were to increase the potency of the 
compound and widen the therapeutic window, while improving the 
compound’s metabolic stability, with aims towards proof-of-concept efficacy 
studies in mice. 
3.3.1  Iterative synthesis of derivatives of CT3 and analysis of SAR 
Biological analysis of fragments of CT3 301-305, fig. 3.5, reveals that the 
benzylic group at the top of the molecule designated R1 did not have any 
bearing on the efficacy of the compound. As such it was classified as 
auxophoric and excluded from the scaffold moving forwards. Both phenyl 
rings were required for CT3 to exhibit the potency of the original hit 
compound. Since the molecular target for this compound is unknown, a broad 
systematic exploration of the requirements for potency was undertaken. 
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The synthesis of analogues of CT3 at ring designated R1 is outlined in fig 3.6. 
Reductive amination of 306 utilizing sodium cyanoborohydride in DCE 
followed by acid catalysed Boc cleavage (fig 3.6 A), or potassium carbonate 
catalysed SN2 displacement of an α-bromo phenyl derivative (fig 3.6 B) 
facilitates the expedient synthesis of a wide variety of analogues in a 
systematic manner to probe the binding pocket. Amide analogues 331, 332, 
336, 337, 342 and 343 are synthesized similarly - reductive amination 
followed by HATU catalysed amide coupling and Boc deprotection yields the 
primary and tertiary amide derivatives. The synthesis of benzoyl and 
sulfonamide derivatives 346 and 347 is also described below; they are 
synthesized by displacement of benzoyl chloride or sulfonyl chloride 
respectively under basic conditions. The first round SAR results are 
summarized in table 3.7 below. The activity and cytotoxicity are reported as 
the EC50 and CC50 respectively – the concentration of compound giving a 50% 
drop in viral load, and the concentration of compound exhibiting 50% 
cytotoxicity, in comparison with the DMSO negative controls. EC50 values are 
the average of at least 3 results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Analysis of fragments of CT3 
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Figure 3.6 Different techniques employed in the synthesis of CT3 derivatives at R1 
N
Boc
NH
H
O
R
Or H
N
N
ii) 4N HCl/Dioxane
A
B
R1
306
H
N
N
H
O
OH
Oi)
ii)    HNR1R2
HATU, DIPEA, DMF
N
O
R2
R1
iii) 4N HCl/Dioxane R1R2 = H/Me
H
N
N
Cl
O
i)
ii) 4N HCl/Dioxane
DCM, NEt3, RTO
H
N
N S
Si)
ii) 4N HCl/Dioxane
DCM, NEt3, RT
O
O
Cl O
O
O
H Alkyl
i) (CH3COO)3BHNa
DCE, RT, O/N
H
N
N
Br
i)
ii) 4N HCl/Dioxane
K2CO3, THF, 60C
R1
N
Boc
NH2
O
H
(CH3COO)3BHNa
DCE, RT, O/N
N
Boc
NH
306
 
 
 
 
 
 
49 
3.4.1 Ring 1 Substitutions 
 
In general, substitutions of hydrogen with moderately lipophilic, weakly 
electron withdrawing substituents such as halogens had a tendency to improve 
potency; Cl and Br substitutions 308, 309, 314 and 315 (Table 3.1) exemplify 
this. Monosubstitution with Cl at either the ortho, meta or para positions 
improved potency to varying degrees across the board, with the meta position 
314 exhibiting the biggest improvement decreasing the EC50 to 0.45µM. The 
same pattern is observed with Br substitutions 315, 309, and 321 meta gives 
the biggest improvements in potency, followed by para and ortho. Para and 
meta F substitutions 310/316 gave modest increases in potency, as did para 
CF3 311, but substitutions at other positions with these atoms did not improve 
potency. Notably, entry 333, meta-Ph, improved the potency of the compound 
series slightly. The steric bulk of the phenyl ring with retention of potency 
indicates that steric clashes with the binding pocket (which remains unknown) 
likely do not affect decreases in potencies, and that the observed SAR in the 
meta and para positions can be well rationalized based on donation or 
withdrawal of electron density into or out of the benzene ring, as well as 
changes in the lipophilicity of the molecule overall - lipophilicity may be a 
crucial factor since the compounds are assessed in a cell-based assay. 
 
p-CN derivative 328 was found to decrease activity, and so the potency may 
be quite reliant on lipophilicity. Electronically donating substituents methoxy 
and alkyl derivatives almost universally lowered the activity of the molecules. 
Amide derivatives 331, 332, 336, 337, 342 and 343 did not display any 
efficacy at the concentration limits of the assay (35µM), but they also did not 
display any toxicity (up to 100µM), potentially indicating that they were either 
not able to enter the cells, or that some sub-cellular localization of the 
materials was disrupted, again possibly alluding to the importance of 
lipophilicity in this series. Thiophene derivatives 324 and 325, introduced as a 
bioisosteric replacement of a phenyl ring, did not maintain potency.  
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Table 3.7 EC50 and CC50 of 1st round CT3 derivatives at R1 
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Based on these results the binding site appears to favour electron withdrawing 
lipophilic substituents, though there is a possibility of halogen bonding arising 
from the antibonding orbital of the halogen substituents in the meta and para 
positions. Deactivating, electron-withdrawing substituents on the phenyl rings 
resulted in conservative increases in the metabolic half-life of the series, as 
described in table 3.8. The emergent trend is one of steric bulk and 
deactivation of the phenyl ring resulting in a longer half-life, which may be 
expected. The most active analogue at this stage, 314, increased the half-life 
from <1 min to 1.6 min. Though improvements were noted, it was clear that 
this was not the main substituent or area effecting the metabolic lability of the 
compound.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.2 Linker 1 substitutions 
 
Linker modifications from the primary amine in the 4-position of the 
piperidine scaffold to substituent R1 were investigated in an attempt to 
improve the properties of the compound, described in table 3.9. Lengthening 
the carbon chain to two, 344 and three carbons 345, was found to slightly 
improve, and slightly decrease the EC50 respectively; amide and sulfonamide 
modifications 346 and 347 were deleterious - introduction of less lipophilic 
substituents again found to decrease the potency of the molecule, or 
alternatively the lone pair on the nitrogen atom now cannot form a salt at 
physiological pH, affecting the distribution of the molecule in the assay 
environment. Substitution of the R1 side chain for n-alkyl 348 and 349 
decreases potency, however the bioisosteric replacements cyclopentyl and 
cyclohexyl 350, 351 were still efficacious, giving the impression of building 
into a lipophilic pocket as before.  
Table 3.8 Top 10 slowest metabolized compounds from round 1 of synthesis arranged in 
order of decreasing half-life. 
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Again, it is noted that none of these compounds had any particularly 
positive effects on the half-life of the molecule. 
 
  
 
 
 
 
 
 
 
 
 
 
 
3.4.3 Ring 1 disubstituted analogues 
 
Based on the efficacy results at this stage several di-substituted analogues 
were synthesized based on observed trends of the increases in potency in the 
Cl and Br series, as well as the increase in half-life. Results are described in 
table 3.10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.9 Effects of R1 linker modifications on the potency of the series 
Table 3.10 Disubstituted R1 analogues display high potency 
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As hypothesized, the molecules synthesized in table 3.10, 353-363 were 
highly potent against HCV. Particularly noteworthy were compounds 353 and 
354: both compounds retained the meta chloro substituent from the first round 
of SAR, and boast sub-µM EC50’s with a therapeutic index of above 25. Again 
for 354 the half-life was modestly increased from 1.6 min (314) to 2.4 min. 
The 3-chloro 4-bromo substituent of 354 shows increased potency and 
increased half-life while retaining the same therapeutic index as the original 
hit molecule.  
While other compounds did out-perform this molecule at this stage in terms of 
half-life or other singular parameters, on balance it was decided that this was 
the most suitable molecule to take forwards for further modification. 
 
3.4.4 Lipophilicity and met-ID analysis 
 
Analysis of the lipophilicity of the compounds synthesised reveals a trend that 
does not correlate potency with a specific cLogP per se, but does appear to 
suggest a cut-off point after which compounds lose potency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regardless of where the substitutions are in the molecule, potency drops off at 
cLogP values approximately equal to or below 3.2. However, if only potent 
compounds are analysed (EC50 less than 5µM), then there does not seem to be 
any correlation at all with lipophilicity and potency. To expedite the process of 
hit optimization from this point forwards target compounds were only 
considered if they possessed a cLogP ≥ 3.0. 
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Figure 3.11. Analysis of how lipophilicity affects potency, calculated using 
ChemDraw 15 Professional (PerkinElmer Informatics) 
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A metabolite identification study (Met-ID) was performed to establish the 
particular points of metabolic susceptibility in the series. 
 
 
 
 
 
 
 
 
 
Analysis of the microsome supernatant using mass spectrometry reveals major 
fragments corresponding to oxidative cleavage (O) in the benzylic position OA 
as well as oxidative scission of the N-C bond towards ring 1, OB, fig 3.9. This 
leads us to the assumption that by modifying the linker between the central 
piperidine scaffold and ring 2 we may be able to effect metabolic changes in 
the molecule. Thus, several analogues were synthesised with modifications in 
the linker: N to Ring 2, table 3.9. Again, reductive amination of 1-Boc 
piperidine with 4-Cl, 3-Br benzaldehyde gives selectively monoalkylated 363, 
which is used as a common intermediate in the synthesis of analogues. 
 
3.4.5 Linker and ring 2 analogues 
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Figure 3.12 Locations of major metabolic cleavage for the CT3 series 
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Table 3.13 Linker modifications and subsequent effect on metabolic stability 
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Besides the exception of the vicinal cyclobutane derivative 370, modifications 
in this linker region were found to unilaterally increase the metabolic half life 
of the series, notably the introduction of the isopropyl moiety in compound 
366 increased the half life by approximately 10-fold from 2.6 min to 23.2 min. 
The large difference in the half-lives for the cyclobutane derivatives 368 and 
369 is especially noteworthy due to the similar structures. Compound 368 
retains similar potency and toxicity profiles to the original 354 however the 
half-life has been increased from 2.6min to 11mins. 368 has fewer degrees of 
freedom and so may not be able to be accommodated into the CYP active site. 
The retention of potency speaks to the orientation of the phenyl ring in relation 
to the rest of the molecule, especially when comparing the potency of 368 and 
369. 1-3 or 1-2-substitution of the cyclobutane ring produces compounds with 
totally different geometries and this is reflected in the anti-HCV activity. It 
seems apparent that a phenyl group that protrudes away from the central 
scaffolding best serves this area of the molecule in terms of efficacy - this 
would mimic a presumed entropically favoured conformation in 354. Meta- 
and para-Br derivatives 368, 371 and 372 respectively, again benefit from 
increases in metabolic stability, notably molecule 372 displays both the 
highest potency and metabolic half life seen in this series. 
 
3.5 Comparative analysis of 372 and 301 
 
A summary of the hit optimisation thus far is described in fig 3.14. Compared 
to original assay hit 301, compound 372 boasts a ~15 fold increase in potency 
in the cell-based HCVCC assay and although the toxicity of the compound has 
increased, the therapeutic index change is offset by the increase in potency. 
The increased in vitro toxicity is definitely concerning but it is hoped that this 
can be addressed in further rounds of SAR. Compound 372 is slightly more 
lipophilic, though this alone does not significantly impact the molecular 
efficiency indices146 - when studying the ligand efficiency (LE) and binding 
efficiency index (BEI), it can be seen that 372 is significantly more efficient in 
terms of potency per non-H atom (LE, fig 3.14), and also potency per unit 
mass (kDa), even with the increased molecular weight (BEI fig 3.14).76 
Ligand-lipophilicity efficiency (LLE) is a parameter that takes into account 
the lipophilicity of the compound founded on the observations of how 
lipophilicity tends to correlate with non-selective toxicity, and that this should 
factor into drug development when considering moving a compound 
forwards.147 
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The number of rotatable bonds has been decreased from 12 in 301 to 5 in 372 
and as such 372 is more rigid and total hydrogen bond count (HBD+HBA) is 
lower. Rotatable bonds are an important molecular descriptor, correlated 
inversely with increased oral bioavailability independent of molecular weight. 
Increased MW tends to correlate with increased RotB, HBD and HBA by 
virtue of probability.148 
 
Crucially the metabolic half-life (T1/2) has been increased substantially from 2 
min to 28.5 min in 372, this was brought about initially by the finding that the 
cyclobutane linker was more metabolically stable, followed by further 
iterative derivatisation, and this value should be improvable in further rounds 
of modifications. Whether it is the alteration of the electronic/steric nature of 
the linker, or the increased rigidity of the molecule, or some other factor that is 
responsible for the change in metabolic lability is unknown. It may be that the 
less conformationally flexible derivative 372 is not able to accommodate into 
the metabolising enzyme’s active site, as the flexibility of the molecule 
decreases and the equilibrium conformation moves away from what can be 
accommodated by an metabolic enzyme. We see an increase in the T1/2, and 
this entropic cost is paid in synthesis of the molecule and its components. The 
drug is not the molecule as drawn, as a static entity, but a probabilistically 
distributed population of physiologically accessible conformational states. The 
goal here is to try to rigidify into the disease-relevant bioactive confirmations, 
and out of the metabolically labile (i.e. undesirable) conformations, assuming 
that these are not equivalent. It was primarily the increase in metabolic 
stability coupled with the retention of potency that led us to investigate the 
pharmacokinetics of 372 upon administration to mice. 
 
Figure 3.14 Comparison of some key chemical and biological descriptors between the CT3 
original assay hit and the current lead - 372 
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3.6 In vivo, single dose, pharmacokinetics of 372 in CD-1 mice 
 
Compound 372 is a lipophilic molecule and is completely insoluble in water 
so to increase its water solubility it was formulated as the oxalate salt (1:1). 
While the oxalate-372 was also insoluble in water, it was found to be soluble 
in several organic/aqueous formulations, among others a 30% w/v solution of 
hydroxypropyl β-cyclodextrin (HPβCD) solubilized 372 at 2 mg/mL while 
remaining suitable for injection into mice. The material was only sparingly 
soluble in solutions below 30% HPβCD.  
 
 
 
 
 
The compound is solubilized in the vehicle and injected into the mouse 
peritoneum at a dose of 10 mg/kg - equivalent to a 62 mg dose in an average 
human. Following administration, maximum concentration is reached in 0.5 h 
in plasma, and 1 h in the liver. The levels of 372 continue to rise in the brain 
throughout the course of the experiment, whereas liver and plasma samples 
possess similar elimination profiles.  
 
 
The maximum concentration reached in the liver is approximately 100-fold of 
the maximum concentration reached in the plasma and 1000-fold of the in-
vitro EC50 of the drug (Cmax liver and plasma: 112µM and 1.5µM respectively 
EC50 0.13µM). In spite of in vitro CC50 of the molecule, no unusual behaviour 
or obvious toxicity of the mice was noted in the course of experiment. 
Figure 3.14 Plasma, liver and brain concentrations of 372 over a 24-hour time period after 
a single IP administration at 10mpk, average of 3 measurements. 
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The elimination phase of the experiment lasted too long, and the curve profile 
is too shallow, to accurately predict a T1/2 from this experiment alone; the 
experiment should be repeated at a lower dose over a longer period of time in 
order to accurately determine the metabolic T1/2.  
 
Integrating the area under the curve AUC to determine the total exposure of 
material reveals that over 24 hours, compound 372 showed preferential liver 
localisation over plasma by a factor of 76. Considering that the compound is 
being developed as an anti-HCV treatment, extensive liver localisation is a 
favourable property, allowing appropriate therapeutic levels to be reached in 
the target organ with smaller doses of the compound. 
 
3.7 Summary, conclusions, and future work. 
 
A high throughout screen of small molecules yielded several candidates for hit 
optimisation and pre-clinical development. We specifically chose to develop 
candidates that target the entry and assembly stages of the HCV life cycle, 
since replication stage inhibitors are now both less suitable for incorporation 
into combination therapies, and more difficult to bring to market, making them 
less attractive to develop. The selected assembly inhibitor, designated CT3, 
has undergone 5 iterations of chemical modifications totalling 65 derivatives. 
This ultimately resulted in lead compound 372 which boasts approximately 15 
fold increase in efficacy against HCV, more than 10 fold increase in metabolic 
half life and an increase in other molecule efficiency metrics as compared to 
the hit, though this is unfortunately offset by an increase in in-vitro 
cytotoxicity.  
 
At this stage the molecule displays favourable liver distribution in-vivo with a 
long metabolic half-life. It must first be determined whether the half-life 
decreases at a lower dose in order to know how the molecule should be 
chemically modified to correctly tailor the molecule to suit daily dosing. SAR 
profiling should be continued to refine the potency, selectivity, toxicity and 
drug-like properties of the molecule, working towards a proof-of-principle 
study of efficacy in mice 
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Photoaffinity labelling in elucidation of the 
mechanism of action of the HCV entry 
inhibitor Chlorcyclizine 
 
4.1  H1-Antihistamines 
H1-antihistamines are histamine receptor inverse agonists that are specific for 
the H1 receptor (of H1-4) The four receptor subtypes have distinct and discrete 
biological functions with histamine as their endogenous ligand149. They are 
classified as inverse agonists as they stabilize the inactive state of the 
constitutively active histamine G-protein-coupled receptor (GPCR). There are 
over forty 1st and 2nd generation H1 antihistamines available for clinical use. 
2nd generation derivatives were introduced in an attempt to mitigate the CNS 
side effects associated with brain penetration.150  
Antihistamine compounds as inhibitors of HCV 
Recently, our group151 and others152 reported on the anti-HCV efficacy of the 
pre-approved drug chlorcyclizine (CCZ) fig 4.1B. Using a previously 
established high-throughput format HCVcc assay, a screen of the NCGC 
pharmaceutical collection (NPC, 2400 small molecules153) was conducted for 
inhibitors of HCV. From this screen, eighteen anti-histamine compounds with 
diverse structural features were identified as primary hits. In a second 
confirmatory screen against HCV-Luc, fifteen exhibited more than 40% 
inhibition of HCV at 10µM concentration with acceptable toxicity profiles. 
Structures are shown below.  
4 
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The molecules are a mixture of both first and second-generation H1 anti-
histamines the anti-HCV potency of these drugs is not correlated with the 
potency of the compounds towards the histamine receptor, also the racemates 
of these compounds (ex. R/S-CCZ) are just as potent anti-HCV agents as their 
chirally pure counterparts, which is not the case in histamine receptor 
antagonism. Together this suggests that these compounds have a mechanism 
of HCV inhibition that is not related to their anti-histamine properties. In 
terms of structural features, these molecules in general possess 2 phenyl rings, 
or a lipophilic area of equivalent size that are attached via a linker (C, O, N) 
that is then joined by a 2-4 atoms linker unit to a basic amine. These amines 
would be largely protonated under physiological conditions and so these 
molecules would be amphiphilic – a lipophilic section composed of 2 phenyl 
rings (phenothiazine, benzhydryl or isosteres of such) linked to a quaternary 
amine.  
 
 
Structure HCV-Luc % Inh ± SD 
ATPlite 
% Tox ± SD 
A 93.8 ± 2.5 7.4 ± 6.9 
B 91.4 ± 6.4 16.4 ± 7.4 
C 89.5 ± 8.7 14.9 ± 7.9 
D 89.3 ± 7.9 5.3 ± 2.1 
E 73.7 ± 9.6 9.4 ± 6.8 
F 70.8 ± 22.1 5.7 ± 5.4 
G 70.3 ± 16.0 15.7 ± 11.0 
H 68.6 ± 18.0 6.2 ± 6.4 
I 68.0 ± 11.3 0.8 ± 12.4 
J 64.4 ± 21.7 8.5 ± 7.3 
K 55.2 ± 14.4 12.8 ± 3.9 
L 53.9 ± 9.2 7.6 ± 4.5 
M 49.7 ± 16.0 8.0 ± 7.2 
N 46.5 ± 16.3 2.3 ± 6.3 
O 45.5 ± 4.5 2.5 ± 1.9 
Cyclosporin 
A 99.7 ± 0.1 14.2 ± 4.5 
Figure 4.1 Antihistamine derivatives that were found to inhibit HCV 
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Compound 4.1B, the pre-approved first generation H1 antihistamine 
chlorcyclizine (CCZ) displays high anti-HCV activity in vitro with an EC50 of 
44 nM, a very acceptable in vitro cytotoxicity profile (CC50 49.8 µM, 
selectivity index 1132) and importantly is synergistic with currently approved 
HCV therapies154. In the human liver uPA-SCID mouse model of HCV 
infection (immunosuppressed mice engrafted with human hepatocyte that are 
stably infected with HCV genotypes 1b and 2a,) CCZ was shown to reduce 
HCV load to 100 fold of its original concentration over the course of 4 weeks 
of treatment with no emergence of resistance over the administration window.  
Following this proof-of-principle experiment, the CCZ scaffold was selected 
for a hit optimization program to further tailor its pharmacological profile 
towards HCV treatment with the aim of increasing both its anti-HCV potency, 
increase and its metabolic half-life. Also we aimed to reduce its H1 ant-
histamine potency to decrease potential CNS side-effects as noted with 1st 
generation anti-histamines – this could be accomplished by either reducing 
affinity for the H1 receptor or decreasing brain penetration.  
Interesting structure-activity relationships emerged from the hit optimisation 
program155. A broad range of substitutions to the molecule were permitted in 
both the phenyl rings and the piperazine ring that allowed activity to be 
retained, so long as the amphiphilic nature of the molecule was disrupted. A 
summary is described presented in figure 4.2. 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Highlighting key structural differences allowed. Substitutions permitted in A 
were broad in nature so long as the amphiphilic nature of the molecule was maintained. 
Removal of the acidity of the terminal N atom by induction with CF3 or delocalization into 
a ring or amide bond abolished activity. C - Lead compound 401. 
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At the R3 position of the piperazine ring as drawn, H, alkyl substituents, and 
long polyethylene glycol derivatives were allowed and retained potency, fig 
4.2A However conversion of the basic amine to an amide or pyridine, 
substitution with CH2CF3 (Et is highly potent), or removal of the nitrogen 
resulted in a complete loss of activity, fig 4.2B. Interestingly the isosteric 
replacement of the piperazine for a morpholine also completely abolished the 
activity suggesting that it is the ability of the terminal basic amine to become 
protonated at physiological pH that is important for its activity as opposed to 
other physicochemical properties (fig 4.2B, Red). Since the compounds are 
being assessed in a cell based assay, the increase in potency could be derived 
from specific intracellular localization caused by protonation in acidic cellular 
compartments such as mitochondria, lysosomes or other endosomal acidic 
compartments.  
A hit optimisation program yielded a promising lead compound 401, which, 
compared to CCZ, possesses 10-fold greater potency, a longer metabolic half-
life, slightly less brain penetration than CCZ in mice, and an improved 
therapeutic window. Compound 401 was found to have 55% oral 
bioavailability at 10 mg/kg oral dosing in mice. Preferential liver distribution 
was observed over plasma with a 23:1 ratio over the course of 24 hours - fig 
4.3. The half life of the material was approximately 4 hours, with a major 
metabolite being identified as the des-ethyl analogue, which itself is a potent 
inhibitor of HCV. A dosing regimen was simulated based on the collected PK 
data arriving at the conclusion that dosing at 10mg/kg daily would be suitable 
to achieve a steady state concentration over one hundred fold the in-vitro EC50 
even at trough concentrations. 
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Figure 4.3 Single dose pharmacokinetic profile and simulated daily dosing regimen to 
achieve therapeutically relevant concentrations. 
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An IP efficacy study founded on the in-vivo PK data was conducted in the 
uPA-SCID mouse model that found daily IP dosing of 5mg/kg was sufficient 
to achieve a 1-log drop (90% decrease) in viral load over 28 days in 3 out of 4 
mice (1 non-responder, data set 3, fig 4.4) with no emergence of resistance as 
is seen for DAA’s in the same circumstances. Based on the data presented, and 
the fact that 401 is a minor and potentially benign modification of a pre-
approved drug, it is an excellent candidate for further investigation with the 
aim of eventual incorporation into an anti-HCV combination drug regimen. 
Extensive pre-clinical evaluation is currently being pursued. 
 
 
 
 
 
 
 
 
 
4.2 Investigating the mechanism of action of CCZ 
As described in Chapter 1 phenotypic screening does not discriminate based 
on biological or molecular mechanism of action, but solely on the ability of 
the small molecule candidate to affect a biological phenotype in question and 
in our system the read-out was reduced viral infection and replication. This 
has the potential to give rise to leads with broad and esoteric mechanisms of 
action that might not have been considered in a target-based approach 
scenario. We cannot know the mechanistic relationship of small molecule to 
HCV load decrease from the phenotypic assay alone and must either alter the 
small molecule to assess changes in outputs from the system (the phenotypic 
assay), or alter the system to assess the effect on the outcome of treatment. In 
this regard, referring to the latter, there are several cell-based HCV derived 
assays that can be used to probe different stages of the viral life cycle as 
described in detail in Chapter 2. 
Figure 4.4 Decrease in HCV RNA copies during treatment with 401 
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4.1.1 HCV life cycle assays 
Based on its efficacy in the HCVsc and HCVcc assays, and the lack of 
potency observed in the HCVpp and HCV replicon assays, CCZ has been 
determined to act in the early stages of the HCV life cycle – before the 
assembly and replication stages, but without specifically targeting the early 
entry stages of the life cycle (extracellular binding events and particle 
endocytosis) as evidenced by a lack of potency in the HCVpp assays.  Time of 
addition assays show that during synchronous entry, CCZ exhibits it’s 
antiviral effect when administered before, during and up to 1 hour after viral 
entry into the cells - the inhibitory effect is lost when administered after 2 
hours post-entry. This is in contrast to the fusion inhibitor Bafilomycin, which 
only showed significant inhibition when added up to 1.5-2 hours after 
synchronous entry.151 Comparatively, this indicates that CCZ targets the late 
stages of entry into the cell - post viral entry but before replication. 
Convergence on a specific stage of the HCV life cycle gives us useful 
information: how best to optimize the material for optimal distribution, when 
might it be useful in a clinical setting, potential interactions with other drugs – 
positive or negative, but it does not give us a specific mechanism of action, 
and to elucidate this we need to ascertain precisely what CCZ binds to in order 
to exert its effect after it enters liver hepatocytes.  
4.1.2 Target deconvolution approaches 
There are several chemical techniques that can be used to deconvolute and 
resolve target protein identity that rely on the specific interaction of a probe 
molecule with a target of interest. Affinity chromatography is a well known 
technique of isolating purified proteins, and is a also an exploited technique in 
target deconvolution investigations, the modification of a small molecule with 
an affinity purification tag, such as biotin permits specific isolation of 
molecular targets, downstream processing and identification, often by mass 
spectrometry and sequencing. This process is known as affinity labelling.  
A high binding affinity is necessary between the molecular probe and its target 
so that background proteins can be effectively removed during purification 
steps, but the reliance on this can be overcome by utilizing a specific cross-
linking reaction between a modified version of the molecular probe and its 
putative target. For CCZ in particular, it may be expected that its potency 
relies to some extent on favourable localization within the cell, and this as 
well as its lack of numerous strongly coordinating groups (H-bond donors and 
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acceptors) implies that it may not have a very strong binding affinity for its 
target. 
4.1.3 Photoaffinity labelling and purification in target deconvolution 
Photoaffinity labelling involves the use of a photo-cleavable reactive group; 
most widely used examples include diazirines, azides and benzophenones, 
each group with their respective advantages and disadvantages156. Once the 
small molecule of interest is reversibly, transiently associated with its protein 
target the photoreactive group is decomposed using UV light yielding a 
reactive intermediate that will covalently capture the target of interest enabling 
its identification. This approach to target identification requires careful 
planning and execution, but it removes the necessity for a high affinity to the 
target and can also increase specificity. 
4.1.4 Proposed probe molecule for photoaffinity labelling  
Trifluoromethyl diazirines157 represent a small non-intrusive modification to 
the molecule of interest that can be reliably decomposed under UV light. 
Incident UV light promotes the decomposition of the CF3-diazirine to a 
carbene with concomitant loss of N2, the reactive singlet carbene species will 
then insert itself into a nearby molecule. In this manner, attachment of a 
diazirine species to a small molecule drug (SM), fig 4.5 allows the irreversible 
labelling of its target. The combined approach of photoaffinity labelling in 
combination with biotin mediated affinity chromatography has been central to 
the discovery of primary and secondary binding partners for several drugs in 
clinical development.158,159 This methodology was applied to attempt to 
elucidate the mechanism of action of CCZ. 
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Figure 4.5 A - Schematic representation of the photoaffinity crosslinking process involving 
covalently attaching a small molecule probe (SM) to its putative target (insertion into 
amino acids) followed by affinity-based purification. B - decomposition pathways in 
364nM UV light 
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Considering the potential time investment of producing a photoaffinity probe 
it is prudent to first examine the pre-existing SAR of the compound class, so 
as to ascertain which particular probe molecule has the largest chance of 
retaining activity as well as labelling the target protein. 
 
For the CCZ scaffold, substitution of the para positions of the phenyl rings is 
permitted and the molecule retains potency throughout a broad range of 
analogues, even in the case of introduction of a sterically demanding OtBu 
group. This presents an attractive location for the introduction of a diazirine 
moiety due to the fact that some steric bulk is tolerated, whilst also being 
localized in the presumed binding pocket. At the top of the molecule as drawn, 
substitutions of the piperazine ring consisting of long polyethylene glycol 
chains have been shown to improve the potency of the molecule, and so with 
the distance from the presumed binding site of the bulk of the central scaffold, 
this represents an ideal place to attach an affinity handle. Indeed biotinylated 
CCZ has already been demonstrated to potently inhibit HCV replication. The 
long distance from the central scaffold of the molecule serves to minimize 
interactions between the biotin moiety and the binding site, retaining potency, 
and secondly to allow the space required for the streptavidin to bind to the 
biotin during pull-down without steric interference from the target protein.  
 
 
 
 
 
 
 
 
 
4.2 Synthesis of Diazirine-CCZ-Biotin 
Several strategies exist for the synthesis of trifluormethyl diazirine 
containing compounds158. In general, these involve the synthesis of a 
trifluoromethyl phenyl ketone, which is then elaborated to the diazirine in a 
short sequence and so the synthesis of the probe molecule was commenced 
along these lines.  
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Figure 4.6 Highlighting key structural differences allowed. Substitutions permitted in A 
were broad in nature so long as the amphiphilic nature of the molecule was maintained. 
Removal of the acidity of the terminal N atom by induction with CF3 or delocalization into 
a ring or amide bond abolished activity. C – Proposed photoaffinity probe, CCZ-Diazirine-
Biotin. 
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The actual diazirine functional group is often developed in the latter 
stages to avoid chemoselectivity issues. Additionally, late stage addition of the 
Biotin handle allows other late stage functionalization to be introduced if 
necessary for example alkyne derivatives for click chemistry. 
 
Nucleophilic displacement of para-iodo benzaldehyde with para-chloro 
magnesium bromide (fig 4.7) yields secondary alcohol 401 in 91% yield 
following column chromatography. Transformation to the alkyl chloride 402 
with SOCl2 in quantitative yield then permits displacement with Boc-protected 
piperazine affording the central scaffold of CCZ, 403.  
 
403 then undergoes lithium halogen exchange with nBuLi: after quenching 
with ethyl trifluoroacetate, furnishing the trifluoroketone intermediate 404 in 
approximately 40% overall yield from 401. Two equivalents of n-BuLi are 
necessary to prevent poisoning of the lithiated CCZ intermediate, 413, by the 
n-butyl iodide side-product as shown in fig 4.8A. Excess butyllithium can 
intercept the primary alkyl iodide that is formed generating non-reactive by 
products. In a confirmation experiment, following addition of BuLi, 
quenching the reaction mixture with deuterated methanol yields deuterium or 
hydrogen insertion adducts when using 2 or 1 eq. of nBuLi respectively 
(detection by LC/MS) figure 4.8B. Transformation from ketone 404 to 
diazirine 407 proceeds via oxime formation from the ketone using 
hydroxylamine HCl under basic conditions, tosylation of oxime 405 to 406 
with tosyl chloride proceeds smoothly in 72% yield after purification. 
Reaction of the tosylate with LiNH2 in liquid ammonia at -78°C afforded the 
Boc-protected 4-diazirinyl CCZ 407 in 91% from 406. Synthesis of the probe 
molecule is completed by removal of the Boc group in HCl/Dioxane 
generating CCZ-diazirine 408, followed by a thermally driven alkylation with 
tosylated polyethylene glycol derivative 412 to give protected intermediate 
409. 
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Figure 4.7 An 11 linear step synthesis of Diazirine-CCZ-Biotin 
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Subsequent Boc cleavage gave primary amine 410, a useful intermediate for a 
range of probe molecules. Condensation with biotin using HATU finally gives 
CCZ-diazirine-biotin 411, which was purified by reverse phase column 
chromatography, and isolated as a TFA salt in its final form.  The diazirine 
CCZ derivatives appear to be stable to ambient light conditions as are 
generally found in a laboratory, but they decompose quickly upon exposure to 
direct sunlight (as determined by LCMS). Once the diazirine functionality had 
been installed the intermediates/reactions were generally stored/conducted in 
the dark to prevent trace decomposition. 
 
4.3 Biological and chemical characterization of Diazirine-CCZ-Biotin 
Analysis of the anti-HCV activity of these probe molecules shows that 
potency is retained or increased in the HCVcc assay (increased in the case of 
411) as outlined in figure 4.9, without increasing cytotoxicity, indicating that 
they share a mechanism of action with CCZ, fig 4.9. On the basis of these 
results, it was decided to move ahead with 411 as the probe molecule for the 
mechanism of action (MoA) studies.  
Figure 4.8 A - 1 equivalent of n-BuLi leads to substrate degradation through quenching of 
the reactive phenyllithium intermediate, which can be circumvented by employing two 
equivalents of n-BuLi, leading to benign spectator side products. B Evidence that reaction 
failure was due to abstraction from n-butyl iodide from lack of deuterium insertion. 
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The degradation of 408 under UV light is studied to determine the optimal 
length of irradiation time of 411 that can be translated to a live-cell 
environment. 4.5mg of 408 is dissolved in 3mL of water, which is added to a 
watch glass and held under either i) a 4 watt TLC UV lamp at a distance of 
2cm or ii) a 100 watt mercury bulb with a 365nM wavelength bypass filter. At 
predetermined time intervals over the course of 2 hours, 100uL is removed 
and analysed by LC/MS, the decomposition of this material and insertion into 
the solvent is outlined in fig 4.10. Using the 4W TLC lamp diazirine 
activations is slow and is completed between 20 and 50 minutes of exposure. 
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Figure 4.9 Diazirinyl CCZ derivatives retain their potency in the HCVcc assay 
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Also observed are significant amounts of the transiently stable diazo 
rearrangement isomer 408C fig 4.11, indicating less than quantitative 
conversion to 415 in the given time frame. After 50 minutes the diazirine is 
completely depleted as detected by LCMS, however the concentration of 415 
continues to increase, presumably due to slow turnover from 413, fig 4.10. On 
the other hand, decomposition using the 100-watt lamp results in full 
conversion to 415 and complete depletion of the diazirine starting material 
within 5 minutes. The results described were instrumental in the planning of 
the in-vitro crosslinking experiments, as described in the experimental section. 
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Figure 4.10 Conversion of CCZ-Diazirine to the water insertion product 415 as analysed 
by LCMS, a comparative analysis of how the wattage of the UV source affects the rate of 
reaction 
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4.4 In-vitro photoaffinity crosslinking  
In a general experimental protocol investigating the binding partners of 
diazirine-CCZ-biotin, compound 411 is added to a cell culture dish containing 
Huh7.5.1 cells that was seeded 12 hours previously. The experiment is 
incubated for a specified amount of time after which, the experiment is 
irradiated from a few centimetres away, on ice, with the UV light source (4-
watt TLC UV lamp or 100-watt mercury lamp with 365 nM filter) converting 
the CCZ-diazirine to the carbene. The cells are lysed, the lysate is harvested, 
and incubated with streptavidin bound to agarose beads (Pierce™ 
NeutrAvidin™ Agarose, cat no. 29200) to extract biotinylated molecules, 
then the beads are washed with detergents to remove non-specific binding 
proteins. The specifically bound, now purified biotinylated proteins can then 
be eluted using a denaturant buffer of 30mM biotin, 6M urea and 2M thiourea 
in PBS160. The protein samples are resolved via SDS-PAGE and transferred to 
a PVDF membrane, which is probed for biotinylated proteins using 
streptavidin-HRP. The bands are subsequently visualized using a high 
sensitivity chemiluminescent HRP substrate, the blot is analysed to look for 
specific bands in the experimental lanes, in comparison to controls.  
 
4.4.1 Results 
 
Initially experiments were performed using 1-hour incubation times at 1µM 
concentration of 411 and 25 minutes of irradiation using a 4-watt TLC lamp, 
with the time course based on experimental evidence – fig 4.10 the PVDF 
membranes are shown in fig 4.12. 1 µM was chosen as the initial 
concentration, being >3-fold greater than the EC90 of 0.3 µM, which should 
ensure receptor saturation, while being significantly below the CC50 for the 
Figure 4.11 Mechanistic pathways involved decomposition of 408 and rationalization of 
the kinetics of diazirine-CCZ decomposition 
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molecule. Despite the increased intensity of the bands in the experimental lane 
(fig 4.12, lane 4), no specific bands were observed and this result could not be 
replicated. It was hoped that greater crosslinking efficiency could be achieved 
by using a high-powered lamp. A 100-watt mercury lamp utilizing a 365nM 
wavelength bypass filter was shown to completely activate the diazirine within 
5 minutes (fig 4.10). However again in the experimental lane no specific 
crosslinking bands were observed. Incubation of the CCZ diazirine probe with 
the cell lysate followed by irradiation yielded no specific crosslinking. 
Increasing the concentration of the probe from 1 µM to 10 µM (>30 x the 
EC90) in an attempt to further saturate the presumed receptor again resulted in 
no specific crosslinking. Repeating these experiments re-affirmed the lack of 
ability to pull down a putative target (fig 4.12 B Lanes 3 and 4). Analysis of 
the cell culture medium from the cell lysate cross linking experiment reveals 
isolation of a protein with the same molecular weight as albumin, with similar 
decomposition products in western blot (fig 4.12, lane 5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12 A Isolated biotinylated proteins from attempted crosslinking of 411 at 1µM in 
a live cell environment. B Isolated biotinylated proteins from attempted crosslinking of 411 
at 10µM in a cell lysate, and live cell environment. 
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4.5 Analysis and discussion - mechanism of action of CCZ  
The probe that was designed and synthesized was highly potent towards HCV, 
demonstrating that the molecule penetrates the cells, reaches its site of action 
and that it very likely interacts with the same target as CCZ. The compound 
decomposes quickly under 100W UV light and yields only the water insertion 
product in the pilot experiment and so seems a suitable candidate for the 
pulldown assay. Biotinylated BSA is used as a positive control for pulldown at 
a concentration of 2ug/mL, in addition to this, analysis of the cell medium 
from the assay reveals the isolation of a protein with the same molecular 
weight as albumin, demonstrating that the molecule has the ability to bind to 
proteins covalently and be extracted from the experiment.  
 
It could be the case that CCZ does not bind to its receptor in a manner 
that would permit covalent binding. If the diazirine is not located towards the 
pocket being occupied then it could be quenched in the solvent resulting in 
inefficient binding that may not be detected. Secondly, if the pocket for CCZ 
is deep, binding between biotin and streptavidin may be disrupted by steric 
clashes from the protein. This could be remedied by making the linker longer, 
however this would adversely affect the penetration of the compound into the 
cell, and the 5-mer PEG chain is as long or longer than literature examples159. 
However albumin was successfully extracted non-specifically from the culture 
medium. 
 
Alternatively, it could be the case that CCZ does not exert its effect 
through binding to a protein target, but that it binds to lipids or DNA, several 
potential mechanisms are discussed below 
 
4.5.1 CCZ as a lysosomotropic agent 
 
CCZ possesses a weakly basic amine as a part of its piperazine moiety, which 
can become protonated at physiological pH. The non-protonated derivative is 
lipophilic and can presumably diffuse passively thorough lipid bilayers, 
however upon protonation the molecule cannot move through the bilayer. This 
property renders the molecule susceptible to being trapped in acidic sub-
cellular compartments such as lysosomes and mitochondria. Lysosomes utilize 
a proton-pumping V-type ATPase that expends ATP to pump protons into the 
lysosome lumen against a concentration gradient, resulting in an acidic interior 
(approx. pH 4.5-5).123 This effectively traps and concentrates some weakly 
basic drugs in lysosomes and acidic endosomes, molecules that localize in 
lysosomes are known as lysosomotropic.24 
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CCZ has been demonstrated to localise extensively in lysosomes (not shown). 
A fluorescent, cell permeable derivative, BODIPY-CCZ localizes in 
lysosomes as determined by comparison with the lysosome detection reagent 
LysoTracker. Lysosomotropic reagents have been shown to be efficacious 
against HCV24, there are a number of plausible molecular mechanisms 
involving the localization and interactions of small molecules with lipid 
membranes that CCZ could be acting through which are worthy of 
investigation. In this manner, the action of CCZ would have to be specific 
towards HCV, as CCZ does not block the entry of other viruses that share 
similar endocytic pathways for entry 
 
Lysosomotropic drugs raise the internal pH of the lysosomes and acidic 
compartments, the endocytic compartments involved in HCV entry gradually 
become more acidic as the entry pathway progresses from pH 6.0–6.5 in early 
endosomes to pH4.5–5.5 in late endosomes and lysosomes.161 The fusion of 
the HCV with the host membrane post entry has been shown to be pH 
dependant and it is therefore hypothesized that compounds increasing 
lysosomal pH have the opportunity to inhibit host/virus fusion.24  
 
4.5.2 Functional inhibition of acid sphingomyelinase 
As well as being pH dependant, the fusion of HCV (and other enveloped 
flaviviridae family viruses - West Nile, Dengue) is also dependant on the lipid 
compositions of both the viral envelope and the target membrane, particularly 
on the presence of lipids cholesterol and sphingomyelin. Cholesterol and 
cholesterol/sphingomyelin-rich microdomains or ‘lipid rafts’ have been shown 
to be important for efficient host-virus fusion162. Notably CD81 mediated 
Figure 4.13. Acidification of the lysosome traps weakly basic drugs in the lumen 
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entry has been shown to be dependant on the presence of ceramide in 
membranes. CD81 has also been implicated in virus fusion.163  
Ceramide is synthesized from sphingomyelin, by the activity of the enzyme 
acid sphingomyelinase. Functional inhibitors of acid sphingomyelinase 
(FIASMAs) are a class of compounds that inhibit the function of ASM.164,165 
FIASMA is a functional classification, however the compounds all seem to 
have particular structural features in common, they are cationic amphiphiles 
with a lipophilic section and a basic amine that is cationic at the pH of the 
lysosomal lumen. These compounds insert themselves into the inner 
(cytosolic) leaflet of the lipid bilayer with the cationic ammonium species 
protruding into the lumen, and interfere with the electrostatic interactions 
anchoring ASM to the membrane.166 ASM detaches and is hydrolysed in the 
lysosome by lysosomal peptidases, greatly altering the ability of cells to 
regulate lipid homeostasis and the constitution of membranes with respect to 
ceramide and sphingomyelin specifically.  
Several antihistamines have been classified as FIASMAs, (ex. 
hydroxyzine, astemizole, chlorpromazine) and several of the ones that are not 
officially designated as antihistamines, display striking similarities to the class 
in terms of chemical structures. In a high-throughput screen of approved drugs 
against Ebola virus, several of the compounds identified as inhibitors of entry 
were designated as FIASMAs.167 Critically, SAR for the CCZ series displays a 
dependence on the maintenance of the aforementioned FIASMA structural 
features – cationic amphilicity, fig 4.2.  
 
4.5.3 Alteration of membrane fluid dynamics 
Phenothiazines have been shown to inhibit hepatitis C virus entry by 
intercalating into cholesterol rich domains of lipid bilayers and increasing 
membrane fluidity.168 Some phenothiazines possess antihistamine activity and 
were included in the small focus library screen of anti-histamines carried out 
by our group to further identify inhibitors of HCV, table in fig. 4.1 - 10. The 
molecules are purported to inhibit HCV by increasing the fluidity of 
cholesterol rich domains, interfering with cholesterol clustering, and 
essentially effecting HCV fusion by changing the physical and structural 
dynamics of the membrane.169 It was also noted that with the removal of the 
piperazine group from the molecule, potency was reduced, indicating that 
these molecules may possess a similar SAR profile to CCZ.  
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Rigid amphiphilic fusion inhibitors (RAFIs) are another compound class that 
are known to interact with biological membranes and effect membrane and 
lipid dynamics.170 RAFIs are groups of compounds, again classified by 
function, that have the ability to insert themselves into biological membranes, 
changing the curvature and structural dynamics, in doing so altering the ability 
of membranes to reorganize on demand, since membrane curvature is not 
simply a passive consequence of cellular activity and lipid structure, but a 
tightly controlled dynamic system. During the fusion process between the 
HCV envelopes and host membranes a local negative membrane curvature 
develops which can be caused by alterations in lipid or membrane protein 
composition, scaffolding, or folding by actin cytoskeletons.169 RAFIs simply 
promote positive curvature of membranes by possessing a hydrophilic head 
portion larger than a hydrophobic, lipophilic tail section, mimicking 
phospholipids, which forces positive membrane curvature, increasing the 
energy barrier for viral fusion.170 
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4.6 Summary, conclusions, and future work 
 
The H1 anti-histamine 401 and structural analogues have been identified as 
potent inhibitors of the late stages of HCV entry. The compound was 
discovered through a phenotypic high-throughput cell based screen and as 
such the molecular mechanism of action of the drug is not known. In an 
attempt to elucidate the binding partner of CCZ I designed and successfully 
implemented the synthesis of a diazirine based photoaffinity probe. The probe 
retains its anti-HCV properties and conversion occurs smoothly to the carbene 
intermediate occurs smoothly upon exposure to UV light. Despite these 
encouraging properties, I was not able to isolate any specific proteins from 
either live cells or cell lysates on increasing concentrations of the probe 
molecule. While it was the case that the CCZ probe was not shown to isolate 
any specific proteins this does not necessarily imply that CCZ does not exert 
its effect through protein binding – it may be the case that no proteins were 
isolated or detected from the pulldown assay for specific experimental 
reasons. Having said that, there are numerous non-experimental reasons 
protein targets may not be isolated. It is hypothesized therefore, that CCZ 
exerts its effects based on a non-protein target, which is founded principally 
on the atypical patterns observed in the SAR – a wide range of substitutions 
are tolerated so long as the principal structural cationic amphiphilicity of the 
molecule is not compromised. The fact that the only active molecules 
synthesized so far are cationic amphiphiles with no exceptions suggests that 
this is intrinsic to the mechanism. These types of molecules have specific 
intrinsic physiological parameters and biological properties; the modulation of 
these particular biological properties should be investigated for their effect on 
HCV. Future work will focus on pursuing these avenues, for which the biotin-
CCZ-diazirine may still be of use. 
 
This work serves to highlight the advantages and disadvantages of 
phenotypic screening – attractive drug candidates may be discovered but the 
mechanisms by which these drugs act may be convoluted, esoteric and 
difficult to rationalise, considering the breadth of all possible targets and 
mechanisms that could result in inhibition of the orchestra that is HCV 
replication. 
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Conclusion 
 
To address therapeutic need in a continuously developing landscape of niche 
patient cohorts in HCV, we specifically chose to develop candidates that target 
the entry and assembly stages, and host factors of the HCV life cycle, as 
combination of these therapeutics with the current replication stage inhibitors 
will reduce the probability of viral resistant mutations as an intrinsic 
pharmacodynamic property of the therapies, as well as reducing treatment 
duration, and Importantly treatment cost. We leveraged the inherent 
advantages of target and phenotype based drug discovery in a complimentary 
manner. 
 
I developed mechanistic parameters of asymmetric transfer hydrogenation of 
ketones, allowing a short, modular and enantioselective synthesis of MeBmt, 
uncovering important factors and subtleties in how intramolecular hydrogen 
bonding effects and possibly even dictates the reactivity of the material. I 
optimised a novel assembly inhibitor of HCV, CT3, resulting in a lead 
compound 372 which boasts approximately 15 fold increase in efficacy 
against HCV, more than 10 fold increase in metabolic half life and an increase 
in other molecular efficiency metrics as compared to the original hit, which 
culminated in an in-vivo PK study in mice, this investigation is on-going. 
 
5 
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Lastly, I designed and successfully implemented a synthesis of a potent 
photoaffinity probe, designed around the framework of a novel inhibitor of 
HCV entry – chlorcyclizine. The probe was utilized in chemical biology 
experiments in an attempt to understand molecular mechanism of action of 
chlorcyclizine against HCV and while no targets have been identified so far, 
work is on-going, and such probe molecule will undoubtedly be of use in 
several ways depending on which direction this line of enquiry is taken.  
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Experimental Section 
 
 
 1 
All air or moisture sensitive reactions were performed under positive pressure 
of nitrogen with oven-or flame dried glassware where stated. Anhydrous 
solvents were purchased from Sigma-Aldrich (St. Louis, MO). ‘Normal phase 
chromatography’, column chromatography, or gradient column 
chromatography refers to automatic purification using a ‘Tyledyne ISCO 
CombiFlash® Rf+’ system with pre-loaded silica gel ‘Redisep RF flash 
columns’ of an appropriate size. Preparative purification was performed on a 
Waters semi-preparative HPLC system (Waters Corp., Milford, MA). The 
column used was a Phenomenex Luna C18 (5 micron, 30 x 75 mm; 
Phenomenex, Inc., Torrance, CA) at a flow rate of 45.0 mL/min. The mobile 
phase consisted of acetonitrile and water (each containing 0.1% trifluoroacetic 
acid). A gradient of 10% to 50% acetonitrile over 8 min was used during the 
purification. Fraction collection was triggered by UV detection at 220 nM. 
Analytical analysis was performed on an Agilent LC/MS (Agilent 
Technologies, Santa Clara, CA). 
-Method 1: A 7-min gradient of 4% to 100% acetonitrile (containing 0.025% 
trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used 
with an 8-min run time at a flow rate of 1.0 mL/min.  
-Method 2: A 3-min gradient of 4% to 100% acetonitrile (containing 0.025% 
trifluoroacetic acid) in water (containing 0.05% trifluoroacetic acid) was used 
with a 4.5-min run time at a flow rate of 1.0 mL/min.  
Retention time (RT) and m/z for M+1 is reported, occasionally M+Na is 
observed exclusively. 
 A Phenomenex Luna C18 column (3 micron, 3 x 75 mm) was used at a 
temperature of 50 °C. Purity determination was performed using an Agilent 
diode array detector for both Method 1 and Method 2. Mass determination was 
performed using an Agilent 6130 mass spectrometer with electrospray 
ionization in the positive mode. 1H and 13C NMR spectra were recorded on 
Varian 400 MHz spectrometers (Agilent Technologies, Santa Clara, CA). 
Signals are described as singlets (s), doublets (d), triplets (t), quadruplets (q), 
septuplets (sept), doublet of doublets (dd) and doublet of triplets (dt). 
 
 
 
 
  
 
 2 
 
 
 
 
 
Methyl-3-hydroxy-4-methyl-2-(N-methylbenzamido)pent-2-enoate 
(209A)115 
 
Isobutyryl chloride (0.506 mL, 4.83 mmol) was added to a stirred solution of 
methyl N-benzoyl-N-methylglycinate (1.0 g, 4.83 mmol)  and 1-methyl-1H-
imidazole (0.462 mL, 5.79 mmol) in DCM (10mL)  at -45 ˚C under an Ar 
atmosphere, followed by stirring at the same temp. for 10 min. TiCl4 (1.862 
mL, 16.89 mmol)and Hunig's base (3.37 mL, 19.30 mmol) were successively 
added to the mixture, which was stirred at the same temp. for 30 min. The 
mixture was quenched with water (20 ml), which was extracted twice with 
EtOAc. The combined organic phase was washed with water, brine, dried over 
MgSO4 and concentrated. The crude oil was purified by column 
chromatography to yield methyl 4-methyl-2-(N-methylbenzamido)-3-
oxopentanoate, 209 as a white solid (0.575 g, 2.075 mmol, 43 % yield) LCMS 
RT (Method 2) 3.24-3.4 min (m/z  278.1) 1H NMR (400 MHz, CDCl3) δ 12.16 
(d, J = 1.5 Hz, 1H), 7.51 – 7.23 (m, 6H), 3.83 – 3.80 (m, 3H), 3.16 (s, 3H), 
2.81 – 2.70 (m, 1H), 1.11 (d, J = 6.8, 3H), 0.77 (d, J = 6.7, 3H 13C NMR (101 
MHz, CDCl3) δ 180.97, 172.64, 170.86, 136.07, 129.72, 127.92, 126.74, 
108.16, 52.16, 37.32, 29.15, 20.38, 17.72. HRMS (ESI) m/z calcd for [M + H] 
278.1392, found 278.1384.  
 
 
 
 
 
Methyl-2-(((benzyloxy)carbonyl)(methyl)amino)-3-hydroxy-4-methylpent-
2-enoate (209B)  
Following the procedure for preparation of 209A, the condensation of 
isobutyryl chloride (0.442 mL, 4.21 mmol) and methyl N-
((benzyloxy)carbonyl)-N-methylglycinate (1.0 g, 4.21 mmol) catalysed by 1-
methyl-1H-imidazole (0.403 mL, 5.06 mmol), TiCl4 (1.627 mL, 14.75 mmol) 
and diisopropylethylamine (2.94 mL, 16.86 mmol) gives methyl 2-
 3 
(((benzyloxy)carbonyl) (methyl)amino)-4-methyl-3-oxopentanoate (0.492 g, 
1.602 mmol, 38% yield) (209B) as a colourless oil. LCMS RT (Method 2) 
3.64 min (m/z  308.1) 1H NMR (400 MHz, CDCl3) enol (major) reported δ 
12.19 (s, 1H), 7.49 – 7.11 (m, 5H), 5.17 – 5.01 (m, 2H), 3.77 – 3.62 (m, 3H), 
3.03 – 2.95 (m, 3H), 2.84 – 2.75 (m, 1H), 1.13 – 0.97 (m, 6H). 13C NMR (101 
MHz, CDCl3) δ 206.64, 180.66, 171.11, 156.63, 136.69, 128.33, 127.87, 
127.74, 105.57, 67.21, 51.81, 37.72, 29.11, 18.88.  
 
 
 
 
 
Methyl N-benzamidoacetate  
To 2-benzamidoacetic acid (5g, 27.9 mmol) in methanol (140 ml) under 
cooling with an ice bath (0-5˚C) was added thionyl chloride (2.85 ml, 39.1 
mmol) over a period of 2 mins. The mixture was stirred overnight, after which 
time TLC indicated consumption of the starting 2-benzamidoacetic acid. The 
reaction mixture was concentrated under reduced pressure to give the crude 
product, which was taken up in ethyl acetate (100mL), washed extracted with 
sat. NaHCO3 (2x30mL) organics were dried over MgSO4 and dried to give a 
crude white solid which was purified by silica gel column chromatography 
(100% ethyl acetate) affording methyl 2-benzamidoacetate (4.37 g, 22.60 
mmol, 81% yield)  as a white solid. LCMS RT (Method 2) 2.40 min (m/z  
194.0) 1H NMR (400 MHz, CDCl3) δ 7.83 – 7.75 (m, 2H), 7.52 – 7.43 (m, 
1H), 7.44 – 7.34 (m, 2H), 6.87 (s, 1H), 4.20 (d, J = 5.1 Hz, 2H), 3.75 (s, 3H 
13C NMR (101 MHz, CDCl3) δ 170.50, 167.51, 133.62, 131.75, 131.48, 
128.54, 127.06, 77.36, 77.04, 76.72, 52.40, 41.68. HRMS (ESI) m/z calcd for 
[M + H] 194.0812, found 194.0815.  
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Procedure ref: J. Am. Chem. Soc., 2005, 127 (9), pp 2854-2855 
 
Isobutyryl chloride (2.66 mL, 25.4 mmol) was added to a stirred solution of 
methyl 2-benzamidoacetate (4.9g, 25.4 mmol)  and 1-methyl-1H-imidazole 
(2.426 mL, 30.4 mmol) in DCM (50mL)  at -45 ˚C under an N2 atmosphere, 
followed by being stirred at the same temperature for 10 min. TiCl4 (9.79 mL, 
89 mmol) and diisopropylethylamine (17.72 mL, 101 mmol) were 
successively added to the mixture, which was stirred at same temp. for 1hr. 
The mixture was quenched with water (100 ml), which was extracted twice 
with EtOAc. The combined organic phase was washed with water, brine, dried 
over with MgSO4 and concentrated. Purification by gradient normal phase 
chromatography yields methyl 2-benzamido-4-methyl-3-oxopentanoate, 216 
(3.61 g, 13.70 mmol, 54 % yield) as a colourless oil. LCMS RT (Method 2) 
3.14 min (m/z  264.1)  1H NMR (400 MHz, CDCl3) δ 7.86 – 7.79 (m, 2H), 
7.52 – 7.46 (m, 1H), 7.45 – 7.38 (m, 2H), 7.37 – 7.34 (m, 1H), 5.59 (d, J = 6.7 
Hz, 1H), 3.78 (s, 3H), 3.19 – 3.02 (sept, 1H), 1.24 – 1.08 (dd, 6H). 13C NMR 
(101 MHz, CDCl3) δ 205.02, 166.94, 132.98, 132.05, 128.59, 127.23, 61.03, 
53.26, 38.76, 18.81, 17.66. HRMS (ESI) m/z calcd for [M + H] 264.1230, 
found 264.1226.  
 
 
 
 
 
Methyl (2S,3S)-2-benzamido-3-hydroxy-4-methylpentanoate 
Under N2, to a solution of methyl 2-benzamido-4-methyl-3-oxopentanoate (2g, 
7.60 mmol) in DCM (25mL) was added 50mL sodium formate solution (5N) 
followed by TBAI (5.61 g, 15.19 mmol) and pre-activated Ru(p-
cymene)[(S,S)-Ts-DPEN] (226) (0.140 g, 0.228 mmol, 3% loading). After 48 
hours the reaction was added to a seperatory funnel and diluted with EtOAc 
and sat. NaHCO3, organics are removed and aqueous is extracted with twice 
with EtOAc, the crude oil was purified by gradient column chromatography 
yielding (2S,3S)-methyl 2-benzamido-3-hydroxy-4-methylpentanoate, 217 
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(1.794 g, 6.76 mmol, 89% yield), a colourless oil, as an inseperable mixture of 
syn and anti diasteromers (12:87 by NMR). Major isomer (anti) reported: 
LCMS RT (Method 2) 2.89 min (m/z  266.1) 1H NMR (400 MHz, CDCl3) δ 
7.82 – 7.75 (m, 2H), 7.52 – 7.43 (m, 1H), 7.43 – 7.34 (m, 2H), 7.29 – 7.20 (m, 
1H), 4.93 (dd, J = 7.6, 3.4 Hz, 1H), 3.76 (s, 3H), 3.63 – 3.51 (m, 1H), 3.27 (d, 
J = 7.7 Hz, 1H), 1.77 (dsept, J = 8.5, 6.7 Hz, 1H), 0.99 (t, J = 6.5 Hz, 6H). 13C 
NMR (101 MHz, CDCl3) δ 171.37, 167.41, 133.41, 131.91, 128.57, 127.16, 
78.71, 55.80, 52.51, 31.38, 19.08. HRMS (ESI) m/z calcd for [M + H+] 
266.1392, found 266.1327. For copies of HPLC chromatograms – see 
appendix.  
 
 
 
 
Methyl (4S,5R)-5-isopropyl-2-phenyl-4,5-dihydrooxazole-4-carboxylate 
(2S,3S)-methyl 2-benzamido-3-hydroxy-4-methylpentanoate, 217 (1.3g, 4.90 
mmol) dissolved in DCM is added portionwise to thionyl chloride (5mL, 68.5 
mmol)  under an atmosphere of N2 with cooling in an ice bath, the reaction is 
stirred overnight. Excess thionyl chloride is removed under vaccuum. Residue 
is dissolved in EtOAc (50mL), washed with 10% Na2CO3 (3x20mL), washed 
with brine, dried over MgSO4, volatiles are again removed under rotary 
evaporation and the crude is purified by gradient column chromatography to 
yield) Methyl 5-isopropyl-2-phenyl-4,5-dihydrooxazole-4-carboxylate 218 
(1.054 g, 4.26 mmol, 87 % yield), a colourless oil, as a seperable mixture of 
syn and anti diastereomers. Major diastereomer, (4R,5S) reported. LCMS RT 
(Method 2) 3.85 min (m/z  248.1) 1H NMR (400 MHz, CDCl3) δ 8.01 – 7.95 
(m, 2H), 7.53 – 7.44 (m, 1H), 7.44 – 7.35 (m, 2H), 4.66 (dd, J = 6.9, 6.3, Hz, 
1H), 4.55 (d, J = 7.1 Hz, 1H), 3.79 (s, 3H), 2.01 – 1.88 (m, J = 6.7 Hz, 1H), 
1.00 (dd, J = 13.7, 6.7, Hz, 6H).. 13C NMR (101 MHz, CDCl3) δ 172.00, 
165.75, 131.79, 128.52, 128.31, 127.08, 87.20, 71.19, 52.68, 32.40, 17.38, 
17.26. HRMS (ESI) m/z calcd for [M + H] 248.1286, found 248.1284.  
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Literature ref. Deyo, D. T.; Aebi, J. D.; Rich, D. H. Synthesis 1988, 608 
 
To a solution of (E)-2-methylhex-4-enoic acid (rac-206) (2.5 g, 19.51 mmol) 
in DCM was added HATU (8.90 g, 23.41 mmol) and DIPEA (4.09 ml, 23.41 
mmol). After allowing 5 minutes for preactivation, (S)-2-amino-2-
phenylethanol (3.48 g, 25.4 mmol) was added and the reaction was stirred 
overnight. The solvent was removed by rotary evaporation, then the crude was 
dissolved in EtOAc, which was washed with 1N HCl, 1N NaOH and brine. 
Organics were dried over MgSO4, filtered, evaporated and purified by column 
chromatography (30% EtOAc in Hexanes) to yield (E)-N-((S)-2-hydroxy-1-
phenylethyl)-2-methylhex-4-enamide (4.36 g, 17.63 mmol, 90 % yield) as a 
seperable mixture of diastereomers.  
 
(R,E)-N-((S)-2-hydroxy-1-phenylethyl)-2-methylhex-4-enamide - A 
LCMS RT (Method 1) 2.89 min (m/z  248.1) 1H NMR (400 MHz, CDCl3) δ 
7.39 – 7.22 (m, 5H), 6.23 (d, J = 7.1 Hz, 1H), 5.51 – 5.38 (m, 1H), 5.32 (dddd, 
J = 15.1, 6.8, 5.2, 1.5 Hz, 1H), 5.03 (dt, J = 7.1, 4.9 Hz, 1H), 3.84 (td, J = 5.0, 
4.4, 1.4 Hz, 2H), 2.96 – 2.88 (m, 1H), 2.35 – 2.20 (m, 2H), 2.15 – 2.01 (m, 
1H), 1.59 (dq, J = 6.3, 1.2 Hz, 3H), 1.15 (d, J = 6.4 Hz, 3H). 13C NMR (101 
MHz, CDCl3) δ 176.67, 139.03, 128.82, 128.12, 127.79, 127.73, 126.66, 
66.69, 55.72, 41.73, 37.34, 17.90, 17.43. HRMS (ESI) m/z calcd for [M + H] 
248.1645, found 248.1647. 
(S,E)-N-((S)-2-hydroxy-1-phenylethyl)-2-methylhex-4-enamide - B 
LCMS RT (Method 1) 2.89 min (m/z  248.1) 1H NMR (400 MHz, CDCl3) δ 
7.39 – 7.13 (m, 5H), 6.73 (d, J = 7.1 Hz, 1H), 5.51 – 5.27 (m, 2H), 5.01 – 4.86 
(m, 1H), 3.71 (d, J = 5.2 Hz, 2H), 3.49 (s, 1H), 2.24 (h, J = 7.1 Hz, 2H), 2.03 
(q, J = 10.5, 9.4 Hz, 1H), 1.69 – 1.56 (m, 3H), 1.04 (d, J = 6.6 Hz, 3H)  13C 
NMR (101 MHz, CDCl3) δ 176.85, 139.31, 128.64, 128.17, 127.55, 126.62, 
66.11, 55.66, 41.33, 37.18, 17.96, 17.28.  
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(R,E)-2-methylhex-4-enoic acid 
A solution of (R,E)-N-((S)-2-hydroxy-1-phenylethyl)-2-methylhex-4-enamide 
(1g, 4.04 mmol) 
 in 6N H2SO4 in 60mL (H2O/Dioxane) is heated to 80˚C for 3 hours, following 
this the reaction is cooled to room temperature. The reaction is diluted with 
water (50mL) and is extracted with DCM and dried with MgSO4. The volatiles 
are removed under reduced pressure to yield (R,E)-2-methylhex-4-enoic acid 
(0.503 g, 3.92 mmol, 97 % yield) as a transllucent, yellow oil. 
LCMS RT (Method 1) 2.95 min (no m/z in +ve mode) 1H NMR (400 MHz, 
CDCl3) δ 5.59 – 5.43 (m, 1H), 5.43 – 5.31 (m, 1H), 2.48 (h, J = 6.9 Hz, 1H), 
2.43 – 2.30 (m, 1H), 2.19 – 2.05 (m, 1H), 1.69 – 1.60 (m, 3H), 1.15 (dd, J = 
7.0, 0.4 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 182.54, 127.76, 127.49, 
39.52, 36.32, 17.88, 16.22.  
 
 
 
 
Methyl (4R,E)-2-benzamido-4-methyl-3-oxooct-6-enoate 
(R,E)-2-methylhex-4-enoic acid (116mg, 0.905 mmol), methyl 
phenylglycinate (150 mg, 0.905 mmol) and 2,2,2-trichloroacetyl chloride 
(0.122 mL, 1.086 mmol) were dissolved in DCM (1mL). This solution was 
added to anhydrous NaH (26.1 mg, 1.086 mmol) in DCM (1mL) with cooling  
inan ice bath. This reaction was stirred for 15 minutes to allow for activation. 
The reaction was then cooled to -45˚C followed by the addition of 1-methyl-
1H-imidazole (0.087 mL, 1.086 mmol), the reaction was stirred for 10 
minutes. TiCl4 (0.349 mL, 3.17 mmol) and N-ethyl-N-isopropylpropan-2-
amine (0.631 mL, 3.62 mmol) are added sequentially and the subsequent black 
solution is stirred for 30 minutes at -45˚C. The reaction is quenched by the 
addition of 5mL of water, the solution is extracted twice with EtOAc, dried 
over MgSO4 and purified by gradient column chromatography yielding methyl 
(4R,E)-4-methyl-3-oxo-2-(phenylamino)oct-6-enoate (57mg, 0.207 mmol, 
22.87 % yield) LCMS RT (Method 2) 3.38 min (m/z  304.1)  1H NMR (400 
MHz, CDCl3) δ 7.85 – 7.81 (m, 2H), 7.53 (ddd, J = 7.8, 6.2, 1.9 Hz, 1H), 7.49 
– 7.34 (m, 3H), 6.21 (s, 1H), 5.56 (dd, J = 11.0, 6.7 Hz, 1H), 5.45 (dddd, J = 
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13.6, 12.2, 8.4, 6.4, Hz, 1H), 5.38 – 5.19 (m, 1H), 3.81 (dd, J = 6.1, 0.7 Hz, 
3H), 3.18 – 3.05 (m, 1H), 2.45 – 2.31 (m, 1H), 2.21 – 1.99 (m, 1H), 1.60 (dq, J 
= 6.4, 1.9, Hz, 3H), 1.23 – 1.03 (m, 3H)  13C NMR (101 MHz, CDCl3) δ 
204.37, 203.98, 167.35, 166.68, 166.28, 132.29, 128.69, 128.02, 127.28, 
126.65, 62.12, 53.25, 44.16, 36.59, 35.32, 17.85, 16.90, 15.56. 
 
 
 
 
Methyl (2S,3S,4R,E)-2-benzamido-3-hydroxy-4-methyloct-6-enoate 
To a methyl (4R,E)-4-methyl-3-oxo-2-(phenylamino)oct-6-enoate (50mg, 
0.165 mmol) under N2 was added degassed DCM (1.7mL), (R,R)- 
RuTethTsDPEN (9.62 mg, 0.016 mmol) followed by TBAI (122 mg, 0.330 
mmol) and 1.7mL of a 5N solution of HCO2Na in H2O. The reaction is stirred 
at 1400RPM for 48 hours. Following complete consumption of the starting 
material, the reaction is diluted with 3mL of sat.NaHCO3, which is extracted 
with 2x3mL of EtOAc. The organics are combined, dried over MgSO4 and 
purified by gradient column chromatography to yield                  methyl 
(2S,3S,4R,E)-2-benzamido-3-hydroxy-4-methyloct-6-enoate (36.7 mg, 0.120 
mmol, 73 % yield) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 7.84 – 
7.76 (m, 2H), 7.56 – 7.48 (m, 1H), 7.44 (ddt, J = 8.2, 6.6, 1.3 Hz, 2H), 7.00 (d, 
J = 7.9 Hz, 1H), 5.54 – 5.30 (m, 2H), 4.96 (dd, J = 7.8, 4.8 Hz, 1H), 3.79 (s, 
3H), 3.79 – 3.73 (m, 1H), 2.81 (s, 1H), 2.19 (dddd, J = 13.3, 5.4, 3.9, 2.6 Hz, 
1H), 2.00 – 1.88 (m, 1H), 1.65 (dq, J = 6.3, 1.2 Hz, 3H), 0.98 (d, J = 6.7 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 171.77, 167.31, 133.42, 131.97, 128.63, 
128.33, 127.42, 127.13, 76.04, 55.67, 52.60, 36.55, 35.99, 17.96, 14.50.HRMS 
(ESI) m/z calcd for [M + H] 306.1705, found 306.1706. IR (neat)3357, 2957, 
1735, 1640, 1526. 
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1-(1H-benzo[d][1,2,3]triazol-1-yl)-2-methylpropan-1-one 
 
Prcedure ref. Katritzky, A. R.; Kirichenko, B. V. Synthesis, 2003, 2777-2780 
 
SOCl2 (1.823 ml, 24.97 mmol) was added to a stirred solution of 1H-
benzo[d][1,2,3]triazole (10.82 g, 91 mmol)  in DCM (114 ml). Stirring was 
continued for 30 min. isobutyric acid (2.062 ml, 22.70 mmol)was added to the 
reaction mixture and stirring was continued for another 16 h. The white 
precipitate was filtered off and washed with CH2Cl2. The combined DCM 
filtrate was washed with 1N NaOH aqueous solution, extracted with sat. 
NaCl(aq), dried over MgSO4, and concentrated to give a yellow oil. The 
product was purified by gradient column chromatography 5-10% etoac/hex to 
yield 1-(1H-benzo[d][1,2,3]triazol-1-yl)-2-methylpropan-1-one (3.741 g, 
19.77 mmol, 87 % yield) as a pale, straw coloured, free flowing oil. LCMS RT 
(Method 2) 3.50 min (no m/z in +ve mode) 1H NMR (400 MHz, CDCl3) δ 
8.28 (d, J = 8.3 Hz, 1H), 8.10 (d, J = 8.3 Hz, 1H), 7.63 (t, J = 7.7 Hz, 1H), 
7.48 (t, J = 7.7 Hz, 1H), 4.14 (hept, J = 6.9 Hz, 1H), 1.41 (s, 3H) 13C NMR 
(101 MHz, CDCl3) δ 176.59, 146.12, 131.27, 130.28, 126.01, 120.04, 114.54, 
77.32, 77.20, 77.00, 76.68, 33.96, 19.07. 
 
 
 
 
 
S-phenyl 2-(N-methylbenzamido)ethanethioate  
Procedure ref. Synthesis 2002, No. 8, 1121–1123 
An oven-dried round-bottomed flask was equipped with a magnetic stirring 
bar. The flask was charged with N-benzoyl-N-methylglycine (3g, 15.53 mmol) 
and anhydrous DCM (31.1 ml, 0.5M) with cooling in an icewater bath. To the 
flask were added successively isobutyl chloroformate (2.333 g, 17.08 mmol) 
and triethylamine (1.571 g, 15.53 mmol), which was allowed 10mins for 
activation. Following this, benzenethiol (3.76 g, 34.2 mmol) and a second 
equivalent of triethylamine (1.571 g, 15.53 mmol) were added and the reaction 
was allowed to warm to room temperature and stirred for 4 hours. The reaction 
is diluted with Et2O (30mL) to facilitate precipitation of triethylamine HCl, 
the salt is filtered off and the filter cake is washed with Et2O, (50mL). The 
combined organics are reduced on a rotary evaporator. The residue is taken up 
in EtOAc, and washed with 1N HCl, 1N NaOH, and brine. Organics are then 
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dried over MgSO4, and concentrated by rotary evaporation. The crude 
material is purified by gradient column chromatography to yield. S-phenyl 2-
(N-methylbenzamido)ethanethioate (3.54 g, 12.42 mmol, 80 % yield) as a 
colourless oil, which eventually solidified on standing. LCMS RT (Method 1) 
1H NMR (400 MHz, CDCl3) (Rotamers) δ 7.73 – 7.31 (m, 10H), 4.55 (s, 
1.4H), 4.24 (s, 0.6 H), 3.13 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 194.86, 
171.97, 135.18, 134.76, 130.02, 129.67, 129.34, 128.48, 127.07, 57.02, 39.14. 
HRMS (ESI) m/z calcd for [M + Na] 308.0716 , found 308.0720.  
 
 
 
 
S-phenyl 2-(((benzyloxy)carbonyl)(methyl)amino)ethanethioate 
Following the procedure above, 2-(((benzyloxy)carbonyl)(methyl)amino) 
acetic acid (5g, 22.40 mmol) was transformed into its derived phenyl thioester 
with isobutyl chloroformate (3.22 ml, 24.64 mmol) benzenethiol (5.03 ml, 
49.3 mmol) and triethylamine (6.24 ml, 44.8 mmol). Following aqueous work-
up the material was purified by gradient column chromatography (10-30% 
EtOAc in hexanes) to yield S-phenyl 2-
(((benzyloxy)carbonyl)(methyl)amino)ethanethioate (6.27g, 19.88 mmol, 89 
% yield) as a colourless oil. LCMS RT (Method 2) 3.57 min (m/z  316.1) 1H 
NMR (400 MHz, CDCl3) δ 7.46 – 7.26 (m, 9H), 5.19 (d, J = 6.9 Hz, 2H), 4.29 
(s, 1H), 4.20 (s, 1H), 3.09 (d, J = 13.5 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 
196.04, 195.74, 156.59, 155.76, 136.36, 136.25, 134.70, 134.61, 129.58, 
129.55, 129.27, 128.50, 128.11, 128.01, 127.86, 126.52, 77.33, 77.01, 76.70, 
67.77, 67.73, 58.65, 58.47, 36.58, 35.81. HRMS (ESI) m/z calcd for [M + H] 
316.1002, found 316.1013.  
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S-phenyl2-((((9H-fluoren-9 yl)methoxy)carbonyl)(methyl)amino)ethane 
thioate 
Following the procedure for above, 2-((((9H-fluoren-9-
yl)methoxy)carbonyl)(methyl)amino)acetic acid (5g, 16.06 mmol) was 
transformed into its derived phenyl thioester with isobutyl carbonochloridate 
(2.309 ml, 17.67 mmol) benzenethiol (3.60 ml, 35.3 mmol) and triethylamine 
(4.48 ml, 32.1 mmol). Following aqueous work-up the material was purified 
by gradient column chromatography (0-30% EtOAc in hexanes) to yield S-
phenyl 2-(((benzyloxy)carbonyl)(methyl)amino)ethanethioate (6.27g, 19.88 
mmol, 89 % yield) as a colourless oil. S-phenyl 2-((((9H-fluoren-
9yl)methoxy)carbonyl)(methyl)amino) ethanethioate (1.07 g, 2.65 mmol, 17 
% yield) LCMS RT (Method 1) 3.83 min (m/z  404.1 (M+H), 426.1 (M+Na) 
1H NMR (400 MHz, CDCl3) δ 7.76 (dd, J = 7.7, 3.0 Hz, 2H), 7.60 (dd, J = 
18.7, 7.5 Hz, 2H), 7.44 – 7.24 (m, 8H), 4.53 – 4.44 (m, 2H), 4.29 (s, 1H), 4.34 
– 4.21 (m, 1H), 4.16 (s, 1H), 3.08 (d, J = 1.9 Hz, 3H), 1.55 (s, 1H). 13C NMR 
(101 MHz, CDCl3) δ 143.81, 141.31, 134.70, 134.60, 129.57, 129.27, 127.71, 
127.08, 125.01, 124.93, 119.99, 77.31, 76.99, 76.67, 68.05, 58.61, 58.35, 
47.23, 36.50, 35.81. HRMS (ESI) m/z calcd for [M + H] 404.1315, found 
404.1298. IR (neat) 3059, 2925, 1694, 1633, 1383 
 
 
 
 
S-phenyl 4-methyl-2-(N-methylbenzamido)-3-oxopentanethioate 
Under N2 with cooling in an ice-bath, magnesium bromide diethyl etherate 
(1.27 g, 4.91 mmol) was added to a stirred solution of1-(1H-
benzo[d][1,2,3]triazol-1-yl)-2-methylpropan-1-one (265 mg, 1.402 mmol) in  
DCM (6ml), which is followed by the addition of S-phenyl 2-(N-
methylbenzamido)ethanethioate (400mg, 1.402 mmol)  and hunig's base 
(0.979 ml, 5.61 mmol). The ice-bath was removed and the reaction is allowd 
to warm to ambient temperature, the reaction was left to stir overnight (18h).  
upon completion, the reaction is cooled back down to 0-5˚C, then 10% 
aqueous HCl (8 mL) was added dropwise. Stirring was continued for 5 min 
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and the mixture was partitioned between EtOAc (30 mL) and H2O (20 mL). 
The aqueous phase was extracted with EtOAc (2 x 20 mL) and the combined 
organic extracts were washed with brine, dried over MgSO4, and evaporated 
to give a cloudy oil. This was purified by gradient column chromatography to 
give S-phenyl 4-methyl-2-(N-methylbenzamido)-3-oxopentanethioate (379 
mg, 1.065 mmol, 76 % yield) as a colourless oil which solidifies upon 
standing.  
 LCMS RT (Method 1) 3.64 min (m/z  356.0)  1H NMR (400 MHz, CDCl3) 
(Mixture of rotamers and tautomers, major product reported) δ 12.79 (d, J = 
1.5 Hz, 1H), 7.69 – 7.57 (m, 2H), 7.46 (s, 5H), 7.43 – 7.30 (m, 3H), 3.37 (s, 
3H), 2.54 (heptd, J = 6.5, 1.8 Hz, 1H), 1.14 (d, J = 6.8 Hz, 3H), 0.69 (d, J = 
6.7 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 195.17, 180.01, 172.73, 135.36, 
135.19, 135.06, 130.23, 129.89, 129.35, 129.20, 128.53, 127.93, 127.52, 
126.87, 126.43, 116.65, 41.35, 38.66, 36.61, 30.26, 29.90, 29.68, 24.66, 20.54, 
19.36, 19.23, 17.60. HRMS (ESI) m/z calcd for [M + H] 356.1320, found 
356.1437 
 
 
 
 
S-phenyl 2-(((benzyloxy)carbonyl)(methyl)amino)-4-methyl-3-
oxopentanethioate 
According the the procedure of above-(1H-benzo[d][1,2,3]triazol-1-yl)-2-
methylpropan-1-one (1.143 g, 6.04 mmol  was coupled to S-phenyl 2-
(((benzyloxy)carbonyl)(methyl)amino)ethanethioate (2g, 6.34 mmol) using 
magnesium bromide diethyl etherate (5.46 g, 21.14 mmol)) and hunig's base 
(4.22 ml, 24.16 mmol) in DCM (24.16 ml), which, following purification by 
gradient column chromatography (15-30%), affords S-phenyl 2-
(((benzyloxy)carbonyl)(methyl)amino)-4-methyl-3-oxopentanethioate (2.165 
g, 5.62 mmol, 93 % yield) as a colourless, mobile oil. Rotameric, keto enol. 1H 
NMR (400 MHz, CDCl3) δ 12.89 – 12.74 (m, 1H), 7.53 – 7.21 (m, 10H), 5.29 
– 5.13 (m, 2H), 3.25 – 3.20 (m, 3H), 2.62 (ttd, J = 8.3, 6.5, 1.5 Hz, 1H), 1.08 
(dd, J =6.8, 0.7 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 195.00, 194.65, 
180.38, 179.41, 156.27, 136.34, 135.24, 135.12, 129.63, 129.58, 129.17, 
129.13, 128.49, 128.40, 128.12, 128.07, 128.05, 127.90, 126.84, 126.76, 
114.04, 67.89, 67.78, 38.36, 38.09, 30.07, 29.85, 19.31, 18.98, 18.69. [M + 
H+]; HRMS (ESI) m/z calcd for [M + H] 386.1421, found 386.1427. IR (neat) 
2967, 1706, 1607, 1454, 1327. 
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S-phenyl 2-((((9H-fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-4-
methyl-3-oxopentanethioate 
According the the procedure above 1-(1H-benzo[d][1,2,3]triazol-1-yl)-2-
methylpropan-1-one (1.117 g, 5.90 mmol) S-phenyl 2-((((9H-fluoren-9-
yl)methoxy)carbonyl)(methyl)amino)ethanethioate (2.5 g, 6.20 mmol) using 
magnesium bromide diethyl etherate (4.57 g, 17.70 mmol) and hunig's (4.12 
ml, 23.60 mmol)  in DCM (23 ml), which, following purification by gradient 
column chromatography (0-30%), S-phenyl 2-((((9H-fluoren-9-
yl)methoxy)carbonyl)(methyl)amino)-4-methyl-3-oxopentanethioate (570mg, 
1.204 mmol, 20 % yield) as a colourless, mobile oil. Rotameric, keto enol. 
LCMS RT (Method 2) 4.0 min (m/z  474.7) 1H NMR (400 MHz, CDCl3) δ 
12.85 (d, J = 1.5 Hz, 1H), 7.81 – 7.71 (m, 2H), 7.65 – 7.49 (m, 2H), 7.46 – 
7.30 (m, 7H), 7.28 – 7.21 (m, 2H), 4.51 (dd, J = 10.3, 7.4 Hz, 1H), 4.31 (dd, J 
= 10.4, 7.2 Hz, 1H), 4.19 (t, J = 7.3 Hz, 1H), 3.16 (s, 3H), 2.67 (sep, J = 6.8, 
1.5 Hz, 1H), 1.10 (dd, J = 6.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 195.09, 
179.62, 156.34, 143.69, 143.64, 141.26, 141.23, 135.23, 135.16, 129.67, 
129.14, 129.13.  
 
 
 
 
N-methyl-N-(4-methyl-1,3-dioxo-1-(phenylamino)pentan-2-yl)benzamide 
(2,2,2-trifluoroacetyl)silver (63.4 mg, 0.309 mmol) was added to a stirring 
solution of S-phenyl 4-methyl-2-(N-methylbenzamido)-3-oxopentanethioate 
(100mg, 0.281 mmol) and aniline (31.4 mg, 0.338 mmol) in THF (2.010 mL). 
EtOAc (20 mL) was added and the mixture was passed through a pad of celite 
with was washed with EtOAc. The filtrate was concentrated followed by 
purification by flash chromatography over silica gel affording (15-35% 
EtOAc/Hexanes affords. N-methyl-N-(4-methyl-1,3-dioxo-1-
(phenylamino)pentan-2-yl)benzamide (89 mg, 0.264 mmol, 94 % yield) as a 
pale yellow oil. Rotameric, keto/enol. LCMS RT (Method 1) 3.49 min (m/z  
339.1) 1H NMR (400 MHz, CDCl3) δ 14.07 (s, 1H), 9.72 (keto, s, 0.3H) 8.41 
(s, 1H), 7.63 (d, J = 8.6 Hz, 2H), 7.48 – 7.30 (m, 6H), 7.21 (dd, J = 12.9, 7.3 
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Hz, 2H), 5.55 (keto, s, 0.3H) 3.20 (s, 3H), 3.11 (s, 1H), 2.47 – 2.33 (m, 1H), 
1.09 (d, J = 6.8 Hz, 3H), 0.50 (d, J = 6.7 Hz, 3H). 13C NMR (101 MHz, 
CDCl3) δ 180.04, 173.32, 168.77, 136.91, 134.49, 130.56, 130.52, 129.07, 
129.01, 128.48, 128.04, 127.46, 125.10, 121.31, 119.99, 109.05, 38.07, 29.36, 
20.51, 17.64. [M + H+]; HRMS (ESI) m/z calcd for [M + H] 339.1703, found 
339.1712.  
 
 
 
 
Benzyl methyl(4-methyl-1,3-dioxo-1-(phenylamino)pentan-2-yl)carbamate 
Following the procedure above amide formation with S-phenyl 2-
(((benzyloxy)carbonyl) (methyl)amino)-4-methyl-3-oxopentanethioate 
(370mg, 0.960 mmol) in THF (6.4 ml) with aniline (134 mg, 1.440 mmol) and 
silver trifluoroacetate (276 mg, 1.248 mmol) afford  benzyl methyl(4-methyl-
1,3-dioxo-1-(phenylamino)pentan-2-yl)carbamate (325 mg, 0.883 mmol, 92 % 
yield). Rotameric, keto/enol LCMS RT (Method 2) 3.61, 3.78 min (m/z  
369.2)  1H NMR (400 MHz, CDCl3) δ 14.01 (d, J = 1.4 Hz, 1H), 7.70 – 6.96 
(m, 11H), 5.31 – 4.98 (m, 2H), 3.13 (s, 3H), 2.55 (sept, J = 7.0, 6.4 Hz, 1H), 
1.06 (dd, J = 66.1, 6.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 169.10, 
158.45, 137.21, 129.00, 128.60, 128.24, 127.77, 124.71, 120.06, 75.21, 68.15, 
60.71, 33.12, 30.22, 19.49, 17.87. HRMS (ESI) m/z calcd for [M + H] 
369.1814, found 369.1810. IR (neat) 3331, 2974, 1686, 16223, 1596, 1532 
1310. 
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(9H-fluoren-9-yl)methylmethyl(4-methyl-1,3-dioxo-1-
(phenylamino)pentan-2-yl)carbamate 
Following the procedure above, amide formation with S-phenyl 2-((((9H-
fluoren-9-yl)methoxy)carbonyl)(methyl)amino)-4-methyl-3-oxopentanethioate 
(370mg, 0.781 mmol)  in THF (5.2mL) with aniline (109 mg, 1.172 mmol) 
and silver trifluoroacetate (224 mg, 1.016 mmol) affords (9H-fluoren-9-
yl)methyl methyl(4-methyl-1,3-dioxo-1-(phenylamino)pentan-2-yl)carbamate 
(193 mg, 0.422 mmol, 54 % yield). Rotameric, keto/enol. LCMS RT (Method 
1) 3.85, 4.01 min (m/z  457.2) 1H NMR (400 MHz, CDCl3) δ 14.23 (s, 1H), 
7.80 – 7.70 (m, 1H), 7.69 – 7.60 (m, 2H), 7.56 – 7.45 (m, 2H), 7.45 – 7.40 (m, 
1H), 7.39 – 7.32 (m, 3H), 7.31 – 7.22 (m, 2H), 7.22 – 7.10 (m, 2H), 7.06 (t, J 
= 7.5 Hz, 1H), 4.55 – 4.34 (m, 1H), 4.28 (d, J = 7.3 Hz, 2H), 3.12 (d, J = 29.3 
Hz, 3H), 2.68 – 2.53 (m, 1H), 1.17 (d, J = 6.7 Hz, 3H), 1.02 (d, J = 6.8 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 180.16, 168.61, 156.94, 143.55, 142.87, 
141.11, 136.76, 129.01, 128.96, 127.76, 127.71, 127.12, 127.08, 125.03, 
124.88, 124.82, 121.16, 120.18, 119.94, 119.90, 47.14, 46.78, 38.00, 36.63, 
29.64, 24.68, 23.37, 19.67, 18.87. [M + H+]; HRMS (ESI) m/z calcd for [M + 
H] 457.2122, found 456.2122.  
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Benzyl ((2S,3R)-3-hydroxy-4-methyl-1-oxo-1-(phenylamino)pentan-2-
yl)(methyl)carbamate – 221. 
To benzyl methyl(4-methyl-1,3-dioxo-1-(phenylamino)pentan-2-yl)carbamate 
(50mg, 0.136 mmol)) under N2 was added degassed DCM (1.75mL), [(R,R)-
Teth-TsDpen Ru] (7.92 mg, 0.014 mmol followed by TBAI (122 mg, 0.330 
mmol) and 1.7mL of a 5N solution of HCO2Na in H2O. The reaction is sealed 
and stirred at 1400RPM for 48 hours. Following complete consumption of the 
starting material, the reaction is diluted with 3mL of sat.NaHCO3, which is 
extracted with 2x3mL of EtOAc. The organics are combined, dried over 
MgSO4 and purified by gradient column chromatography to yield                  
methyl benzyl ((2S,3R)-3-hydroxy-4-methyl-1-oxo-1-(phenylamino)pentan-2-
yl)(methyl)carbamate (32.2 mg, 0.087 mmol, 64 % yield) as a white solid. 
LCMS RT (Method 1) 3.38 min (m/z  371.1) 1H NMR (400 MHz, CDCl3) δ 
8.20 (s, 1H), 7.43 (d, J = 7.6 Hz, 2H), 7.40 – 7.26 (m, 7H), 7.14 – 7.09 (m, 
1H), 5.27 – 5.14 (m, 2H), 4.79 – 4.70 (m, 1H), 3.99 – 3.91 (m, 1H), 3.56 (d, J 
= 4.4 Hz, 1H), 3.13 (s, 3H), 1.81 (h, J = 6.7 Hz, 1H), 0.99 (dd, J = 35.7, 6.7 
Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 169.10, 158.45, 129.00, 128.60, 
128.24, 127.77, 124.71, 120.06, 77.00, 75.21, 68.15, 30.22, 19.49, 17.87. ) 
HRMS (ESI) m/z calcd for [M + H] 371.1965, found 371.1963. IR (neat) 
3313, 2934, 1666, 1599, 1532, 1441. See appendix (A5) for crystal structure 
analysis. Chiral HPLC CHIRALPAK AD (4.6 x 250 mm, 5 uM) Mobile 
Phase: Methanol/ Diethylamine 100:0.01 Flow rate: 1.0 mL/min. peak area:  
(2R,3S) : (2S,3R) : (2S,3S) : (2R,3R) 1.8 : 97.9 : 0.3 : 0. 
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(9H-fluoren-9-yl)methyl((2S,3R)-3-hydroxy-4-methyl-1-oxo-1-
(phenylamino)pentan-2-yl)(methyl) carbamate. 
Following an analagous procedure for 221 above, (9H-fluoren-9-
yl)methylmethyl(4-methyl-1,3-dioxo-1-(phenylamino)pentan-2-yl)carbamate 
undergoes transferhydrogenation to yield (9H-fluoren-9-yl)methyl((2S,3R)-3-
hydroxy-4-methyl-1-oxo-1-(phenylamino)pentan-2-yl)(methyl) carbamate as a 
white solid. LCMS RT (Method 2) 3.77 min (m/z  459.2) 1H NMR (400 MHz, 
CDCl3) δ 8.19 (s, 1H), 7.75 (dd, J = 7.5, 4.9 Hz, 2H), 7.57 (dd, J = 7.6, 4.0 Hz, 
2H), 7.47 (d, J = 8.0 Hz, 2H), 7.39 – 7.24 (m, 6H), 7.13 (t, J = 7.4 Hz, 1H), 
4.68 (d, J = 5.5 Hz, 1H), 4.52 (qd, J = 10.8, 6.8 Hz, 2H), 4.26 (t, J = 6.7 Hz, 
1H), 3.95 (d, J = 5.3 Hz, 1H), 3.06 (s, 3H), 1.77 (q, J = 6.8 Hz, 1H), 1.03 (d, J 
= 6.7 Hz, 3H), 0.94 (d, J = 6.7 Hz, 3H).13C NMR (101 MHz, CDCl3) δ 168.94, 
158.30, 143.69, 143.44, 141.36, 137.22, 128.99, 127.83, 127.08, 124.82, 
120.25, 120.03, 75.17, 68.11, 47.25, 36.61, 30.21, 24.66, 23.33, 19.56, 17.77. 
HRMS (ESI) m/z calcd for [M + H] 459.2278, found 459.2288. Chiral HPLC 
dr > 95:5, er > 99:1 
 
 
 
 
N-((2S,3R)-3-hydroxy-4-methyl-1-oxo-1-(phenylamino)pentan-2-yl)-N-
methylbenzamide 
Following an analagous procedure for 221 above, N-methyl-N-(4-methyl-1,3-
dioxo-1-(phenylamino)pentan-2-yl)benzamide undergoes transfer 
hydrogenation to N-((2S,3R)-3-hydroxy-4-methyl-1-oxo-1-
(phenylamino)pentan-2-yl)-N-methylbenzamide as a white solidLCMS RT 
(Method 2) 3.18 min (m/z  341.1). 1H NMR (400 MHz, CDCl3) δ 8.87 (s, 1H), 
7.53 (dd, J = 15.0, 8.0 Hz, 4H), 7.45 (p, J = 6.6 Hz, 3H), 7.34 (t, J = 7.8 Hz, 
2H), 7.13 (t, J = 7.4 Hz, 1H), 5.17 (d, J = 4.8 Hz, 1H), 4.06 – 3.99 (m, 1H), 
3.16 (s, 3H), 1.96 (dq, J = 13.3, 6.6 Hz, 1H), 1.12 (d, J = 6.6 Hz, 3H), 0.99 (d, 
J = 6.8 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 178.65, 174.00, 137.42, 
130.87, 129.06, 128.57, 127.88, 124.66, 120.07, 75.61, 74.03, 30.56, 19.34, 
18.26. 
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1H NMR (400 MHz, Deuterium Oxide) δ 3.73 (dd, J = 7.1, 5.0 Hz, 1H), 3.60 
(d, J = 7.1 Hz, 1H), 2.79 – 2.74 (m, 4H), 1.85 (tdd, J = 13.1, 6.7, 1.6 Hz, 1H), 
1.00 (dd, J = 6.8, 4.9 Hz, 6H). 13C NMR (101 MHz, cd3od) δ 169.88, 73.44, 
65.79, 31.18, 30.98, 17.46, 14.10. 
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SOCl2 (157 µl, 2.146 mmol) was added to a stirring solution of 1H-
benzo[d][1,2,3]triazole (929 mg, 7.80 mmol) in DCM (9mL), in one portion at 
room temperature. Stirring was continued for 30 min. (R,E)-2-methylhex-4-
enoic acid (250mg, 1.951 mmol) in DCM (1mL) was added to the reaction 
mixture, followed by almost immediate precipitation of 1H-
benzo[d][1,2,3]triazole HCl. Reaction mixture is agitated to continue stirring. 
Stirring is continued overnight. The white precipitate was filtered off and 
washed with DCM. The combined DCM filtrate was evaporated and the crude 
slurry was purified by column chromatography (100% DCM) to yield (R,E)-1-
(1H-benzo[d][1,2,3]triazol-1-yl)-2-methylhex-4-en-1-one (422mg, 1.841 
mmol, 94 %).  αD20 – 64.5 (c 1.00, CHCl3) LCMS RT (Method 1) 3.68 min 
(m/z  230.1) 1H NMR (400 MHz, CDCl3) δ 8.29 (dt, J = 8.3, 1.0 Hz, 1H), 8.11 
(dt, J = 8.3, 1.0 Hz, 1H), 7.64 (ddd, J = 8.3, 7.1, 1.0 Hz, 1H), 7.49 (ddd, J = 
8.2, 7.1, 1.1 Hz, 1H), 5.57 – 5.37 (m, 2H), 4.13 (h, J = 6.9 Hz, 1H), 2.68 – 
2.55 (m, 1H), 2.41 – 2.29 (m, 1H), 1.61 – 1.54 (m, 3H), 1.38 (d, J = 6.9 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 175.80, 146.17, 131.21, 130.27, 128.34, 
127.00, 126.03, 120.05, 114.57, 39.35, 36.54, 17.85, 16.78.  
 
 
 
 
 
S-phenyl (4R,E)-2-(((benzyloxy)carbonyl)(methyl)amino)-4-methyl-3-oxooct-
6-enethioate 
 
To a stirring solution of (R,E)-1-(1H-benzo[d][1,2,3]triazol-1-yl)-2-
methylhex-4-en-1-one (385 mg, 1.679 mmol) in anhydrous DCM (6.72 mL) 
under cooling with an ice bath was added S-phenyl 2-
(((benzyloxy)carbonyl)(methyl)amino)ethanethioate (556 mg, 1.763 mmol) 
followed by magnesium bromide diethyl etherate (1518 mg, 5.88 mmol) and 
N, N-diisopropylethylamine (1.231 mL, 7.05 mmol). The ice bath was 
removed and the reaciton is allowed to warm to rrom temperature. The 
reaction is monitroed by TLC and stirred for 24h. At this point the reaction is 
cooled back to 0C and is slowly quenched by the initially dropwise addition of 
1N HCl (10mL) stirring is continued with cooling for 5 minutes, the ice bath is 
removed. The reaction is diluted with brine and EtOAc, organics are 
separated, aqueous is reextracted with EtOAc, dried over MgSO4 and 
evaporated to yield an oil which is purified by gradient column 
chromatography (0-30% EtOAc in Hexanes over 10 CV) to yield S-phenyl 
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(4R,E)-2-(((benzyloxy)carbonyl)(methyl)amino)-4-methyl-3-oxooct-6-
enethioate as a colourless oil (426mg, 1.001 mmol, 60 % yield). LCMS RT 
(Method 2) 4.03 min (m/z  426.1) TLC Rf 0.5 (15%EtOAc in Hexanes) 1H 
NMR (400 MHz, CDCl3) δ 7.70 – 6.94 (m, 10H), 5.46 (dd, J = 13.6, 6.9 Hz, 
1H), 5.37 – 5.20 (m, 2H), 5.07 (dd, J = 25.8, 12.4 Hz, 1H), 3.18 (d, J = 16.7 
Hz, 3H), 2.57 – 2.37 (m, 1H), 2.23 (ddt, J = 26.6, 12.6, 7.1 Hz, 1H), 2.11 – 
1.96 (m, 1H), 1.65 – 1.52 (m, 3H), 1.04 (dd, J = 59.9, 7.2 Hz, 3H).13C NMR 
(101 MHz, CDCl3) δ 195.03, 194.88, 178.79, 178.64, 156.29, 136.34, 136.29, 
135.24, 135.14, 135.12, 129.64, 129.59, 129.17, 129.13, 128.51, 128.48, 
128.41, 128.40, 128.34, 128.14, 128.09, 128.07, 128.00, 127.98, 127.95, 
127.94, 127.86, 127.81, 127.57, 127.55, 126.75, 126.70, 115.03, 114.66, 
67.86, 67.78, 67.75, 38.34, 38.12, 36.66, 36.40, 36.27, 35.59, 17.86, 17.82, 
17.01, 17.00. HRMS (ESI) m/z calcd for [M + H] 426.1734, found 426.1744. 
 
 
 
 
 
 
Benzyl methyl((4R,E)-4-methyl-1,3-dioxo-1-(phenylamino)oct-6-en-2-
yl)carbamate 
 
 
To a solution of S-phenyl (4R,E)-2-(((benzyloxy)carbonyl)(methyl)amino)-4-
methyl-3-oxooct-6-enethioate (300mg, 0.705 mmol) and aniline (77 µl, 0.846 
mmol) in THF (5mL) at room temerature was added silver trifluoroacetate 
(187 mg, 0.846 mmol) with stirring. Precipitation of Ag salts requires efficient 
stirring. Upon completion the reaction is diluted with EtOAc and filtered 
through celite. 1H NMR (400 MHz, CDCl3) δ 14.01 (s, 1H) 7.54 – 7.19 (m, 
9H), 7.18 – 7.07 (m, 1H), 5.58 – 5.29 (m, 2H), 5.23 – 4.95 (m, 2H), 3.19 – 
3.02 (m, 3H), 2.40 (d, J = 6.9 Hz, 1H), 2.35 – 2.22 (m, 1H), 2.12 – 1.98 (m, 
1H), 1.63 – 1.56 (m, 3H), 1.04 (dd, J = 65.2, 6.8 Hz, 3H).). 13C NMR (101 
MHz, CDCl3) δ 208.77, 179.14, 168.45, 156.12, 128.98, 128.60, 128.56, 
128.24, 128.10, 128.01, 127.56, 124.83, 120.83, 68.25, 67.87, 38.32, 36.78, 
36.36, 17.92, 17.82. HRMS (ESI) m/z calcd for [M + H] 409.2122, found 
409.2131. 
 
 
 
 
 
 21 
 
 
 
 
 
Benzyl ((2S,3R,4R,E)-3-hydroxy-4-methyl-1-oxo-1-(phenylamino)oct-6-
en-2-yl)(methyl)carbamate 
To benzyl methyl((4R,E)-4-methyl-1,3-dioxo-1-(phenylamino)oct-6-en-2-
yl)carbamate (26mg, 0.064 mmol) under N2 was added degassed DCM 
(0.5mL), [(R,R)-Teth-TsDpenRu] (3.72 mg, 6.36µmol) followed by TBAI (47 
mg, 0.127 mmol) and 0.5mL of a 5N solution of HCO2Na in H2O. The 
reaction is sealed and stirred at 1400RPM for 48 hours. Following complete 
consumption of the starting material, the reaction is diluted with 3mL of 
sat.NaHCO3, which is extracted with 2x3mL of EtOAc. The organics are 
combined, dried over MgSO4 and purified by gradient column 
chromatography to yield benzyl ((2S,3R,4R,E)-3-hydroxy-4-methyl-1-oxo-1-
(phenylamino)oct-6-en-2-yl)(methyl)carbamate (10.3mg, 0.025 mmol, 39.4 % 
yield). 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 7.59 – 7.26 (m, 9H), 7.12 
(t, J = 7.7 Hz, 1H), 5.45 (dt, J = 12.4, 6.0 Hz, 2H), 5.20 (q, J = 12.2 Hz, 2H), 
4.77 (d, J = 4.1 Hz, 1H), 4.01 (dt, J = 7.9, 3.9 Hz, 1H), 3.86 (s, 1H), 3.14 (s, 
3H), 2.39 (d, J = 13.4 Hz, 1H), 1.96 (dt, J = 13.7, 7.8 Hz, 1H), 1.65 (d, J = 5.8 
Hz, 4H), 0.88 (d, J = 6.6 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 169.40, 
158.45, 137.18, 136.11, 128.99, 128.89, 128.60, 128.23, 127.74, 127.13, 
124.72, 120.11, 74.33, 68.16, 60.34, 35.35, 35.06, 33.32, 18.01, 15.82.  
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(2S,3R,4R,E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid, 
MeBmt – 202. 
Lit. ref. Evans D. A., J. Am. Chem. Soc. 1986, 108, 6757 
benzyl(E)-(3-hydroxy-4-methyl-1-oxo-1-(phenylamino)oct-6-en-2-
yl)(methyl)carbamate (20mg, 0.049 mmol) was added to 0.5mL of 2N KOH, 
in a sealed reaction vessel and heated to 80C by means of an oil bath. The 
reaction is stirred as such overnight. The following day the reaction is cooled 
to room temperature and diluted with 2mL of water, which is extracted with 
2x2mL Et2O. The resultant aqueous layer is acidified with DOWEX ion 
exchange resin, which is washed with water and the amino acid is eluted with 
1N NH3 in H2O, to yield (E)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic 
acid as a white solid. LCMS RT (Method 2) 2.24 min (m/z) 202.1. 1H NMR 
(400 MHz, D2O) δ 5.56 – 5.31 (m, 2H), 3.68 (t, J = 6.0 Hz, 1H), 3.54 (d, J = 
6.0 Hz, 1H), 2.65 (s, 3H), 2.19 (d, J = 13.9 Hz, 1H), 1.87 – 1.74 (m, 1H), 1.61 
(dtd, J = 9.6, 6.5, 3.3 Hz, 1H), 1.56 (dd, J = 5.9, 1.3 Hz, 3H), 0.85 (d, J = 6.8 
Hz, 3H).  
 
 
 
 
 
 
 
 
 
 
 
Lit. Spectra 202
5.52-5.29 (m. 2 H) δ 5.56 – 5.31 (m, 2H)
3.65 (t, 1 N-CH3) 3.68 (t, J  = 6.0 Hz, 1H)
3.50 (d, 1 H, J = 5.8 Hz) 3.54 (d, J  = 6.0 Hz, 1H)
2.61 (s, 3 H) 2.65 (s, 3H)
2.15 (br d, 1 H, 13.0 Hz) 2.19 (d, J  = 13.9 Hz, 1H)
1.82-1.70 (m, 1 H) 1.87 – 1.74 (m, 1H)
1.62-1.53 (m, 1 H) 1.61 (dtd, J  = 9.6, 6.5, 3.3 Hz, 1H)
1.52 (d, 3 H, J = 5.4) 1.56 (dd, J  = 5.9, 1.3 Hz, 3H)
 0.81 (d, 3 H, J = 6.7)  0.85 (d, J  = 6.8 Hz, 3H)
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1-Boc-4-amino piperidine (commercially available) 
1H NMR (400 MHz, CDCl3) δ 4.00 (s, 2H), 2.74 (m, 3H), 1.74 (d, J = 10.6 
Hz, 2H), 1.42 (s, 9H), 1.33 – 1.10 (m, 4H). 
 
 
 
 
 
 
 
 
tert-butyl 4-(phenethylamino)piperidine-1-carboxylate – 306 
 
To the solution of tert-butyl 4-aminopiperidine-1-carboxylate (5 g, 24.97 
mmol) and 2-phenylacetaldehyde (3.15 g, 26.2 mmol) in MeOH (Volume: 45 
ml) was added acetic acid (0.143 ml, 2.497 mmol). After 15 minutes, sodium 
cyanoborohydride (2.353 g, 37.4 mmol) was added in three portions. The 
resulting solution was stirred at room temperature for 30 minutes and then 
partitioned between ethyl acetate and water. The separated organic layer was 
washed with brine, dried over magnesium sulfate and concentrated in vacuo. 
Purified by normal phase chromatography (100%) EtOAc to yield tert-butyl 4-
(phenethylamino)piperidine-1-carboxylate (6.23 g, 20.47 mmol, 82 % yield) 
as a thick yellow oil. LCMS RT (Method 2) 2.78 min (m/z  305.1) 1H NMR 
(400 MHz, CDCl3) δ 7.37 – 7.25 (m, 2H), 7.23 – 7.08 (m, 3H), 4.01 (s, 2H), 
2.91 (dd, J = 8.1, 6.8 Hz, 2H), 2.86 – 2.67 (m, 4H), 2.62 (tt, J = 10.5, 3.9 Hz, 
1H), 1.98 (s, 1H), 1.86 – 1.76 (m, 2H), 1.43 (s, 9H), 1.30 – 1.16 (m, 2H). 13C 
NMR (101 MHz, CDCl3) δ 154.67, 139.22, 128.84, 128.61, 128.53, 128.29, 
126.36, 79.48, 55.02, 47.59, 42.30, 35.76, 31.69, 28.39. HRMS (ESI) m/z 
calcd for [M + Na]+ 327.2043, found 327.2028 .  
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Tert-butyl 4-(benzylamino)piperidine-1-carboxylate 
To a solution of tert-butyl 4-aminopiperidine-1-carboxylate (5 g, 24.97 mmol) 
and benzaldehyde (2.67 ml, 26.2 mmol) in MeOH (45 ml) was added acetic 
acid (0.143 ml, 2.497 mmol)and after  1 hour, sodium cyanoborohydride 
(2.353 g, 37.4 mmol)was added in three portions. The resulting solution was 
stirred at room temperature overnight and then partitioned between ethyl 
acetate and water. The separated organic layer was washed with brine, dried 
over magnesium sulfate and concentrated in vacuo. Crude was purified by 
column chromatography gradient 55-80% Hexane:EtOAc. Tert-butyl 4-
(benzylamino)piperidine-1-carboxylate (5.67 g, 19.52 mmol, 78 % yield) 
LCMS RT (Method 2) 2.62 min (m/z  291.1) 1H NMR (400 MHz, CDCl3) δ 
7.38 – 7.17 (m, 5H), 4.01 (s, 2H), 3.81 (s, 2H), 2.78 (t, J = 12.4 Hz, 2H), 2.65 
(tt, J = 10.2, 3.8 Hz, 1H), 1.85 (d, J= 12.3 Hz, 2H), 1.44 (s, 9H), 1.38 – 1.20 
(m, 2H). 13C NMR (101 MHz, CDCl3) δ 154.62, 128.67, 128.58, 127.58, 
128.58, 79.51, 54.17, 49.94, 42.35 (broad), 31.25, 28.40. HRMS (ESI) m/z 
calcd for [M + Na]+ 313.1886, found 313.1882. 
 
 
 
 
 
 
 
Tert-butyl 4-((4-bromo-3-chlorobenzyl)amino)piperidine-1-carboxylate – 
363 
To a solution of tert-butyl 4-aminopiperidine-1-carboxylate (5 g, 24.97 mmol) 
and 4-bromo-3-chlorobenzaldehyde (7.12 g, 32.5 mmol) in MeOH (45 ml) 
was added acetic acid (0.143 ml, 2.497 mmol)and after  1 hour, sodium 
cyanoborohydride (2.353 g, 37.4 mmol)was added in three portions. The 
resulting solution was stirred at room temperature overnight and then 
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partitioned between ethyl acetate and water. The separated organic layer was 
washed with brine, dried over magnesium sulfate and concentrated in vacuo. 
Crude was purified by column chromatography gradient 55-80% 
Hexane:EtOAc. tert-butyl 4-((4-bromo-3-chlorobenzyl)amino)piperidine-1-
carboxylate RT (Method 1) 2.85 min (m/z  403.0) 1H NMR (400 MHz, CDCl3) 
δ 7.51 (d, J = 8.2 Hz, 1H), 7.44 (d, J = 2.0 Hz, 1H), 7.09 (dd, J = 8.2, 2.0 Hz, 
1H), 3.99 (d, J = 15.3 Hz, 2H), 3.74 (s, 2H), 3.23 (s, 1H), 2.73 (t, J = 12.5 Hz, 
2H), 2.64 (tt, J = 10.3, 3.9 Hz, 1H), 1.89 – 1.76 (m, 2H), 1.41 (s, 9H), 1.36 – 
1.23 (m, 2H).13C NMR (101 MHz, CDCl3) δ 154.64, 140.12, 134.44, 133.65, 
130.10, 127.83, 120.96, 79.51, 54.26, 49.11, 42.21, 31.76, 28.39. HRMS (ESI-
TOF) m/z calcd for [M + H] 403.0782, found 403.0767. 
General procedure A – Synthesis of CT3 derivatives by reductive 
amination 
 
 
 
 
 
Representative example – synthesis of N-benzyl-N-phenethylpiperidin-4-
amine, 307 
To a solution of tert-butyl 4-(phenethylamino)piperidine-1-carboxylate (50mg, 
0.164 mmol) in dichloroethane (DCE) (0.5ml) was added benzaldehyde 
(33µL, 0.328 mmol) followed by sodium triacetoxyborohydride (55.7 mg, 
0.263 mmol). The reaction was stirred at room temperature overnight.  
 
The reaction is quenched with NaHCO3 (3mL), and extracted with EtOAc 
(2x4mL). The combined organics are removed by blowing down under a 
stream of nitrogen at 40C, followed by the addition of 2ml of 4N HCl in 
dioxane to facilitate Boc deprotection - the reaction is stirred for 2 hours. 
Completion is determined by complete loss of starting material (LCMS) the 
dioxane is removed by blowing down under a stream of nitrogen at 40C, the 
crude is dissolved in a solution of MeOH/DMSO and purified by semi-
preparative scale reverse phase HPLC. Pure fractions are lyophilised and 
combined to give N-benzyl-N-phenethylpiperidin-4-amine,  307. (63mg, 0.120 
mmol, 73 % yield) as a di-TFA salt > 95% purity by LCMS. LCMS RT 
(Method 2) 3.15 min (m/z  295.2). 1H NMR (400 MHz, DMSO-d6) δ 11.65 (s, 
1H), 9.47 (d, J = 9.3 Hz, 1H), 9.35 (q, J = 9.8 Hz, 1H), 7.82 (dd, J = 6.5, 3.0 
Hz, 2H), 7.51 – 7.40 (m, 3H), 7.28 (t, J = 7.2 Hz, 2H), 7.21 (t, J = 7.3 Hz, 1H), 
7.11 (d, J = 6.9 Hz, 2H), 4.52 (dd, J = 13.1, 3.9 Hz, 1H), 4.35 (dd, J = 13.1, 
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7.0 Hz, 1H), 3.77 – 3.65 (m, 1H), 3.40 (d, J = 10.4 Hz, 2H), 3.15 (t, J = 13.5 
Hz, 3H), 3.01 – 2.79 (m, 3H), 2.43 (t, J = 14.9 Hz, 2H), 2.25 (dt, J = 20.2, 12.6 
Hz, 2H). 13C NMR (101 MHz, DMSO-d6) δ 137.42, 131.89, 130.75, 129.87, 
129.20, 129.07, 128.99, 127.28, 58.12, 53.87, 50.60, 42.32, 30.07, 23.06, 
22.95. HRMS (ESI) m/z calcd for [M + H] 295.2169, found 295.2161.  
N-benzyl-N-phenethylpiperidin-4-amine, 307 
 
 
 
 
 
 
 
 
 
 
Appearance: Cloudy, white/transparent oil as free base, white solid as di-TFA 
salt. 
LCMS RT (Method 2) 3.15 min (m/z  295.2) .  
HRMS (ESI) m/z calcd for [M + H] 295.2169, found 295.2161.  
IR (neat) 2934, 2808, 1602, 1493, 1451. 
Free base: 1H NMR (400 MHz,) δ 7.48 – 6.89 (m, 10H), 3.73 – 3.63 (m, 2H), 
3.10 – 2.84 (m, 2H), 2.68-2.48 (m, J = 8.0 Hz, 5H), 2.36 (t, J = 11.7 Hz, 2H), 
1.59 (d, J = 11.3 Hz, 2H), 1.34 (d, J = 10.5 Hz, 2H). 13C NMR (101 MHz, 
DMSO-d6) δ 141.56, 140.98, 129.05, 128.51, 128.48, 128.43, 126.86, 126.09, 
57.94, 54.18, 52.36, 45.95, 35.24, 29.01 
 
 
 
 
 
 
 
Di- TFA Salt: 1H NMR (400 MHz, DMSO-d6) δ 11.65 (s, 1H), 9.47 (d, J = 
9.3 Hz, 1H), 9.35 (q, J = 9.8 Hz, 1H), 7.82 (dd, J = 6.5, 3.0 Hz, 2H), 7.51 – 
A 3.10 - 2.84 (m, 2H) 
B 2.36 (dd, J = 2H) 
C 1.34 (d, J = 2H) 
D 1.59 (d, J = 11.3 Hz, 2H) 
E 2.60 (m, 1H) 
F 3.73 - 3.63 (m, 2H) 
G 2.60 (m, 2H) 
H 2.60 (m, 2H) 
Ph 7.48 - 6.89 (m, 10H) 
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7.40 (m, 3H), 7.28 (t, J = 7.2 Hz, 2H), 7.21 (t, J = 7.3 Hz, 1H), 7.11 (d, J = 6.9 
Hz, 2H), 4.52 (dd, J = 13.1, 3.9 Hz, 1H), 4.35 (dd, J = 13.1, 7.0 Hz, 1H), 3.77 
– 3.65 (m, 1H), 3.40 (d, J = 10.4 Hz, 2H), 3.15 (t, J = 13.5 Hz, 3H), 3.01 – 
2.79 (m, 3H), 2.43 (t, J = 14.9 Hz, 2H), 2.25 (dt, J = 20.2, 12.6 Hz, 2H). 13C 
NMR (101 MHz, DMSO-d6) δ 137.42, 131.89, 130.75, 129.87, 129.20, 
129.07, 128.99, 127.28, 58.12, 53.87, 50.60, 42.32, 30.07, 23.06, 22.95. 
See appendix A8 for hard copies of spectal and chromatographic 
analyses. 
General procedure B – Synthesis of CT3 derivatives by displacement of 
primary alkyl-bromides 
Representative example – synthesis of N-(2-bromobenzyl)-N-
phenethylpiperidin-4-amine 
 
 
 
 
 
 
 
 
N-(2-bromobenzyl)-N-phenethylpiperidin-4-amine - 321 
 
To a solution of tert-butyl 4-(phenethylamino)piperidine-1-carboxylate (60mg, 
0.197 mmol) in MeCN (1 ml) was added 2-bromobenzyl bromide (54.2 mg, 
0.217 mmol) followed by K2CO3 (43.6 mg, 0.315 mmol). The reaction was 
stirred at room temperature overnight, completion confirmed by LCMS. 
 
The reaction was diluted with NaCl(aq) (3mL) and EtOAc (4mL), organics are 
separated and the aqueous was extracted twice with EtOAc (2x4mL). 
Combined organics were blown down under a stream of nitrogen. To the 
resultant crude oil was added 2ml of 4N HCl in Dioxane to facilitate Boc 
deprotection. The reaction was stirred for 2 hours, then blown down under N2. 
The crude is dissolved in a solution of MeOH/DMSO and purified by semi-
preparative scale reverse phase HPLC. Pure fractions are lyophilised and 
combined to give N-(2-bromobenzyl)-N-phenethylpiperidin-4-amine, 321. (51 
mg, 0.085 mmol, 43 % yield) as a di-TFA salt, >95% purity by LCMS.  
LCMS RT (Method 2) 3.43 min (m/z  375.1) 1H NMR (400 MHz, DMSO-d6) 
δ 8.95 (d, J = 64.5 Hz, 1H), 8.60 (s, 1H), 8.22 (s, 1H), 7.58 (d, J = 8.8 Hz, 
1H), 7.51 – 7.41 (m, 1H), 7.32 (d, J = 7.0 Hz, 1H), 7.28 – 7.20 (m, 3H), 7.17 
(d, J = 7.1 Hz, 1H), 7.12 (d, J = 7.2 Hz, 2H), 3.36 (dd, J = 34.8, 13.0 Hz, 4H), 
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3.01 – 2.79 (m, 4H), 2.68 (s, 3H), 2.32 – 2.14 (m, 1H), 1.88 (s, 2H), 1.70 (s, 
2H). 13C NMR (101 MHz, dmso) δ 158.74, 139.18, 132.94, 129.10, 128.68, 
126.45, 125.39, 118.76, 54.05, 52.52, 43.47, 32.09, 25.13.19F NMR (376 
MHz, DMSO-d6) δ -73.91. HRMS (ESI-TOF) m/z calcd for [M + H] 
375.1262, found 375.1255. 
General Procedure C – Synthesis of CT3 amide analogues 331, 332, 336, 
337, 342 and 343 
Representative example – synthesis of N,N-dimethyl-2-((phenethyl(piperidin-
4-yl)amino)methyl)benzamide – 336 
 
 
 
 
 
N,N-dimethyl-2-((phenethyl(piperidin-4-yl)amino)methyl)benzamide – 
342 
To a solution of tert-butyl 4-(phenethylamino)piperidine-1-carboxylate 
(500mg, 1.642 mmol) in dichloroethane (DCE)  (8 ml) was added 2-
formylbenzoic acid (370 mg, 2.464 mmol) followed by sodium 
triacetoxyborohydride (557 mg, 2.63 mmol). The reaction was stirred at room 
temperature overnight: conversion to carboxyl intermediate is confirmed by 
LCMS. Volatiles were removed by blowing down under a stream of nitrogen 
at 40°C. The crude material was dissolved in 6mL of DMF with sonication 
and a 2mL aliquot was removed and added to a new reaction vessel (approx 
0.5mmol of intermediate). To this was added HATU (347 mg, 0.912 mmol) 
and the resulting homogenous solution was stirred for 10 min at room 
temperature. Dimethylamine hydrochloride (93 mg, 1.140 mmol) was added 
followed by DIPEA (0.119 ml, 0.684 mmol). The mixture was stirred for 16 h 
at room temperature. 
 
The reaction is quenched with NaHCO3 (3mL), and extracted with EtOAc 
(2x4mL). The combined organics are removed by blowing down under a 
stream of nitrogen at 40C, followed by the addition of 3ml of 4N HCl in 
dioxane to facilitate Boc deprotection - the reaction is stirred for 2 hours. 
Completion is determined by complete loss of starting material (LCMS) the 
dioxane is removed by blowing down under a stream of nitrogen at 40C, the 
crude is dissolved in a solution of MeOH/DMSO and purified by reverse 
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phase column chromatography to yield N,N-dimethyl-2-((phenethyl(piperidin-
4-yl)amino)methyl)benzamide, 342. (5.4 mg, 0.015 mmol, 13 % yield).  
LCMS RT (Method 2) 3.00 min (m/z  366.2) 1H NMR (400 MHz, DMSO-d6) 
δ 7.37 – 7.26 (m, 3H), 7.26 – 7.18 (m, 3H), 7.18 – 7.07 (m, 3H), 3.70 (s, 2H), 
2.98 (s, 4H), 2.86 (s, 3H), 2.73 – 2.55 (m, 5H), 2.47 – 2.35 (m, 2H), 1.80 – 
1.66 (m, 1H), 1.63 (d, J = 11.2 Hz, 2H), 1.35 (q, J = 9.6 Hz, 2H). 13C NMR 
(101 MHz, DMSO-d6) δ 170.71, 141.83, 140.94, 136.69, 129.40, 129.06, 
128.48, 128.43, 126.92, 126.12, 125.53, 58.06, 53.90, 52.38, 46.03, 35.22, 
35.13, 29.15.19F NMR (376 MHz, DMSO-d6) δ -73.47. HRMS (ESI-TOF) m/z 
calcd for [M + H] 366.2540, found 366.2556. 
N-(4-chlorobenzyl)-N-phenethylpiperidin-4-amine - 308 
LCMS RT (Method 2) 3.50 min (m/z  329.2) 1H NMR (400 MHz, DMSO-d6) 
δ 10.36 (s, 1H), 8.85 (s, 1H), 8.55 (s, 1H), 7.62 – 7.39 (m, 4H), 7.27 (t, J = 7.4 
Hz, 2H), 7.19 (s, 1H), 7.14 (d, J = 7.4 Hz, 2H), 4.37 (br, 1H), 3.97 (s, 2H), 
3.39 (s, 3H), 3.16 (s, 1H), 2.92 (s, 3H), 2.79 (s, 1H), 2.22 (s, 2H), 1.93 (s, 2H). 
13C NMR (151 MHz, DMSO-d6) δ 161.49, 139.71, 136.27, 131.79, 130.02, 
117.01, 60.53, 55.80, 53.55, 45.18, 32.73, 26.13. 19F NMR (376 MHz, DMSO-
d6) δ -73.94. HRMS (ESI-TOF) m/z calcd for [M + H] 329.1779, found 
329.1769.  
N-(4-bromobenzyl)-N-phenethylpiperidin-4-amine - 309 
LCMS RT (Method 2) 3.54 min (m/z  373.1) 1H NMR (400 MHz, DMSO-d6) 
δ 10.33 (s, 1H), 8.86 (s, 1H), 8.56 (s, 1H), 7.71 – 7.49 (m, 4H), 7.29 (t, J = 7.4 
Hz, 2H), 7.16 (d, J = 7.4 Hz, 2H), 4.38 (s, 1H), 4.03 (s, 2H), 3.71 (s, 1H), 3.40 
(s, 3H), 3.18 (s, 1H), 2.94 (s, 3H), 2.25 (s, 1H), 1.84 (m, Hz, 3H). 13C NMR 
(151 MHz, DMSO-d6) δ 161.25, 139.78, 136.50, 134.88, 131.79, 129.77, 
126.42, 118.98, 60.49, 55.87, 53.55, 45.22, 32.72, 26.17.19F NMR (376 MHz, 
DMSO-d6) δ -73.94. HRMS (ESI-TOF) m/z calcd for [M + H] 373.1274, 
found 373.1278.  
N-(4-fluorobenzyl)-N-phenethylpiperidin-4-amine - 310 
LCMS RT (Method 2) 3.27 min (m/z  313.4) 1H NMR (400 MHz, DMSO-d6) 
δ 10.03 (s, 1H), 8.78 (s, 1H), 8.44 (s, 1H), 8.04 (s, 1H), 7.79 – 6.89 (m, 9H), 
4.47 (d, J = 49.3 Hz, 1H), 3.65 (s, 4H), 3.50 – 3.43 (m, 1H), 3.26 (d, J = 19.5 
Hz, 2H), 3.00 (s, 1H), 2.82 (s, 1H), 2.66 (s, 1H), 2.30 (s, 1H), 1.98 (s, 1H), 
1.81 (s, 1H), 1.63 (s, 1H). 19F NMR (376 MHz, DMSO-d6) δ -73.82. 13C NMR 
(151 MHz, DMSO-d6) δ 161.17, 139.61, 136.78, 132.88, 131.78, 131.25, 
130.15, 129.54, 117.96, 60.53, 55.83, 53.36, 45.19, 32.67, 26.10.HRMS (ESI-
TOF) m/z calcd for [M + H] 313.2075, found 313.2071.  
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N-phenethyl-N-(4-(trifluoromethyl)benzyl)piperidin-4-amine – 311 
 
LCMS RT (Method 2) 3.77 min (m/z  363.2)  1H NMR (400 MHz, DMSO-d6) 
δ 10.49 (s, 1H), 8.65 (s, 1H), 7.82 – 7.58 (m, 5H), 7.25 (t, J = 7.3 Hz, 2H), 
7.21 – 7.15 (m, 1H), 7.16 – 7.08 (m, 2H), 4.38 (s, 2H), 3.83 (s, 1H), 3.35 (s, 
3H), 3.23 – 3.05 (m, 1H), 2.99 – 2.83 (m, 3H), 2.76 (s, 1H), 1.87 (s, 4H). 13C 
NMR (151 MHz, DMSO-d6) δ 161.47, 134.93, 133.26, 131.79, 131.50, 
129.96, 128.67, 126.36, 122.86, 118.91, 57.61, 55.99, 53.88, 45.82, 32.58, 
26.28.19F NMR (376 MHz, DMSO-d6) δ -60.83 (s, 3F, CF3), -74.00 (s, 6F 2-
TFA). HRMS (ESI) m/z calcd for [M + H] 363.2043, found 363.2040. 
N-phenethyl-N-(4-(trifluoromethoxy)benzyl)piperidin-4-amine – 312 
 
LCMS RT (Method 2) 3.91 min (m/z  379.2) 1H NMR (400 MHz, DMSO-d6) 
δ 10.36 (s, 1H), 8.83 (s, 1H), 8.56 (s, 1H), 7.64 (s, 1H), 7.41 (s, 3H), 7.26 (t, J 
= 7.1 Hz, 2H), 7.20 (q, J = 6.1, 5.6 Hz, 1H), 7.12 (d, J = 7.0 Hz, 2H), 4.11 (s, 
2H), 3.70 (s, 1H), 3.39 (s, 3H), 3.17 (s, 1H), 2.92 (s, 3H), 2.75 (s, 1H), 2.21 (s, 
2H), 1.93 (s, 2H). 13C NMR (151 MHz, DMSO-d6) δ 161.28, 139.60, 136.56, 
132.82, 131.76, 129.94, 124.33, 116.97, 60.81, 55.74, 53.62, 45.25, 32.73, 
26.07.19F NMR (376 MHz, DMSO-d6) δ -56.80 (s, 3F, OCF3), -73.98 (s, 6F, 
2TFA). HRMS (ESI) m/z calcd for [M + H] 379.1922, found 379.1995. 
N-(4-methylbenzyl)-N-phenethylpiperidin-4-amine – 313  
LCMS RT (Method 2) 3.43 min (m/z  309.3) 1H NMR (400 MHz, DMSO-d6) 
δ 10.40 (s, 1H), 9.07 (d, J = 10.7 Hz, 1H), 8.78 (d, J = 11.4 Hz, 1H), 7.54 – 
7.43 (m, 2H), 7.34 – 7.18 (m, 5H), 7.18 – 7.10 (m, 2H), 4.39 (d, J = 37.0 Hz, 
2H), 3.77 – 3.63 (m, 1H), 3.44 (d, J = 12.5 Hz, 2H), 3.25 – 3.13 (m, 2H), 2.98 
(q, J = 12.0 Hz, 3H), 2.81 (s, 1H), 2.31 (s, 5H), 2.10 – 1.93 (m, 2H). 13C NMR 
(101 MHz, DMSO-d6) δ 158.90, 139.62, 137.16, 131.52, 129.92, 129.07, 
127.68, 127.34, 112.29, 57.91, 53.84, 50.74, 42.50, 30.11, 23.45, 21.22. 19F 
NMR (376 MHz, DMSO-d6) δ -74.47.  HRMS (ESI-TOF) m/z calcd for [M + 
H] 309.2325, found 309.2327. 
 
N-(3-chlorobenzyl)-N-phenethylpiperidin-4-amine – 314  
 
LCMS RT (Method 2) 3.50 min (m/z  329.2) 1H NMR (400 MHz, DMSO-d6) 
δ 9.05 (d, J = 11.5 Hz, 1H), 8.73 (d, J = 11.5 Hz, 1H), 7.70 (s, 1H), 7.56 – 
7.43 (m, 3H), 7.28 (dd, J = 8.1, 6.6 Hz, 2H), 7.24 – 7.18 (m, 1H), 7.17 – 7.11 
(m, 2H), 4.38 (s, 2H), 3.66 (s, 1H), 3.44 (d, J = 12.5 Hz, 2H), 3.16 (t, J = 8.5 
Hz, 2H), 2.98 (q, J = 12.1 Hz, 2H), 2.86 (s, 2H), 2.26 (d, J = 12.8 Hz, 2H), 
1.98 (dd, J = 18.9, 8.4 Hz, 2H).13C NMR (101 MHz, DMSO-d6) δ 159.25, 
133.90, 131.11, 129.80, 129.08, 127.29, 115.34, 57.88, 53.28, 51.07, 42.57, 
30.41, 23.60. 19F NMR (376 MHz, DMSO-d6) δ -74.35 HRMS (ESI-TOF) m/z 
calcd for [M + H] 329.1779, found 329.1767. 
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N-(3-bromobenzyl)-N-phenethylpiperidin-4-amine - 315 
LCMS RT (Method 2) 3.64 min (m/z  375.1) 1H NMR (400 MHz, DMSO-d6) 
δ 10.41 (s, 1H), 8.86 (s, 1H), 8.59 (s, 1H), 7.59 (d, J = 12.5 Hz, 2H), 7.43 – 
7.32 (m, 1H), 7.31 – 7.23 (m, 3H), 7.20 (d, J = 7.1 Hz, 1H), 7.13 (d, J = 7.6 
Hz, 2H), 4.21 (s, 2H), 3.72 (s, 1H), 3.39 (s, 3H), 3.16 (s, 1H), 2.93 (s, 3H), 
2.73 (s, 1H), 2.26 (s, 1H), 1.94 (s, 3H). NMR (376 MHz, DMSO-d6) δ -73.93.  
HRMS (ESI-TOF) m/z calcd for [M + H] 375.1255, found 375.1255. 
N-(3-fluorobenzyl)-N-phenethylpiperidin-4-amine - 316 
LCMS RT (Method 2) 3.32 min (m/z  313.21H NMR (400 MHz, DMSO-d6) δ 
10.44 (s, 1H), 8.81 (s, 1H), 8.51 (s, 1H), 7.44 (s, 3H), 7.29 – 7.24 (m, 2H), 
7.20 (d, J = 6.8 Hz, 1H), 7.13 (d, J = 7.0 Hz, 3H), 4.19 (s, 2H), 3.38 (s, 3H), 
3.08 (s, 1H), 2.92 (s, 3H), 2.77 (s, 1H), 2.34 – 2.05 (m, 2H), 1.88 (s, 2H] 19F 
NMR (376 MHz, DMSO-d6) δ -73.97, -112.14.  HRMS (ESI-TOF) m/z calcd 
for [M + H] 313.2075, found 313.2070. 
N-phenethyl-N-(3-(trifluoromethyl)benzyl)piperidin-4-amine - 317 
LCMS RT (Method 2) 3.80 min (m/z  363.20) 1H NMR (400 MHz, DMSO-d6) 
δ 10.63 (s, 1H), 8.84 (s, 1H), 8.58 (s, 1H), 7.63 (s, 4H), 7.25 (t, J = 7.1 Hz, 
2H), 7.19 (d, J = 5.9 Hz, 1H), 7.11 (d, J = 6.9 Hz, 2H), 4.48 (s, 3H), 3.80 (s, 
1H), 3.38 (s, 2H), 2.92 (s, 3H), 2.72 (s, 2H), 2.25 (s, 1H), 1.88 (s, 3H). 13C 
NMR (151 MHz, DMSO-d6) δ 161.28, 139.57, 138.48, 134.94, 132.88, 
131.73, 129.96, 129.49, 126.30, 116.93, 60.58, 55.88, 53.56, 45.25, 32.56, 
27.65, 26.40.19F NMR (376 MHz, DMSO-d6) δ -61.11 (s, 3H, CF3), -74.02 (s, 
3H, 2TFA) HRMS (ESI-TOF) m/z calcd for [M + H] 363.2043, found 
363.2036. 
N-phenethyl-N-(3-(trifluoromethoxy)benzyl)piperidin-4-amine - 318 
LCMS RT (Method 2) 3.93 min (m/z  379.2) 1H NMR (400 MHz, DMSO-d6) 
δ 10.64 (s, 1H), 8.65 (d, 2H), 7.55 (s, 4H), 7.28 (t, J = 7.2 Hz, 2H), 7.22 (d, J = 
6.9 Hz, 1H), 7.17 – 7.07 (m, 2H), 4.07 (s, 6H), 3.39 (s, 2H), 2.94 (d, J = 10.9 
Hz, 2H), 2.75 (s, 1H), 2.18 (s, 2H), 1.89 (s, 2H). 13C NMR (151 MHz, DMSO-
d6) δ 161.30, 151.56, 134.00, 131.72, 131.57, 129.37, 126.80, 125.23, 123.99, 
122.29, 115.42, 61.09, 55.86, 53.67, 45.29, 32.71, 26.38. 19F NMR (376 MHz, 
DMSO-d6) δ -56.74, -74.03. HRMS (ESI-TOF) m/z calcd for [M + H] 
379.1992, found 379.1998. 
 
 
 
 
 32 
N-(3-methylbenzyl)-N-phenethylpiperidin-4-amine, 319 
LCMS RT (Method 2) 3.43 min (m/z  309.3) 1H NMR (400 MHz, DMSO-d6) 
δ 10.26 (s, 1H), 8.93 (s, 1H), 8.64 (s, 1H), 7.52 – 7.19 (m, 7H), 7.14 (d, J = 7.0 
Hz, 2H), 4.40 (d, J = 69.3 Hz, 2H), 3.61 (s, 5H), 3.44 (s, 2H), 3.19 (s, 1H), 
3.03 – 2.94 (m, 2H), 2.76 (s, 1H), 2.35 – 2.30 (m, 3H), 2.01 (s, 2H), 1.74 (s, 
1H). 13C NMR (151 MHz, DMSO-d6) δ 161.67 (q, TFA), 141.40, 139.72, 
134.74, 133.41, 131.95, 131.76, 131.34, 130.05,123.09 (q, TFA), 60.73, 56.65, 
53.31, 45.22, 32.50, 26.30, 26.08, 24.01.  19F NMR (376 MHz, DMSO-d6) δ -
73.81.  HRMS (ESI-TOF) m/z calcd for [M + H] 309.2325, found 309.2313. 
N-(2-chlorobenzyl)-N-phenethylpiperidin-4-amine - 320 
LCMS RT (Method 2) 3.35 min (m/z  329.2) 1H NMR (400 MHz, DMSO-d6) 
δ 10.00 (s, 1H), 8.63 (s, 1H), 8.26 (s, 1H), 7.46 (s, 3H), 7.35 – 7.29 (m, 1H), 
7.27 – 7.23 (m, 2H), 7.18 (d, J = 6.8 Hz, 1H), 7.13 (d, J = 7.3 Hz, 2H), 4.33 (s, 
3H), 3.86 (s, 1H), 3.35 (s, 3H), 2.95 – 2.83 (m, 3H), 2.72 (s, 1H), 1.90 (s, 2H), 
1.80 – 1.59 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ 161.18, 142.67, 
135.14, 131.79, 131.47, 128.61, 116.87, 57.50, 53.97, 46.06, 45.96, 37.30, 
27.53.19F NMR (376 MHz, DMSO-d6) δ -74.06. HRMS (ESI-TOF) m/z calcd 
for [M + H] 329.1779, found 329.1769. 
N-(2-bromobenzyl)-N-phenethylpiperidin-4-amine - 321 
LCMS RT (Method 2) 3.43 min (m/z  375.1) 1H NMR (400 MHz, DMSO-d6) 
δ 8.95 (d, J = 64.5 Hz, 1H), 8.60 (s, 1H), 8.22 (s, 1H), 7.58 (d, J = 8.8 Hz, 
1H), 7.51 – 7.41 (m, 1H), 7.32 (d, J = 7.0 Hz, 1H), 7.28 – 7.20 (m, 3H), 7.17 
(d, J = 7.1 Hz, 1H), 7.12 (d, J = 7.2 Hz, 2H), 3.36 (dd, J = 34.8, 13.0 Hz, 4H), 
3.01 – 2.79 (m, 4H), 2.68 (s, 3H), 2.32 – 2.14 (m, 1H), 1.88 (s, 2H), 1.70 (s, 
2H).19F NMR (376 MHz, DMSO-d6) δ -73.91. HRMS (ESI-TOF) m/z calcd 
for [M + H] 375.1262, found 375.1255. 
 
N-(2-fluorobenzyl)-N-phenethylpiperidin-4-amine - 322 
LCMS RT (Method 2) 3.18 min (m/z  313.21H NMR (400 MHz, DMSO-d6) δ 
10.26 (s, 1H), 8.84 (s, 1H), 8.49 (s, 1H), 7.52 (d, J = 40.9 Hz, 3H), 7.30 – 7.25 
(m, 3H), 7.22 (s, 1H), 7.16 (d, J = 6.8 Hz, 2H), 4.20 (s, 2H), 3.78 (s, 1H), 3.38 
(s, 3H), 3.14 (s, 1H), 2.93 (s, 3H), 2.83 (s, 1H), 2.15 (s, 1H), 1.90 (s, 3H). 13C 
NMR (101 MHz, DMSO-d6) δ 158.50, 147.55, 129.10, 128.91, 125.16, 
124.78, 118.70, 59.97, 51.85, 47.40, 42.99, 30.68, 24.12.19F NMR (376 MHz, 
DMSO-d6) δ -73.98, -114.12.)  HRMS (ESI-TOF) m/z calcd for [M + H] 
313.2075, found 313.2064. 
 
 
 33 
N-phenethyl-N-(2-(trifluoromethyl)benzyl)piperidin-4-amine - 323 
LCMS RT (Method 2) 4.06 min (m/z  363.21H NMR (400 MHz, DMSO-d6) δ 
8.55 (s, 1H), 8.14 (d, J = 19.3 Hz, 1H), 7.67 (dd, J = 12.8, 7.8 Hz, 2H), 7.53 (t, 
J = 7.6 Hz, 1H), 7.40 (t, J = 7.7 Hz, 1H), 7.27 – 7.19 (m, 2H), 7.19 – 7.12 (m, 
1H), 3.83 (s, 2H), 3.28 (d, J = 12.4 Hz, 2H), 2.88 (dq, J = 24.3, 12.8 Hz, 4H), 
2.67 (d, J = 7.7 Hz, 3H), 1.83 (d, J = 13.4 Hz, 2H), 1.63 (q, J = 12.8, 12.0 Hz, 
2H 13C NMR (101 MHz, DMSO-d6) δ 158.39, 132.82, 130.16, 129.08, 128.60, 
126.33, 125.92, 55.10, 52.70, 50.07, 43.61, 34.73, 25.06.19F NMR (376 MHz, 
DMSO-d6) δ -58.35, -73.92.  HRMS (ESI-TOF) m/z calcd for [M + H] 
363.2043, found 363.2036. 
N-phenethyl-N-(thiophen-3-ylmethyl)piperidin-4-amine – 324 
 
LCMS RT (Method 2) 3.12 min (m/z  301.1) 1H NMR (400 MHz, DMSO-d6) 
δ 10.37 (s, 1H), 8.93 (s, 1H), 8.64 (s, 1H), 7.89 (s, 1H), 7.66 (s, 1H), 7.29 (t, J 
= 7.2 Hz, 3H), 7.25 – 7.19 (m, 1H), 7.15 (d, J = 7.0 Hz, 2H), 4.44 (s, 2H), 3.66 
(s, 3H), 3.40 (s, 2H), 3.17 (s, 1H), 2.94 (s, 2H), 2.76 (s, 1H), 2.30 (s, 2H), 1.96 
(s, 2H). 13C NMR (151 MHz, DMSO-d6) δ 161.33, 139.72, 133.51, 132.49, 
132.31, 131.80, 130.91, 130.06, 119.14, 60.62, 53.35, 51.22, 45.17, 32.76, 
26.27.19F NMR (376 MHz, DMSO-d6) δ -73.80. HRMS (ESI) m/z calcd for 
[M + H] 301.1733, found 301.1744. 
N-phenethyl-N-(thiophen-2-ylmethyl)piperidin-4-amine - 325 
LCMS RT (Method 2) 3.11 min (m/z  301.2) 1H NMR (400 MHz, DMSO-d6) 
δ 10.55 (s, 1H), 8.72 (s, 2H), 7.64 (s, 1H), 7.31 (dd, J = 16.0, 8.6 Hz, 3H), 7.23 
(d, J = 7.1 Hz, 1H), 7.19 (d, J = 7.0 Hz, 2H), 7.10 (s, 1H), 4.68 (s, 2H), 3.94 
(s, 4H), 3.38 (s, 2H), 2.94 (s, 2H), 2.82 (s, 1H), 2.16 (s, 2H), 1.85 (s, 2H). 13C 
NMR (101 MHz, DMSO-d6) δ 137.41, 133.14, 129.12, 128.93, 127.27, 
115.84, 52.09, 50.91, 48.36, 42.76, 32.07, 24.12. 19F NMR (376 MHz, DMSO-
d6) δ -73.90. HRMS (ESI-TOF) m/z calcd for [M + H] 301.1733, found 
301.1733. 
N-([1,1'-biphenyl]-4-ylmethyl)-N-phenethylpiperidin-4-amine – 326 
 
LCMS RT (Method 2) 3.98 min (m/z  371.2) 1H NMR (400 MHz, DMSO-d6) 
δ 10.31 (s, 1H), 8.93 (s, 1H), 8.63 (s, 1H), 7.90 – 7.53 (m, 6H), 7.46 (t, J = 7.5 
Hz, 2H), 7.42 – 7.34 (m, 1H), 7.28 (t, J = 7.1 Hz, 2H), 7.21 (d, J = 7.0 Hz, 
1H), 7.16 (d, J = 7.1 Hz, 2H), 4.48 (d, J = 52.7 Hz, 2H), 3.82 (d, J = 42.5 Hz, 
3H), 3.45 (s, 2H), 3.27 (s, 1H), 2.99 (s, 2H), 2.81 (s, 1H), 2.31 (s, 1H), 2.03 (s, 
2H). 13C NMR (151 MHz, DMSO-d6) δ 161.49, 144.32, 142.15, 139.71, 
134.95, 132.14, 131.80, 130.14, 129.83, 117.10, 60.65, 56.34, 53.51, 45.21, 
32.71, 26.23.19F NMR (376 MHz, DMSO-d6) δ -73.85. HRMS (ESI) m/z calcd 
for [M + H] 371.2482, found 371.2490. 
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N-(4-methoxybenzyl)-N-phenethylpiperidin-4-amine – 327  
LCMS RT (Method 2) 3.31 min (m/z  325.2) 1H NMR (400 MHz, DMSO-d6) 
δ 10.26 (s, 1H), 9.04 (d, J = 10.7 Hz, 1H), 8.75 (d, J = 11.4 Hz, 1H), 7.57 – 
7.47 (m, 2H), 7.33 – 7.25 (m, 2H), 7.25 – 7.18 (m, 1H), 7.18 – 7.11 (m, 2H), 
7.05 – 6.97 (m, 2H), 4.39 (s, 3H), 3.76 (d, J = 0.6 Hz, 3H), 3.73 – 3.62 (m, 
1H), 3.44 (d, J = 12.6 Hz, 2H), 3.23 – 3.13 (m, 2H), 2.99 (dd, J = 17.4, 5.9 Hz, 
2H), 2.83 (s, 1H), 2.29 (d, J = 13.2 Hz, 2H), 2.01 (qd, J = 12.9, 4.0 Hz, 2H). 
13C NMR (101 MHz, DMSO-d6) δ 160.55, 158.84, 137.15, 133.13, 129.08, 
127.36, 122.35, 114.72, 57.78, 55.66, 53.69, 50.55, 42.51, 30.19, 23.43. 19F 
NMR (376 MHz, DMSO-d6) δ -74.38. HRMS (ESI-TOF) m/z calcd for [M + 
H] 325.2274, found 325.2267. 
 
4-((phenethyl(piperidin-4-yl)amino)methyl)benzonitrile - 328 
LCMS RT (Method 2) 3.25 min (m/z 320.2)  1H NMR (400 MHz, DMSO-d6) 
δ 10.46 (s, 1H), 8.58 (s, 1H), 8.21 (s, 1H), 7.82 (s, 2H), 7.54 (s, 1H), 7.42 – 
6.98 (m, 4H), 4.82 – 3.90 (m, 5H), 3.90 – 3.72 (m, 1H), 3.34 (s, 2H), 2.96 – 
2.82 (m, 2H), 2.81 – 2.60 (m, 2H), 2.12 – 1.51 (m, 3H). 13C NMR (151 MHz, 
DMSO-d6) δ 161.12, 135.31, 131.80, 131.41, 129.03, 121.80, 118.87, 57.55, 
56.15, 55.01, 46.07, 37.44, 27.83. 19F NMR (376 MHz, DMSO-d6) δ -74.03.  
HRMS (ESI-TOF) m/z calcd for [M + H] 320.2121, found 320.2112. 
N-phenethyl-N-(pyridin-4-ylmethyl)piperidin-4-amine – 329  
LCMS RT (Method 2) 2.88 min (m/z  296.2) 1H NMR (400 MHz, DMSO-d6) 
δ 8.80 (d, J = 10.3 Hz, 1H), 8.74 (d, J = 5.6 Hz, 2H), 8.54 – 8.43 (m, 1H), 7.79 
(d, J = 5.7 Hz, 2H), 7.24 (dd, J = 8.1, 6.5 Hz, 2H), 7.20 – 7.10 (m, 2H), 4.08 
(s, 2H), 3.07 (s, 1H), 2.85 (t, J = 11.9 Hz, 3H), 2.73 (dd, J = 9.6, 5.7 Hz, 2H), 
1.94 (d, J = 13.1 Hz, 2H), 1.81 – 1.56 (m, 2H). 13C NMR (101 MHz, DMSO-
d6) δ 159.19, 143.12, 139.59, 129.16, 128.70, 126.61, 126.00, 114.29, 56.18, 
53.04, 52.52, 43.26, 32.81, 24.79. 19F NMR (376 MHz, DMSO-d6) δ -74.43. 
HRMS (ESI-TOF) m/z calcd for [M + H] 296.2121, found 296.2133. 
 
N-([1,1'-biphenyl]-3-ylmethyl)-N-phenethylpiperidin-4-amine - 333 
LCMS RT (Method 2) 3.88 min (m/z  371.3) 1H NMR (400 MHz, DMSO-d6) 
δ 10.45 (s, 1H), 8.95 (s, 1H), 8.65 (s, 1H), 7.96 (s, 1H), 7.79 (s, 1H), 7.69 (s, 
2H), 7.61 (s, 2H), 7.49 (t, J = 7.5 Hz, 2H), 7.43 – 7.37 (m, 1H), 7.32 – 7.17 
(m, 3H), 7.14 (d, J = 7.4 Hz, 2H), 4.53 (d, J = 68.1 Hz, 2H), 3.78 (s, 4H), 3.46 
(s, 2H), 3.27 (s, 1H), 3.00 (s, 2H), 2.77 (s, 1H), 2.35 (d, J = 8.8 Hz, 1H), 2.04 
(s, 1H). 13C NMR (101 MHz, DMSO-d6) δ 158.57, 130.43, 129.97, 129.39, 
129.07, 128.26, 127.18, 126.99, 118.43, 58.78, 54.12, 49.97, 42.60, 30.00, 
23.60. 19F NMR (376 MHz, DMSO-d6) δ -73.82. HRMS (ESI-TOF) m/z calcd 
for [M + H] 371.2482, found 371.2476. 
 35 
N-phenethyl-N-(pyridin-3-ylmethyl)piperidin-4-amine – 334 
LCMS RT (Method 2) 2.73 min (m/z  296.2) 1H NMR (400 MHz, DMSO-d6) 
δ 9.21 – 8.54 (m, 4H), 8.42 (s, 1H), 8.06 – 7.89 (m, 1H), 7.58 – 7.45 (m, 1H), 
7.41 – 7.00 (m, 5H), 3.96 (s, 5H), 3.38 (s, 2H), 3.26 – 3.13 (m, 1H), 2.97 – 
2.88 (m, 2H), 2.78 (s, 1H), 2.21 – 1.92 (m, 2H), 1.88 – 1.63 (m, 2H). 13C NMR 
(101 MHz, DMSO-d6) δ 129.09, 128.80, 127.29, 126.78, 124.68, 124.15, 
65.71, 51.25, 43.14, 41.96, 32.01, 25.71. 19F NMR (376 MHz, DMSO-d6) δ -
73.93.  HRMS (ESI-TOF-TOF) m/z calcd for [M + H] 296.2121, found 
296.2125. 
N-(3-((phenethyl(piperidin-4-yl)amino)methyl)phenyl)acetamide - 335 
LCMS RT (Method 2) 2.92 min (m/z  352.2) 1H NMR (400 MHz, DMSO-d6) 
δ 10.17 (d, J = 25.8 Hz, 2H), 8.98 (s, 1H), 8.70 (s, 1H), 7.97 (s, 1H), 7.50 (d, J 
= 7.4 Hz, 1H), 7.39 (s, 1H), 7.35 – 7.19 (m, 4H), 7.17 (d, J = 7.2 Hz, 2H), 4.44 
(d, J = 48.3 Hz, 2H), 3.70 (s, 1H), 3.44 (s, 2H), 3.21 (s, 2H), 2.97 (s, 3H), 2.81 
(s, 1H), 2.31 (s, 2H), 2.06 (s, 3H), 1.98 (d, J = 13.8 Hz, 2H). 13C NMR (101 
MHz, DMSO-d6) δ 168.93, 140.17, 129.12, 125.80, 121.71, 120.21, 66.63, 
58.04, 54.29, 42.71, 30.28, 24.41, 23.48.19F NMR (376 MHz, DMSO-d6) δ -
73.86. HRMS (ESI-TOF) m/z calcd for [M + Na] 374.2203, found 374.2207. 
3-((phenethyl(piperidin-4-yl)amino)methyl)benzamide - 337 
LCMS RT (Method 2) 2.63 min (m/z  338.2) 1H NMR (400 MHz, DMSO-d6) 
δ 7.90 (s, 1H), 7.83 (s, 1H), 7.71 (d, J = 7.6 Hz, 1H), 7.44 (d, J = 7.5 Hz, 1H), 
7.39 – 7.26 (m, 2H), 7.22 (t, J = 7.3 Hz, 2H), 7.13 (dd, J = 16.7, 7.2 Hz, 3H), 
3.71 (s, 2H), 3.05 – 2.88 (m, 2H), 2.64 (s, 4H), 2.41 (t, J = 12.0 Hz, 2H), 1.75 
(t, J = 11.5 Hz, 1H), 1.66 (d, J = 10.5 Hz, 2H), 1.47 – 1.28 (m, 2H). 13C NMR 
(101 MHz, DMSO-d6) δ 168.00, 141.34, 140.47, 134.08, 130.92, 128.57, 
128.05, 127.83, 127.40, 125.66, 125.58, 57.62, 53.62, 52.03, 45.53, 34.76, 
28.66. 19F NMR (376 MHz, DMSO-d6) δ -73.45. HRMS (ESI-TOF) m/z calcd 
for [M + H] 338.2227, found 338.2239. 
N-(3-((phenethyl(piperidin-4-
yl)amino)methyl)phenyl)methanesulfonamide – 338 
LCMS RT (Method 2) 3.00 min (m/z  388.2) 1H NMR (400 MHz, DMSO-d6) 
δ 10.26 (s, 1H), 9.93 (d, J = 17.5 Hz, 1H), 8.89 (s, 1H), 8.59 (s, 1H), 7.39 (s, 
3H), 7.26 (d, J = 7.0 Hz, 3H), 7.21 (d, J = 6.3 Hz, 1H), 7.14 (d, J = 7.1 Hz, 
2H), 4.44 (d, J = 46.6 Hz, 2H), 3.83 (s, 3H), 3.40 (s, 2H), 3.15 (s, 1H), 2.98 (s, 
3H), 2.94 (s, 1H), 2.78 (s, 2H), 2.28 (s, 2H), 1.98 (s, 2H). 13C NMR (101 
MHz, DMSO-d6) δ 158.52, 139.26, 131.65, 130.38, 129.09, 127.34, 115.85, 
58.18, 53.94, 50.92, 42.69, 30.34, 23.59.19F NMR (376 MHz, DMSO-d6) δ -
73.89. HRMS (ESI) m/z calcd for [M + Na] 410.1873, found 401.1884. 
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N-(2-methoxybenzyl)-N-phenethylpiperidin-4-amine - 339 
LCMS RT (Method 2) 3.32 min (m/z  325.2) 1H NMR (400 MHz, DMSO-d6) 
δ 9.49 (s, 1H), 8.97 (s, 1H), 8.67 (s, 1H), 7.49 (s, 2H), 7.35 – 7.26 (m, 2H), 
7.24 (d, J = 6.7 Hz, 1H), 7.18 (d, J = 7.2 Hz, 2H), 7.16 – 7.07 (m, 1H), 7.02 (s, 
1H), 4.48 (d, J = 11.9 Hz, 1H), 4.27 (s, 1H), 3.83 (s, 3H), 3.72 (s, 2H), 3.47 (s, 
2H), 3.25 (s, 2H), 2.99 (s, 2H), 2.91 (s, 1H), 2.28 (d, J = 20.6 Hz, 2H), 2.16 – 
1.91 (m, 2H). 13C NMR (151 MHz, DMSO-d6) δ 161.01, 139.88, 135.92, 
134.91, 131.79, 130.07, 123.74, 114.53, 60.74, 58.68, 54.65, 52.14, 45.27, 
32.59, 26.56, 25.42.19F NMR (376 MHz, DMSO-d6) δ -73.77.  HRMS (ESI-
TOF) m/z calcd for [M + H] 325.2274, found 325.2282. 
N-phenethyl-N-(pyridin-2-ylmethyl)piperidin-4-amine – 340 
LCMS RT (Method 2) 4.63 min (m/z  296.2) 1H NMR (400 MHz, DMSO-d6) 
δ 8.85 (s, 1H), 8.64 (ddd, J = 4.9, 1.8, 0.9 Hz, 1H), 7.92 (td, J = 7.7, 1.8 Hz, 
1H), 7.56 (d, J = 7.8 Hz, 1H), 7.45 (ddd, J = 7.6, 4.8, 1.1 Hz, 1H), 7.34 – 7.10 
(m, 5H), 4.44 (s, 2H), 3.55 (d, J = 13.1 Hz, 1H), 3.39 (d, J = 12.7 Hz, 2H), 
3.18 (t, J = 8.3 Hz, 2H), 2.89 (qd, J = 9.7, 8.3, 4.8 Hz, 4H), 2.24 – 2.07 (m, 
2H), 1.86 (dt, J = 14.5, 11.0 Hz, 2H).13C NMR (151 MHz, DMSO-d6) δ 
160.91, 156.62, 152.25, 141.14, 139.92, 131.84, 131.73, 129.98, 127.21, 
119.08, 82.15, 65.15, 56.22, 44.67, 31.13, 28.86. 19F NMR (376 MHz, DMSO-
d6) δ -73.80. HRMS (ESI-TOF) m/z calcd for [M + H] 296.2121, found 325. 
296.2136. 
N-(2-((phenethyl(piperidin-4-yl)amino)methyl)phenyl)acetamide – 341 
LCMS RT (Method 2) 3.05 min (m/z  352.3) 1H NMR (400 MHz, DMSO-d6) 
δ 9.97 (s, 1H), 8.89 (s, 1H), 8.57 (s, 1H), 8.23 (s, 1H), 4.53 – 3.90 (m, 5H), 
3.75 (s, 1H), 3.37 (s, 2H), 2.90 (s, 2H), 2.70 (s, 2H), 2.21 (s, 2H), 1.95 (s, 2H), 
1.73 (s, 2H). 13C NMR (151 MHz, DMSO-d6) δ 173.32, 161.44, 161.22, 
140.65, 135.68, 131.67, 131.42, 129.98, 126.65, 124.50, 116.87, 60.92, 54.09, 
46.19, 45.24, 33.06, 27.48, 26.09. 19F NMR (376 MHz, DMSO-d6) δ -70.19. 
HRMS (ESI) m/z calcd for [M + H] 352.2383, found 352.2386. 
N,N-dimethyl-2-((phenethyl(piperidin-4-yl)amino)methyl)benzamide - 
342 
LCMS RT (Method 2) 3.3 min (m/z  366.2) 1H NMR (400 MHz, DMSO-d6) δ 
7.43 (d, J = 7.3 Hz, 1H), 7.35 – 7.19 (m, 4H), 7.12 (dd, J = 12.2, 6.6 Hz, 4H), 
3.57 (s, 4H), 2.97 (s, 4H), 2.73 (s, 3H), 2.58 (d, J = 15.2 Hz, 4H), 2.41 (t, J = 
11.3 Hz, 2H), 1.81 – 1.66 (m, 1H), 1.62 (d, J = 8.2 Hz, 2H), 1.33 (q, J = 12.3, 
11.1 Hz, 2H).  13C NMR (101 MHz, DMSO-d6) δ 170.38, 140.96, 137.96, 
137.33, 129.95, 128.98, 128.59, 128.57, 127.03, 126.26, 126.15, 57.80, 52.26, 
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51.54, 45.97, 38.72, 34.80, 34.43. 19F NMR (376 MHz, DMSO-d6) δ -73.47. 
HRMS (ESI-TOF) m/z calcd for [M + H] 366.2540, found 366.2543. 
2-((phenethyl(piperidin-4-yl)amino)methyl)benzamide - 343 
LCMS RT (Method 2) 2.90 min (m/z  338.2) 1H NMR (400 MHz, DMSO-d6) 
δ 8.39 (d, J = 22.4 Hz, 1H), 7.46 (d, J = 7.5 Hz, 2H), 7.39 – 7.33 (m, 2H), 7.32 
– 7.27 (m, 1H), 7.23 (t, J = 7.3 Hz, 2H), 7.17 – 7.12 (m, 1H), 7.07 (d, J = 7.0 
Hz, 2H), 3.83 (s, 2H), 3.32 (s, 4H), 2.99 (dd, J = 26.5, 11.3 Hz, 2H), 2.68 – 
2.62 (m, 2H), 2.57 – 2.54 (m, 1H), 1.76 (t, J = 10.8 Hz, 1H), 1.67 (d, J = 10.9 
Hz, 2H), 1.47 – 1.33 (m, 2H)  13C NMR (101 MHz, DMSO-d6) δ 140.78, 
137.58, 130.33, 129.67, 129.01, 128.57, 127.04, 126.19, 58.01, 52.11, 45.77, 
35.26, 28.46, 22.83.19F NMR (376 MHz, DMSO-d6) δ -73.45. HRMS (ESI-
TOF) m/z calcd for [M + Na] 360.2046, found 360.2063. 
N,N-diphenethylpiperidin-4-amine - 344 
LCMS RT (Method 2) 3.41 min (m/z  309.4) 1H NMR (400 MHz, DMSO-d6) 
δ 10.06 (s, 1H), 8.75 (s, 1H), 8.37 (s, 1H), 7.29 (d, J = 23.4 Hz, 10H), 3.78 (s, 
1H), 3.40 (s, 6H), 3.12 – 2.90 (m, 5H), 2.22 (s, 2H), 1.91 (d, J = 12.8 Hz, 2H). 
19F NMR (376 MHz, DMSO-d6) δ -73.67. HRMS (ESI-TOF) m/z calcd for [M 
+ H] 309.2325, found 309.2324. 
N-phenethyl-N-(3-phenylpropyl)piperidin-4-amine - 345 
LCMS RT (Method 2) 3.59 min (m/z  323.2)  1H NMR (400 MHz, DMSO-d6) 
δ 9.65 (s, 1H), 8.63 (s, 1H), 8.28 (s, 1H), 7.47 – 7.01 (m, 10H), 3.69 (s, 1H), 
3.23 (s, 3H), 3.07 – 2.87 (m, 4H), 2.66 (s, 2H), 2.18 (d, J = 11.9 Hz, 2H), 2.02 
(d, J = 8.2 Hz, 2H), 1.84 (d, J = 13.5 Hz, 2H), 1.59 (d, J = 53.5 Hz, 2H), 1.24 
(s, 1H). 19F NMR (376 MHz, DMSO-d6) δ -73.55. HRMS (ESI-TOF) m/z 
calcd for [M + H] 323.2482, found 323.2487. 
N-phenethyl-N-(piperidin-4-yl)benzamide – 346 
 
To a solution of tert-butyl 4-(phenethylamino)piperidine-1-carboxylate (60mg, 
0.197 mmol) in DCM (0.5 mL) was added benzoyl chloride (0.027 ml, 0.237 
mmol) followed by triethylamine (0.060 ml, 0.434 mmol) and DMAP (2.408 
mg, 0.020 mmol)  at room temperature. The reaction was stirred overnight, 
solvent was removed under nitrogen. Boc deprotection and purification was 
carried out in an analogous manner to general procedure A, yielding N-
phenethyl-N-(piperidin-4-yl)benzamide, as a mono-TFA salt. LCMS RT 
(Method 2) 3.83 min (m/z  309.2) 1H NMR (400 MHz, DMSO-d6) δ 8.63 (s, 
1H), 8.34 (s, 1H), 7.44 (dd, J = 5.0, 1.9 Hz, 3H), 7.37 – 7.31 (m, 2H), 7.21 (d, 
J = 18.0 Hz, 4H), 6.83 (s, 1H), 4.23 (s, 1H), 3.52 (s, 2H), 3.31 (d, J = 15.5 Hz, 
3H), 2.78 (d, J = 48.4 Hz, 3H), 2.25 (s, 1H), 1.81 (d, J = 68.1 Hz, 3H). 13C 
NMR (151 MHz, DMSO-d6) δ 161.10, 142.33, 141.19, 140.54, 139.80, 
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132.49, 131.58, 129.52, 129.10, 117.23, 56.71, 54.07, 51.61, 46.33, 45.63, 
39.34, 37.68, 29.51, 29.05. 19F NMR (376 MHz, DMSO-d6) δ -73.71. [M + 
H+]; HRMS (ESI) m/z calcd for [M + H] 309.1961, found 309.1957. 
 
N-phenethyl-N-(piperidin-4-yl)benzenesulfonamide - 347 
To a solution of tert-butyl 4-(phenethylamino)piperidine-1-carboxylate (60mg, 
0.197 mmol) in DCM (0.5mL) was added benzenesulfonyl chloride (30.2 µl, 
0.237 mmol) followed by triethylamine (35.7 µl, 0.256 mmol) at room 
temperature, the reaction was stirred overnight. Boc deprotection and 
purification is carried out in an analogous manner to general procedure A to 
yield N-phenethyl-N-(piperidin-4-yl)benzenesulfonamide. LCMS RT (Method 
2) 4.19 min (m/z  345.2 1H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 2H), 7.92 – 
7.82 (m, 2H), 7.70 – 7.62 (m, 1H), 7.62 – 7.54 (m, 2H), 7.34 – 7.25 (m, 2H), 
7.21 (tt, J = 7.9, 1.4 Hz, 3H), 3.99 (tt, J = 12.0, 3.9 Hz, 1H), 3.24 (tdd, J = 8.5, 
5.7, 3.5 Hz, 4H), 3.00 – 2.79 (m, 4H), 1.83 (qd, J = 13.1, 4.1 Hz, 2H), 1.51 
(dd, J = 13.7, 3.6 Hz, 2H 13C NMR (101 MHz, DMSO-d6) δ 141.01, 138.81, 
133.37, 129.98, 129.10, 128.94, 127.10, 126.96, 53.21, 45.82, 43.35, 38.01, 
27.25. 19F NMR (376 MHz, DMSO-d6) δ -73.58.  [M + H+]; HRMS (ESI) m/z 
calcd for [M + H] 345.1631, found 345.1641. 
N-phenethyl-N-propylpiperidin-4-amine - 348 
LCMS RT (Method 2) 2.61 min (m/z  247.1) 1H NMR (400 MHz, DMSO-d6) 
δ 10.07 (s, 1H), 8.95 (s, 1H), 8.63 (s, 1H), 7.49 – 7.15 (m, 5H), 3.76 – 3.63 (m, 
1H), 3.43 (s, 3H), 3.29 (s, 2H), 3.13 (s, 2H), 3.04 – 2.93 (m, 3H), 2.20 (s, 2H), 
1.91 (q, J = 10.3, 9.3 Hz, 2H), 1.73 (s, 2H), 0.93 (t, J = 7.3 Hz, 3H). 13C NMR 
(101 MHz, DMSO-d6) δ 129.26, 129.03, 127.34, 57.53, 52.01, 51.60, 42.55, 
30.44, 23.40, 18.17, 11.33.19F NMR (376 MHz, DMSO-d6) δ -73.71. HRMS 
(ESI-TOF) m/z calcd for [M + H]247.2169, found 247.2165. 
N-isobutyl-N-phenethylpiperidin-4-amine – 349  
LCMS RT (Method 2) 3.02 min (m/z  261.2) HRMS (ESI) m/z calcd for [M + 
H] 261.2325, found 261.2337. 
N-(cyclopentylmethyl)-N-phenethylpiperidin-4-amine - 350 
LCMS RT (Method 2) 3.22 min (m/z  287.4)  1H NMR (400 MHz, DMSO-d6) 
δ 9.70 (s, 1H), 8.95 (s, 1H), 8.64 (s, 1H), 7.39 – 7.22 (m, 5H), 3.80 – 3.71 (m, 
1H), 3.59 (s, 2H), 3.44 (d, J = 11.7 Hz, 2H), 3.30 (s, 1H), 3.19 (s, 2H), 3.02 (d, 
J = 22.7 Hz, 3H), 2.34 – 2.13 (m, 3H), 2.03 – 1.78 (m, 4H), 1.59 (d, J = 39.7 
Hz, 4H), 1.23 (s, 2H). 13C NMR (101 MHz, DMSO-d6) δ 158.60, 137.27, 
129.27, 129.06, 127.36, 57.86, 55.64, 52.39, 42.54, 36.12, 31.07, 30.13, 24.93, 
23.41, 22.86.19F NMR (376 MHz, DMSO-d6) δ -73.76. HRMS (ESI-TOF) m/z 
calcd for [M + H] 287.2482 , found 287.2484. 
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N-(cyclohexylmethyl)-N-phenethylpiperidin-4-amine – 351 
 
LCMS RT (Method 2) 3.40 min (m/z  301.4) 1H NMR (400 MHz, DMSO-d6) 
δ 9.49 (s, 1H), 8.90 (s, 1H), 8.59 (s, 1H), 7.54 – 6.98 (m, 5H), 3.70 (s, 1H), 
3.42 (d, J = 12.6 Hz, 2H), 3.27 (s, 2H), 3.01 (d, J = 10.2 Hz, 5H), 2.19 (dd, J = 
27.0, 12.4 Hz, 2H), 1.98 – 1.56 (m, 7H), 1.33 – 1.05 (m, 3H), 0.95 (dd, J = 
17.1, 7.3 Hz, 2H). 13C NMR (151 MHz, DMSO-d6) δ 161.30, 139.89, 131.99, 
131.74, 130.04, 119.18, 60.74, 59.60, 55.81, 45.14, 36.73, 33.38, 32.70, 28.54, 
28.09, 28.01, 26.07, 25.15.19F NMR (376 MHz, DMSO-d6) δ -73.76. HRMS 
(ESI-TOF) m/z calcd for [M + H] 301.2638, found 301.2638. 
 
N-(3,5-dichlorobenzyl)-N-phenethylpiperidin-4-amine – 352 
LCMS RT (Method 2) 3.91 min (m/z  363.1) 1H NMR (600 MHz, DMSO-d6) 
δ 8.60 (s, 1H), 8.26 (s, 1H), 7.64 (d, J = 66.3 Hz, 1H), 7.57 – 7.36 (m, 1H), 
7.26 (s, 2H), 7.19 (s, 1H), 7.14 (d, J = 6.3 Hz, 2H), 4.86 – 3.83 (m, 3H), 3.68 
(s, 1H), 3.43 – 3.18 (m, 2H), 3.01 – 2.77 (m, 3H), 2.77 – 2.59 (m, 2H), 2.31 – 
1.46 (m, 4H).13C NMR (101 MHz, DMSO-d6) δ 158.54, 135.52, 134.50, 
133.92, 129.10, 128.78, 128.28, 126.79, 115.65, 52.75, 51.76, 45.44, 43.10, 
41.94, 32.07, 24.45. 19F NMR (376 MHz, DMSO-d6) δ -73.50 HRMS (ESI) 
m/z calcd for [M + H] 363.1389, found 363.1396. 
N-(3-bromo-5-chlorobenzyl)-N-phenethylpiperidin-4-amine – 353 
1H NMR (600 MHz, DMSO-d6) δ 10.58 (s, 1H), 8.56 (s, 1H), 8.19 (s, 1H), 
7.78 (s, 3H), 7.42 – 6.94 (m, 7H), 3.68 (s, 2H), 3.35 (s, 3H), 2.71 (s, 7H), 1.79 
(s, 4H). 13C NMR (151 MHz, DMSO-d6) δ 161.26, 139.56, 137.31, 131.79, 
131.48, 129.96, 125.38, 116.82, 60.83, 55.30, 55.16, 53.85, 45.73, 32.59, 
26.76. . 19F NMR (376 MHz, DMSO-d6) δ -70.13 [M + H+]; HRMS (ESI) m/z 
calcd for [M + Na] 431.0683, found 431.0704. 
 
N-(4-bromo-3-chlorobenzyl)-N-phenethylpiperidin-4-amine – 354 
LCMS RT (Method 2) 3.79 min (m/z  407.1) 1H NMR (600 MHz, DMSO-d6) 
δ 8.29 – 6.79 (m, 8H), 3.88 (d, J = 278.1 Hz, 4H), 3.28 (d, J = 115.5 Hz, 3H), 
2.86 (d, J = 47.3 Hz, 4H), 2.30 – 1.45 (m, 4H). 13C NMR (151 MHz, DMSO-
d6) δ 161.24, 137.01, 135.98, 134.70, 133.29, 131.81, 131.57, 129.80, 116.84, 
60.63, 55.30, 53.82, 45.43, 32.67, 26.1219F NMR (376 MHz, DMSO-d6) δ -
73.11 HRMS (ESI) m/z calcd for [M + H] 407.0884, found 407.0899. 
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N-(3-chloro-4-fluorobenzyl)-N-phenethylpiperidin-4-amine – 355 
LCMS RT (Method 2) 3.68 min (m/z  347.7) 1H NMR (400 MHz, DMSO-d6) 
δ 10.52 (s, 1H), 9.05 (s, 1H), 8.87 (s, 1H), 8.16 – 7.01 (m, 8H), 3.36 (d, J = 
10.8 Hz, 2H), 3.15 (s, 1H), 3.01 – 2.82 (m, 3H), 2.76 (s, 1H), 2.19 (t, J = 13.1 
Hz, 4H). 13C NMR (151 MHz, DMSO-d6) δ 161.31, 136.58, 133.60, 131.79, 
131.58, 129.95, 120.17, 117.01, 60.43, 55.24, 53.49, 45.42, 32.62, 26.14. 19F 
NMR (376 MHz, DMSO-d6) δ -73.92, -114.90. HRMS (ESI) m/z calcd for [M 
+ Na] 369.1504, found 369.1486. 
 
N-(3,4-dichlorobenzyl)-N-phenethylpiperidin-4-amine – 356 
LCMS RT (Method 2) 3.93 min (m/z  363.1) 1H NMR (400 MHz, DMSO-d6) 
δ 10.51 (s, 1H), 8.64 (s, 1H), 8.28 (s, 1H), 7.58 (s, 2H), 7.25 (ddd, J = 8.8, 4.4, 
2.5 Hz, 2H), 7.23 – 7.17 (m, 1H), 7.14 (d, J = 7.2 Hz, 2H), 4.20 (br, 7H), 2.98 
– 2.81 (m, 3H), 2.73 (s, 2H), 2.04 – 1.52 (m, 4H). 13C NMR (151 MHz, dmso) 
δ 161.23, 134.47, 133.57, 131.80, 131.37, 129.41, 117.04, 60.43, 55.26, 53.56, 
46.06, 37.49, 27.78. 19F NMR (376 MHz, DMSO-d6) δ -73.90. HRMS (ESI) 
m/z calcd for [M + H] 363.1389, found 363.1373. 
N-(3-bromo-4-chlorobenzyl)-N-phenethylpiperidin-4-amine – 357 
LCMS RT (Method 2) 3.85 min (m/z  407.1) 1H NMR (600 MHz, DMSO-d6) 
δ 10.51 (s, 1H), 8.90 (s, 1H), 8.57 (s, 1H), 8.07 (s, 1H), 7.60 (s, 2H), 7.41 – 
6.96 (m, 5H), 4.39 (s, 2H), 3.66 (s, 2H), 3.23 (s, 1H), 3.00 – 2.65 (m, 4H), 
2.26 (s, 2H), 2.08 – 1.52 (m, 4H).13C NMR (101 MHz, DMSO-d6) δ 158.53, 
135.18, 131.86, 131.46, 130.97, 129.12, 128.86, 127.28, 52.53, 45.44, 42.96, 
40.55, 32.07, 25.58. 19F NMR (376 MHz, DMSO-d6) δ -73.89. HRMS (ESI) 
m/z calcd for [M + H] 407.0884, found 407.0874. 
N-(2,3-dichlorobenzyl)-N-phenethylpiperidin-4-amine – 358 
LCMS RT (Method 2) 3.90 min (m/z  363.1) 1H NMR (400 MHz, DMSO-d6) 
δ 8.57 (s, 1H), 8.19 (s, 1H), 7.49 (s, 1H), 7.47 – 7.36 (m, 1H), 7.37 – 7.19 (m, 
3H), 7.14 (dd, J = 17.8, 7.1 Hz, 3H), 3.77 (s, 2H), 3.29 (d, J = 10.6 Hz, 3H), 
3.00 – 2.78 (m, 3H), 2.70 (d, J = 40.5 Hz, 3H), 1.87 (s, 2H), 1.67 (s, 2H). 13C 
NMR (151 MHz, DMSO-d6) δ 176.30, 143.84, 131.81, 131.77, 131.66, 
131.54, 131.24, 130.89, 128.98, 57.89, 55.39, 54.91, 46.30, 37.56, 27.81. 19F 
NMR (376 MHz, DMSO-d6) δ -73.77 HRMS (ESI) m/z calcd for [M + Na] 
385.1209, found 385.1190. 
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N-(2-chloro-3-(trifluoromethyl)benzyl)-N-phenethylpiperidin-4-amine – 
359 
LCMS RT (Method 2) 4.23 min (m/z  397.2 1H NMR (400 MHz, DMSO-d6) δ 
8.85 (s, 1H), 8.54 (s, 1H), 7.81 – 7.61 (m, 2H), 7.51 – 7.37 (m, 1H), 7.34 – 
7.19 (m, 2H), 7.19 – 7.09 (m, 2H), 4.41 (s, 1H), 3.86 (s, 2H), 3.33 (d, J = 45.2 
Hz, 2H), 3.00 – 2.78 (m, 3H), 2.75 (s, 1H), 2.65 (d, J = 8.6 Hz, 2H), 1.86 (s, 
2H), 1.65 (s, 2H). 13C NMR (151 MHz, DMSO-d6) δ 161.14, 144.01, 143.13, 
137.15, 131.82, 131.28, 130.38, 129.06, 125.25, 58.05, 55.34, 54.10, 46.20, 
37.45, 27.68.19F NMR (376 MHz, DMSO-d6) δ -60.88, -74.03. HRMS (ESI) 
m/z calcd for [M + H] 397.1653, found 397.1655. 
N-(2-chloro-3-fluorobenzyl)-N-phenethylpiperidin-4-amine – 360 
LCMS RT (Method 2) 3.6 min (m/z  347.1) 1H NMR (600 MHz, DMSO-d6) δ 
8.59 (s, 1H), 8.17 (s, 1H), 7.45 – 7.27 (m, 3H), 7.24 (t, J = 7.2 Hz, 2H), 7.17 
(d, J = 7.3 Hz, 1H), 7.15 – 7.09 (m, 2H), 4.18 (s, 4H), 3.83 (s, 2H), 2.88 (s, 
3H), 2.69 (s, 2H), 1.89 (s, 2H), 1.68 (s, 2H).13C NMR (151 MHz, DMSO-d6) δ 
161.19, 136.88, 131.82, 131.28, 130.38, 129.07, 127.04, 125.24, 118.80, 
58.01, 55.32, 54.09, 46.18, 37.58, 27.66. 19F NMR (376 MHz, DMSO-d6) δ -
74.00 [M + H+]; HRMS (ESI) m/z calcd for [M + H] 347.1685, found 
347.1684 
N-(2,4-dichlorobenzyl)-N-phenethylpiperidin-4-amine - 361 
LCMS RT (Method 2) 3.85 min (m/z  363.1) 1H NMR (400 MHz, DMSO-d6) 
δ 8.59 (s, 1H), 8.21 (s, 1H), 7.60 (s, 1H), 7.47 (d, J = 5.1 Hz, 1H), 7.37 (s, 
1H), 7.27 (t, J = 7.4 Hz, 3H), 7.20 (d, J = 7.1 Hz, 1H), 7.16 (d, J = 7.3 Hz, 
3H), 4.35 (s, 5H), 3.79 (s, 2H), 2.89 (d, J = 9.9 Hz, 2H), 2.71 (s, 2H), 1.90 (s, 
2H), 1.70 (s, 2H13C NMR (151 MHz, DMSO-d6) δ 161.17, 140.07, 136.41, 
134.57, 131.82, 131.34, 130.32, 129.12, 116.89, 57.86, 55.19, 53.50, 46.12, 
37.45, 27.67.19F NMR (376 MHz, DMSO-d6) δ -74.08. HRMS (ESI-TOF) m/z 
calcd for [M + H] 363.1389, found 363.1392.  
N-(2-chloro-4-fluorobenzyl)-N-phenethylpiperidin-4-amine – 362 
LCMS RT (Method 2) 3.55 min (m/z  346.1) 1H NMR (400 MHz, DMSO-d6) 
δ 8.60 (s, 1H), 8.21 (s, 1H), 7.40 (s, 3H), 7.25 (t, J = 7.4 Hz, 2H), 7.16 (dd, J = 
18.4, 7.1 Hz, 3H), 4.27 (s, 2H), 3.80 (s, 2H), 3.32 (s, 2H), 2.90 (s, 3H), 2.65 (s, 
2H), 1.88 (s, 2H), 1.74 (s, 2H). 13C NMR (101 MHz, dmso) δ 158.45, 129.11, 
128.71, 126.60, 126.19, 116.77, 114.68, 52.24, 50.75, 43.38, 42.04, 24.87, 
24.78. 19F NMR (376 MHz, DMSO-d6) δ -68.22. HRMS (ESI) m/z calcd for 
[M + H] 347.1685, found 347.1677. 
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N-(4-bromo-3-chlorobenzyl)-N-(2-methyl-2-phenylpropyl)piperidin-4-
amine – 364 
LCMS RT (Method 2) 5.08 min (m/z  437.01H NMR (600 MHz, DMSO-d6) δ 
8.37 – 8.23 (m, 1H), 7.99 – 7.79 (m, 1H), 7.63 (d, J = 8.2 Hz, 1H), 7.39 (d, J = 
1.9 Hz, 1H), 7.37 – 7.30 (m, 2H), 7.23 (t, J = 7.7 Hz, 2H), 7.16 – 7.08 (m, 
2H), 3.33 (s, 2H), 3.19 (d, J = 12.4 Hz, 2H), 2.59 (d, J = 15.5 Hz, 4H), 2.32 (tt, 
J = 11.9, 3.7 Hz, 1H), 1.72 – 1.62 (m, 2H), 1.47 (qd, J = 13.3, 4.1 Hz, 2H), 
1.23 (s, 6H). 13C NMR (151 MHz, dmso) δ 166.51, 145.90, 136.58, 132.56, 
131.22, 130.99, 129.14, 122.13, 65.41, 58.32, 55.58, 46.41, 29.94, 27.31. 19F 
NMR (376 MHz, dmso) δ -73.90. HRMS (ESI) m/z calcd for [M + H] 
437.1176, found 437.1158. 
N-(4-bromo-3-chlorobenzyl)-N-(2-phenylcyclopentyl)piperidin-4-amine – 
365  
LCMS RT (Method 2) 3.55 min (m/z  449.0)  HRMS (ESI) m/z calcd for [M + 
H] 449.1177, found 449.1168. 
N-(4-bromo-3-chlorobenzyl)-N-(3-methyl-2-phenylbutyl)piperidin-4-
amine – 366 
LCMS RT (Method 2) 4.46 min (m/z  449.0)  1H NMR (600 MHz, DMSO-d6) 
δ 8.49 (s, 1H), 8.14 (s, 2H), 7.55 (s, 1H), 7.31 – 7.20 (m, 2H), 7.17 (s, 1H), 
7.11 (s, 1H), 7.02 (d, J = 6.1 Hz, 2H), 6.91 (s, 1H), 4.09 (s, 3H), 3.57 (s, 1H), 
3.44 (s, 1H), 3.33 – 3.13 (m, 2H), 2.83 (s, 1H), 2.73 (s, 2H), 2.60 (d, J = 34.9 
Hz, 2H), 1.81 (s, 2H), 1.56 (s, 2H), 1.38 (s, 1H), 0.85 (s, 2H), 0.58 (s, 2H). 13C 
NMR (151 MHz, dmso) δ 161.18, 145.96, 136.30, 135.82, 132.89, 131.83, 
131.39, 130.71, 128.94, 120.62, 57.27, 55.98, 55.66, 53.71, 46.29, 33.71, 
28.16, 26.44, 24.35, 23.07. 19F NMR (376 MHz, dmso) δ -73.60 [M + H+]; 
HRMS (ESI) m/z calcd for [M + H] 451.1333, found 451.1353. 
N-(4-bromo-3-chlorobenzyl)-N-(2,3-dihydro-1H-inden-2-yl)piperidin-4-
amine – 367 
LCMS RT (Method 2) 4.13 min (m/z  421.0) 1H NMR (600 MHz, DMSO-d6) 
δ 8.69 – 8.44 (m, 1H), 8.36 – 8.05 (m, 1H), 7.86 – 7.49 (m, 2H), 7.39 – 7.24 
(m, 1H), 7.21 – 7.13 (m, 2H), 7.13 – 7.01 (m, 2H), 4.46 (s, br, 1H), 3.75 (s, 
2H), 3.37 – 3.24 (m, 2H), 3.11 – 2.95 (m, 2H), 2.91 – 2.83 (m, 2H), 1.90 (s, 
2H), 1.70 (s, 2H).13C NMR (151 MHz, dmso) δ 161.21, 144.01, 136.79, 
136.08, 129.60, 129.20, 127.65, 127.39, 118.59, 74.30, 64.23, 58.10, 46.14, 
40.20, 28.90. 19F NMR (376 MHz, dmso) δ -73.68. HRMS (ESI) m/z calcd for 
[M + H] 421.0863, found 421.0879. 
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N-(4-bromo-3-chlorobenzyl)-N-(3-phenylcyclobutyl)piperidin-4-amine – 
368 
LCMS RT (Method 2) 3.76 min (m/z  435.1) 1H NMR (600 MHz, DMSO-d6) 
δ 10.63 (s, 1H), 8.90 (s, 1H), 8.64 (s, 1H), 7.84 (d, J = 48.1 Hz, 2H), 7.48 (s, 
1H), 7.34 – 7.24 (m, 2H), 7.25 – 7.10 (m, 3H), 4.31 (d, J = 44.5 Hz, 2H), 4.00 
(s, 1H), 3.62 (s, 2H), 3.39 (s, 3H), 3.08 (s, 1H), 2.94 (s, 2H), 2.68 (s, 1H), 2.16 
(d, J = 52.6 Hz, 3H), 1.95 (s, 2H).13C NMR (151 MHz, dmso) δ 161.31, 
145.86, 137.13, 136.04, 134.67, 131.58, 131.40, 129.67, 126.05, 117.01, 
59.60, 56.11, 53.57, 46.30, 45.17, 38.96, 35.10, 26.69. 19F NMR (376 MHz, 
dmso) δ -74.02. HRMS (ESI) m/z calcd for [M + H] 435.1020, found 
435.1025. 
N-(4-bromo-3-chlorobenzyl)-N-(2-phenylbutyl)piperidin-4-amine – 369 
LCMS RT (Method 2) 4.27 min (m/z  437.0) 1H NMR (600 MHz, DMSO-d6) 
δ 8.51 (s, 1H), 8.14 (s, 1H), 7.70 – 7.54 (m, 1H), 7.31 – 7.24 (m, 2H), 7.20 (q, 
J = 7.6, 7.0 Hz, 1H), 7.09 (s, 2H), 7.04 (s, 1H), 3.57 (d, J = 51.1 Hz, 2H), 3.27 
(d, J = 28.5 Hz, 2H), 2.79 (s, 2H), 2.66 (s, 1H), 2.57 (s, 2H), 1.79 (d, J = 44.2 
Hz, 3H), 1.61 (s, 1H), 1.53 (s, 2H), 1.41 (s, 1H), 0.66 (s, 3H).13C NMR (151 
MHz, dmso) δ 161.39, 136.45, 135.86, 132.85, 131.46, 131.14, 130.93, 
129.06, 118.60, 59.27, 57.26, 55.98, 49.08, 46.29, 29.29, 26.94, 15.06. 19F 
NMR (376 MHz, dmso) δ -73.77. HRMS (ESI) m/z calcd for [M + H] 
437.1176, found 437.1168. 
N-(4-bromo-3-chlorobenzyl)-N-(3-(3-bromophenyl)cyclobutyl)piperidin-
4-amine – 371  
LCMS RT (Method 2) 4.17 min (m/z  513.1) 1H NMR (400 MHz, DMSO-d6) 
δ 9.00 (s, 1H), 8.76 (s, 1H), 7.91 – 7.74 (m, 2H), 7.51 – 7.33 (m, 3H), 7.33 – 
7.17 (m, 2H), 4.51 (s, 2H), 4.22 (s, 2H), 3.94 (s, 1H), 3.54 (s, 1H), 3.39 (d, J = 
12.3 Hz, 3H), 2.93 (t, J = 11.7 Hz, 2H), 2.61 (s, 1H), 2.11 (s, 2H), 2.03 – 1.88 
(m, 2H). 13C NMR (101 MHz, dmso) δ 158.91, 146.14, 134.51, 133.79, 
130.88, 129.83, 126.35, 126.31, 122.20, 56.71, 53.14, 50.72, 42.72, 32.05, 
23.88. 19F NMR (376 MHz, dmso) δ -74.13. HRMS (ESI) m/z calcd for [M + 
H] 513.0125, found 513.0119. 
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N-(4-bromo-3-chlorobenzyl)-N-(3-(4-bromophenyl)cyclobutyl)piperidin-
4-amine, 372, mixture of syn and anti cylclobutane isomers. 
 
 
 
 
 
 
 
 
 
 
 
Appearance: Transparent, colourless oil as free base, off-white solid as di-
TFA or 1:1 oxalate salt. 
LCMS RT (Method 2) 4.16 min (m/z  512.9) 
HRMS (ESI-TOF) m/z calcd for [M + H] 513.0125, found 513.0137. 
Free base: 
1H NMR (400 MHz, CDCl3) δ 7.54 – 7.44 (m, 2H), 7.39 (ddd, J = 14.5, 8.5, 
2.1 Hz, 2H), 7.16 – 6.95 (m, 3H), 3.59 (dd, J = 9.1, 1.8 Hz, 2H), 3.46 – 3.25 
(m, 1H), 3.12 (d, J = 11.8 Hz, 2H), 2.99 (td, J = 9.8, 7.3 Hz, 1H), 2.60 (td, J = 
11.9, 2.8 Hz, 1H), 2.53 (t, J = 12.2 Hz, 2H), 2.46 – 2.31 (m, 2H), 2.23 (s, 2H), 
2.20 – 2.09 (m, 1H), 1.86 (tdd, J = 10.9, 6.9, 2.5 Hz, 2H), 1.53 – 1.38 (m, 2H). 
13C NMR (101 MHz, CDCl3) δ 143.89, 143.63, 134.05, 133.24, 133.22, 
131.35, 131.23, 129.61, 129.51, 128.48, 128.23, 127.32, 127.17, 119.85, 
119.53, 77.30, 57.45, 57.38, 53.46, 52.19, 49.89, 49.53, 46.43, 36.86, 34.86, 
32.63, 32.57, 29.75.  
1:1 Oxalate salt – Salt form for PK studies: 
1H NMR (400 MHz, DMSO-d6) δ 7.67 (dd, J = 8.2, 7.5 Hz, 1H), 7.56 (dd, J = 
9.5, 2.0 Hz, 1H), 7.52 – 7.38 (m, 2H), 7.29 – 7.09 (m, 3H), 3.70 – 3.50 (m, 
3H), 3.44 – 3.30 (m, 1H), 3.22 (d, J = 12.0 Hz, 2H), 3.02 (p, J = 9.1 Hz, 1H), 
2.75 (t, J = 12.0 Hz, 2H), 2.37 (ddd, J = 11.2, 9.0, 5.2 Hz, 2H), 2.20 – 2.01 (m, 
1H), 1.84 – 1.65 (m, 4H), 1.58 (q, J = 14.1, 12.9 Hz, 2H). 13C NMR  
Di- TFA Salt: 
1H NMR 13C NMR (151 MHz, dmso)  δ 161.27, 145.29, 137.14, 136.10, 
134.64, 134.22, 132.02, 126.07, 122.58, 59.57, 55.99, 53.59, 45.30, 38.81, 
37.57, 34.53, 26.60, 25.86.  
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See appendix A9 for hard copies of spectal and chromatographic 
analyses. 
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Chapter 4.  
General: 
It was noted that the piperazine compounds have a tendency to decompose 
under normal phase silica gel chromatography, the addition of 0.2% of 
triethylamine v/v into the hexanes mobile phase was sufficient to stop the 
(presumably) acid catalysed decomposition of the products. In such 
circumstances where the products undergo normal phase chromatographic 
purification, this additive was used as a precaution in every case, as stated. 
 
 
 
 
(4-chlorophenyl)(4-iodophenyl)methanol, 402.  
A flame-dried 500 mL round-bottom flask was charged with 4-
iodobenzaldehyde (5 g, 21.55 mmol) and Et2O (170 ml) under nitrogen. The 
mixture was cooled to 0 °C and (4-chlorophenyl)magnesium bromide (22.63 
ml, 22.63 mmol) was added dropwise. The reaction was stirred at 0 °C for 1h. 
H2O (25 mL) was added to quench the reaction, the mixture was poured into a 
seperatory funnel, diluted with brine (100mL) and EtOAc. Organics are 
seperated and the aqueous layer was extracted twice with EtOAc (2x150mL). 
The combined organic phases were dried over magnesium sulfate, and 
concentrated under reduced pressure to give the crude product, which is 
purified by gradient column chromatography 15-30% EtOAc in hexanes to 
yield 1-(4-chlorophenyl)(4-iodophenyl)methanol, 402, as a white solid. (6.78 
g, 19.68 mmol, 91 % yield) LCMS RT (Method 2)  3.61 min, (no m/z in +ve 
mode) 1H NMR (400 MHz, CDCl3) δ 7.74 – 7.60 (m, 2H), 7.36 – 7.23 (m, 
4H), 7.13 – 7.07 (m, 2H), 5.75 (s, 1H), 2.25 (s, 1H). 13C NMR (400 MHz, , 
CDCl3) δ 142.98, 141.68, 137.64, 133.60, 128.74, 128.37, 127.83, 93.35, 
77.32, 77.00, 76.68, 75.06. IR (neat) 3332, 1903, 1586, 1481.  
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1-chloro-4-(chloro(4-iodophenyl)methyl)benzene - 403. 
1-(4-chlorophenyl)(4-iodophenyl)methanol (1) (4g, 11.61 mmol) was 
dissolved in DCM (20 ml) in an oven-dried 50mL round-bottom flask at room 
temperature, to this was added N,N-dimethylformamide (0.1mL, 1.291 mmol) 
followed by dropwise addition of  thionyl chloride (2.54 mL, 34.8 mmol), 
evoluion of gas is noted. The reaction was stirred for 90 minutes and was 
found to be complete by TLC. The majority of volatiles were then removed 
under rotary evaporation, followed by further evaporation under high vaccum 
to give the title compound -chloro-4-(chloro(4-iodophenyl)methyl)benzene 
403, as a sand-coloured solid (crude product 4.57 g, 12.59 mmol). Crude 
product was taken through to the next step. LCMS RT (Method 2) 4.02min, 
(no m/z in +ve mode), 1H NMR (400 MHz, CDCl3) δ 7.71 – 7.66 (m, 2H), 
7.35 – 7.29 (m, 4H), 7.14 – 7.11 (m, 2H), 6.02 (s, 1H). 13C NMR (101 MHz, , 
CDCl3) δ 140.29, 139.00, 137.75, 134.21, 129.53, 129.04, 128.82, 94.05, 
77.32, 77.00, 76.68, 62.66. IR (neat) 1901, 1582, 1483, 1398.  
 
 
 
 
 
 
 
Tert-butyl4-((4-chlorophenyl)(4-iodophenyl)methyl)piperazine-1-
carboxylate - 404 
To a stirring solution of 1-chloro-4-(chloro(4-iodophenyl)methyl)benzene, 403 
(4.5 g, 12.40 mmol) in N,N-dimethylformamide (35 ml) in a 100mL round-
bottom flask was added potassium carbonate (3.43 g, 24.79 mmol), potassium 
iodide (2.264 g, 13.64 mmol) and tert-butyl piperazine-1-carboxylate (6.93 g, 
37.2 mmol). The reaction vessel is fitted with a reflux condenser and stirred at 
75°C for 16 hours.The reaction is poured into a seperatory funnel, diluted with 
brine EtOAc (150mL) which is extracted with brine (3x100mL). The organic 
phase was dried over magnesium sulfate, and concentrated under reduced 
pressure to give the crude product, which is purified by gradient column 
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chormatography 0-35% gradient EtOAc in hexanes (containing 0.2% 
triethylamine v/v) to yield tert-butyl 4-((4-chlorophenyl)(4-
iodophenyl)methyl)piperazine-1-carboxylate, 404, as a white solid. (4.86g, 
9.48 mmol, 76 % yield for 2 steps) LCMS RT (Method 2) 3.65min  (m/z 
513.1) 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 8.4 Hz, 2H), 7.30 (d, J = 8.6 
Hz, 2H), 7.25 (d, J = 8.8 Hz, 2H), 7.12 (d, J = 8.3 Hz, 2H), 4.16 (s, 1H), 3.41 
(s-br, 4H), 2.30 (s-br, 4H), 1.43 (s, 9H). 13C NMR (101 MHz, CDCl3 ) δ 
154.71, 141.65, 140.29, 137.77, 132.99, 129.69, 129.03, 128.86, 92.63, 79.61, 
74.75, 51.56, 43.94 (weak, broad), 28.38. IR(neat) 2975, 2812, 1680, 1482, 
1402. 
 
 
 
 
 
Tert-butyl4-((4-chlorophenyl)(4-(2,2,2-
trifluoroacetyl)phenyl)methyl)piperazine-1-carboxylate, 405  
To a solution of tert-butyl 4-((4-chlorophenyl)(4-iodophenyl)methyl) 
piperazine-1-carboxylate, 404 (2g, 3.90 mmol) in THF (Volume: 40 mL) in a 
flame-dried 250mL round bottom flask at -78 °C was added  n-butyllithium 
(5.00 mL of 1.6M solution in hexanes, 8.00 mmol) dropwise and the reaction 
was stirred for 20 minutes at -78 °C. To this was added ethyl 2,2,2-
trifluoroacetate (0.928 mL, 7.80 mmol) and the reaction is stirred for 20 
minutes at -78 °C then allowed to warm to room temperature, and stirring is 
continued for 30 mins. Reaction is quenched with sat.NH4Cl(aq) (20mL), 
poured into a seperatory funnel and diluted with EtOAc, which is washed with 
sat. NaCl(aq) organics dried over magnisium sulfate, evaporated under reduced 
pressure and purified by gradient column chromatography 10-25% gradient 
EtOAc in hexanes (containing 0.2% triethylamine v/v). Yields tert-butyl 4-((4-
chlorophenyl)(4-(2,2,2-trifluoroacetyl)phenyl)methyl)piperazine-1-
carboxylate 405 as an off-white/yellow solid (1.122 g, 2.116 mmol, 58% 
yield) LCMS RT (Method 2) 3.133 (m/z 501.2 (hydrate)) 1H NMR (400 MHz, 
CDCl3) δ 8.03 – 7.97 (m, 2H), 7.59 (dd, J = 8.6, 2.1 Hz, 2H), 7.35 – 7.26 (m, 
4H), 4.31 (s, 1H), 3.43 (m, 4H), 2.34 (d, J = 6.9 Hz, 4H), 1.43 (s, 9H) 13C 
NMR (101 MHz, CDCl3) δ 154.68, 150.42, 139.24, 133.50, 130.73, 129.19, 
129.11, 129.04, 128.94, 128.88, 128.29, 79.72, 75.06, 51.62, 44.47, 28.38. 19F 
NMR (376 MHz, CDCl3) δ -71.44. HRMS (ESI) m/z calcd for [M (hydrate) + 
H] 501.1767, found 501.1731. IR (neat) 2975, 1668, 1420, 1246. 
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Tert-butyl4-((4-chlorophenyl)(4-(2,2,2-trifluoro-1-
(hydroxyimino)ethyl)phenyl)methyl)piperazine-1-carboxylate, 406. 
tert-butyl4-((4-chlorophenyl)(4-(2,2,2-trifluoroacetyl)phenyl)methyl) 
piperazine-1-carboxylate, 405 (976 mg, 2.021 mmol) was dissolved in 
pyridine 20mL, hydroxylamine hydrochloride (211 mg, 3.03 mmol) is added, 
the reaction was stirred at 70C for 3 hours, then stirred at room temperature 
over night. The reaction was subjected to rotary evaporation to remove the 
pyridine, resultant crude oil was then purified directly by gradient column 
chromatography 0-30% gradient EtOAc in hexanes (containing 0.2% 
triethylamine v/v) to yield tert-butyl 4-((4-chlorophenyl)(4-(2,2,2-trifluoro-1-
(hydroxyimino)ethyl)phenyl)methyl)piperazine-1-carboxylate, 406 as a white 
solid. NMRs display approx 1:0.8 mixture of conformational isomers (viz. 
syn/anti oximes).  LCMS RT (Method 2) 3.36 min  (498.1 m/z) 1H NMR (400 
MHz, CDCl3) δ 7.49 – 7.22 (m, 8H), 4.23 (d, J = 4.1 Hz, 1H), 3.42 (d, J = 5.3 
Hz, 4H), 2.33 (t, J = 5.0 Hz, 4H), 2.22 (d, J = 4.6 Hz, 1H), 1.43 (s, 9H). 13C 
NMR (101 MHz, CDCl3) δ 154.91, 154.89, 148.98, 144.09, 143.75, 140.00, 
139.97, 136.93, 133.11, 129.57, 129.24, 129.17, 129.13, 129.02, 128.89, 
128.70, 127.79, 127.75, 127.65, 125.41, 124.08, 117.03, 79.94, 75.18, 51.67, 
51.64, 44.62, 28.37. 19F NMR (376 MHz, CDCl3)  -62.30, -66.19. HRMS 
(ESI) m/z calcd for [M + H] 498.1766, found 498.1790. IR (neat) 2977, 1662, 
1431, 1247, 1164. 
 
 
 
 
 
 
 
 
 
 
 
 
 50 
 
 
 
 
 
 
 
 
 
Tert-butyl(Z)-4-((4-chlorophenyl)(4-(2,2,2-trifluoro-1 
((tosyloxy)imino)ethyl)phenyl)methyl) piperazine-1-carboxylate, 407. 
To a solution of (Z)-tert-butyl 4-((4-chlorophenyl)(4-(2,2,2-trifluoro-1 
(hydroxyimino)ethyl)phenyl) methyl)piperazine-1-carboxylate (1.2g, 2.410 
mmol)  in acetone (15 mL) at 0°C was added triethylamine (1.008 mL, 7.23 
mmol). Following this, 4-methylbenzene-1-sulfonyl chloride (0.551 g, 2.89 
mmol)  was added and the reaction mixture was stirred at room temperature 
for 1 or until determined complete as monitored by TLC. Upon completion the 
volatiles were removed by rotaty evaporation and the crude transparent red oil 
was purified directly by gradient column chromatography 0-40% gradient 
EtOAc in hexanes over 10 CV (containing 0.2% triethylamine v/v) which gave 
(Z)-tert-butyl4-((4-chlorophenyl)(4-(2,2,2-trifluoro-1((tosyloxy)imino)ethyl) 
phenyl)methyl)piperazine-1-carboxylate (6) (1.132 g, 1.735 mmol, 72 % 
yield) as a transparent colourless oil. LCMS RT (Method 2) 3.83min 
(652.2m/z) 1H NMR (400 MHz, CDCl3) δ 7.87 (d, J = 8.4 Hz, 2H), 7.50 (d, J 
= 8.4 Hz, 2H), 7.40 – 7.27 (m, 6H), 4.26 (s, 1H), 3.43 (d, J = 5.2 Hz, 4H), 2.47 
(s, 3H), 2.37 – 2.27 (m, 4H), 1.44 (d, J = 1.0 Hz, 9H). 13C NMR (101 MHz, 
CDCl3) δ 154.69, 153.14, 146.12, 146.06, 139.59, 133.29, 131.09, 129.82, 
129.27, 129.25, 129.00, 128.02, 123.34, 120.94, 79.62, 51.61, 28.37, 21.76. 
19F NMR (376 MHz, CDCl3) δ -61.50, -66.46.  
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Procedure reference: 163 
tert-butyl 4-((4-chlorophenyl)(4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)phenyl)methyl)piperazine-1-carboxylate - 408 
To condensed neat liquid ammonia (5mL) at -78°C was added tert-butyl (Z)-4-
((4-chlorophenyl)(4-(2,2,2-trifluoro-1 ((tosyloxy)imino)ethyl)phenyl)methyl) 
piperazine-1-carboxylate (400 mg, 0.613 mmol) dissolved in 3mL of Et2O. To 
this was added lithium amide (70.4 mg, 3.07 mmol). The sealed tube was 
closed and the reaction was allowed to warm to room temperature and stirred 
overnight, The following day, the reaction was cooled to -78°C, opened, and 
allowed to warm to room temperature under a stream of nitrogen. White solid 
resulted after ether and ammonia had evaporated which was taken up in 
solvent DCM and purified directly by gradient column chromatography 0-80% 
gradient EtOAc in hexanes over 15 CV (containing 0.2% triethylamine v/v) 
yielding tert-butyl 4-((4-chlorophenyl)(4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)phenyl)methyl)piperazine-1-carboxylate (0.760 g, 1.535 mmol, 91 % yield). 
LCMS RT (Method 2) 3.82 min (m/z 495.1) 1H NMR (400 MHz, CDCl3) δ 
7.43 – 7.37 (m, 2H), 7.31 – 7.21 (m, 4H), 7.12 – 7.06 (m, 2H), 4.21 (s, 1H), 
3.44 – 3.32 (m, 4H), 2.28 (s, 4H), 1.42 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 
154.69, 143.75, 140.04, 133.12, 129.07, 128.91, 128.13, 128.12, 126.81, 
126.80, 123.39, 120.66, 79.62, 74.80, 51.57, 36.61, 28.36, 24.65. 19F NMR 
(376 MHz, CDCl3) δ -65.23. HRMS (ESI) m/z calcd for [M + H] 495.1769, 
found 495.1784.   
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1-((4-chlorophenyl)(4-(3-(trifluoromethyl)-3H-diazirin-3yl)phenyl)methyl) 
piperazine - 409 
 
To tert-butyl 4-((4-chlorophenyl)(4-(3-(trifluoromethyl)-3H-diazirin-
3yl)phenyl)methyl) piperazine-1-carboxylate (550mg, 1.111 mmol) at 0C in 
the dark was added a commercially available solution of HCl in Dioxane (4M, 
9 mL, 36.0 mmol) followed by 1mL of methanol. The reaction was allowed to 
warm to room temperature was stirred for 3 hours. On completion as 
determined by LCMS, the solvent was removed by rotary evaporation under 
reduced pressure. Diazirinyl CCZ · HCl is isolated as a yellow solid in 
quantitative yield and is used as such for the next step. LCMS RT (Method 2) 
3.09 min (m/z 395.0) 1H NMR (400 MHz, CDCl3) δ 9.67 (s, 2H), 7.97 (s, 2H), 
7.83 (s, 2H), 7.39 (s, 2H), 7.25 (d, J = 9.2 Hz, 4H), 5.69 (s, 1H), 3.84 (s, 4H), 
3.52 (s, 4H). 13C NMR (101 MHz, CDCl3) δ 135.61, 131.36, 130.48, 129.97, 
128.87, 127.74, 123.18, 120.45, 74.28, 48.46, 41.20, 28.35, 27.94.19F NMR 
(376 MHz, CDCl3) δ -65.04. [M + H+]; HRMS (ESI) m/z calcd for [M + H] 
395.1245, found 395.1226. IR (neat) 3378, 2933, 2490, 1641, 1438. 
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14-(4-((4-chlorophenyl)(4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)phenyl)methyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecan-1-amine – 
410 
 
To a solution of 1-((4-chlorophenyl)(4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)phenyl)methyl)piperazine (200mg, 0.507 mmol) in DMF (Volume: 2.533 
mL) with K2CO3 (280mg, 2.086 mmol) was added 2,2-dimethyl-4-oxo-
3,8,11,14,17-pentaoxa-5-azanonadecan-19-yl 4-methylbenzenesulfonate (398 
mg, 0.810 mmol) and the reaction was stirred at 60˚C and monitored by 
LCMS. After 6 hours, almost full consumption of starting material was noted, 
with the concomitant production of Boc-(410) (LCMS RT (Method 2) 3.46 
min (m/z  714.2)). At this point, the solvent was removed by rotary 
evaporation under reduced pressure. The crude is solubilised in approx 1mL of 
anhydrous dioxane and 0.5mL of MeOH, followed by the addition of 4mL of 
4N HCl in dioxane at room temperature, disappearance of the peak for Boc-
(410) was noted after 30 mins by LCMS. Excess HCl was removed from the 
reaction mixture by bubbling with nitrogen for 20 minutes, followed by 
evaporation of volatiles under reducted pressure and purification by gradient 
reverse phase chromtography and lyophilisation of pure fractions to yield 14-
(4-((4-chlorophenyl)(4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)phenyl)methyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecan-1-amine – 410, 
an oil, as a TFA salt. (83mg, 0.135 mmol, 26.7 % yield) LCMS RT (Method 
2) 2.95 min (m/z 614.2) 1H NMR (400 MHz, CDCl3) δ 8.30 (s, 3H), 7.95 (d, J 
= 7.9 Hz, 2H), 7.82 (d, J = 7.3 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 7.20 (d, J = 
7.9 Hz, 2H), 5.73 (s, 1H), 3.98 (s, 4H), 3.82 (t, J = 4.6 Hz, 2H), 3.74 – 3.52 
(m, 18H), 3.36 (s, 2H), 3.19 (s, 2H). 13C NMR (101 MHz, CDCl3) δ 135.63, 
130.31, 130.07, 129.94, 129.04, 127.70, 123.19, 120.47, 70.03, 69.88, 69.49, 
66.47, 64.68, 61.61, 56.76, 48.38, 39.73. HRMS (ESI) m/z calcd for [M + H] 
614.2720, found 614.2729. 
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N-(14-(4-((4-chlorophenyl)(4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)phenyl)methyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecyl)-5-
((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanamide – CCZ-Diazirine-Biotin – 411. 
To a solution of Biotin (9.01 mg, 0.037 mmol) in DMF (Volume: 307 µl) at 
room temperature under an atmosphere of nitrogen was added HATU (14.03 
mg, 0.037 mmol)  and Hunig'sBase (6.44 µl, 0.037 mmol) . The reaction was 
allowed 15 minutes stirring for pre-activation then to this was added 14-(4-((4-
chlorophenyl)(4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)phenyl)methyl)piperazin-1-yl)-3,6,9,12-tetraoxa tetradecan-1-amine 
hydrochloride (20mg, 0.031 mmol). followed by 3 further equivalents of 
Hunigs base. The reaction was stirred for 2 hours and monitored by LCMS. 
Following completion the reaction mixture was purified directly by gradient 
reverse phase preparative HPLC and lyophilized to yield N-(14-(4-((4-
chlorophenyl)(4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)phenyl)methyl)piperazin-1-yl)-3,6,9,12-tetraoxatetradecyl)-5-
((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide 
(15.8mg, 0.019 mmol, 40.8 % yield)  diazirine-CCZ-Biotin  a white solid as its 
TFA salt. 
LCMS RT (Method 2) 3.14min  (m/z 840.2) 1H NMR (400 MHz, CDCl3) δ 
7.56 (d, J = 8.4 Hz, 2H), 7.44 (d, J = 8.5 Hz, 2H), 7.33 (d, J = 8.5 Hz, 2H), 
7.18 (d, J = 8.2 Hz, 2H), 6.94 (s, 1H), 6.75 (s, 1H), 4.72 (s, 1H), 4.60 (dd, J = 
7.9, 4.7 Hz, 1H), 4.40 (dd, J = 7.9, 4.5 Hz, 1H), 3.88 – 3.80 (m, 2H), 3.69 – 
3.49 (m, 19H), 3.43 (d, J = 4.6 Hz, 2H), 3.37 – 3.31 (m, 2H), 3.25 – 3.16 (m, 
1H), 3.08 (s, 4H), 2.95 (dd, J = 13.1, 4.9 Hz, 1H), 2.77 (d, J = 13.1 Hz, 1H), 
2.28 (td, J = 7.2, 3.4 Hz, 2H), 1.68 (tt, J = 13.5, 7.5 Hz, 4H), 1.45 (p, J = 7.1 
Hz, 2H). 19F NMR (376 MHz, CDCl3) δ -65.20, -75.96. 13C NMR (101 MHz, 
CDCl3) δ 174.84, 164.79, 160.78, 139.18, 135.62, 132.97, 129.70, 129.16, 
128.17, 127.51, 116.88, 114.00, 74.48, 70.22, 70.19, 70.08, 69.84, 69.41, 
64.93, 62.34, 60.80, 56.51, 55.17, 51.34, 48.49, 40.26, 39.44, 35.24, 27.67, 
25.35. HRMS (ESI) m/z calcd for [M + H] 840.3496, found 840.3521 
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Biology 
Materials and Methods 
Growth and Maintenance of cells 
Human hepatoma cell line Huh7.5.1 were maintained as a 2D monolayer in 
Dulbecco’s modification of Eagle’s medium (DMEM) (Life Technologies, 
Grand Island, NY, USA) with 10% fetal bovine serum (FBS) and 1% 
Penicillin/Streptomycin within a breathable culture flask (Falcon) in 5% CO2 
at 37°C.  
Passaging protocol 
Once the cells reached 80 % confluence, the medium was removed and the 
flask rinsed with sterile PBS. The cells were then incubated in trypsin/0.05 
%EDTA (Invitrogen) for 4 min at 37 °C to detach from the flask and 
neighboring cells. The reaction is terminated by adding DMEM to the flask 
(4x volume of trypsin used), the cells may then be pelleted by centrifugation 
(2000RPM, 5min) and suspended in DMEM. 50 µl of the cell suspension was 
pipetted into a new flask along with 15 ml of fresh growth medium. Cells were 
incubated in a 37C/ 5 % CO2 incubator. After cells reached passage 30 they 
were discarded. 
HCVcc Assay and ATP Lite Assay 
Huh 7.5.1 cells were cultured as described, and plated in white bottomed 96-
well plates at a density of 104 cells/well and incubated for 24 hours. The cells 
were then infected with HCV-Luc in the presence of increasing concentrations 
of the compound of interest to develop a 10-point dose response curve. The 
viral load was measured 48 hours following treatment using a Renilla 
luciferase assay system (Promega, Madison, WI, USA), efficacy is expressed 
as a percentage in terms of a measured minimal response (DMSO control 
wells) and theoretical maximal response (0 Luminescence). ATP-based cell 
viability assay was carried out in parallel using an ATPlite assay kit 
(PerkinElmer, Waltham, MA, USA) cytotoxicity is expressed as a percentage 
in terms of a measured minimal response (DMSO control wells) and 
theoretical maximal cytotoxicity (0 Luminescence). The concentration of the 
compound of interest that led to 50% viral inhibition or 50% cytotoxicity 
(EC50 and CC50 respectively) was calculated and graphs are produced using the 
nonlinear regression equation in GraphPad Prism 5.0 (GraphPad Software Inc, 
La Jolla, CA, USA). Cyclosporin A was utilized as a positive control in the 
HCVcc assay. 
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Photoaffinity cross-linking protocol 
• 3x106 Huh7.5.1 cells in 10mL of DMEM (10%FBS, 1% 
penicillin/streptomycin) are plated in a 10cm dish and left to adhere 
overnight, for 24 hours. 
• Medium is removed and 2mL of DMEM containing HCVLuc followed 
by an aliquot of CCZ-Diazirine-Biotin from a 10mM stock solution in 
DMSO, to an appropriate concentration depending on the experimentla 
protocol underway (1mM/10mM) 
• Samples are incubated for stated times (0.5-3hours), samples are timed 
so that the irradiation occurs in a direct successive series. Irradtion is 
carried out with a 4-watt TLC lamp at 365nm for 20 minutes or a UVP 
Blak-Ray™ 100watt, 115V mercury lamp with a 365nm filter. (Fisher 
Scientific catalogue no. UVP95004403) for 5 minutes, from a distance 
of approx 5cm from light source, on ice. 
• Supernatant is removed and kept if necessary, cells are washed well 
with 2 x 5mL cold phosphate buffered saline 
• 1mL of lysis buffer (30mM Tris pH 7.5, 1mM EDTA, 150mM NaCl, 
0.3%NP40, 0.05% SDS) is added to each experiment plate and 110uL 
of protease inhibitor cocktail, which is washed around the plate for 1 
minute. 
• The cells are scraped off and left to lyse minutes on ice in an eppendorf 
vial for a 15 mins, vortex for 20 seconds, then 15 mins more lyse time. 
• Cells are spun at 4C at 20k RCF on centrifuge, 5 mins. 
• Supernatant is removed, labeled and stored on ice. 
 
• 50uL of Neutravidin resin slurry (Pierce NeutrAvidin Agarose, 
ThermoFisher product no. 29200) is spun down and the supernatant is 
discarded, the beads are washed with 1mL of PBS x2. 
• To each of the Neutravidin resin beds is added the appropriate cell 
lysate sample for affinity purification, samples are mixed and placed 
on rocker for 60 minutes. 
• Samples are spun down and supernatant is discarded.  
• Wash with 2x1000uL PBS, 2x1mL lysis buffer described above, and 
1000uL PBS, spin down, discard supernatant. 
•  
Preparing samples for gel.  
Procedure ref. for quantitative elution: Proteomics 2004, 4, 2296–2299 Buffer 
for elution of biotinylated proteins comprised of 2% SDS, 3mM biotin, 6M 
urea and 2M thiourea in PBS. 
• Add 20uL of elution buffer and 8uL of 1:4 laemmli sample buffer to 
experiments A-G incubate at RT for 10 mins. 
• BiotinBSA standard: 2uL of 2ug/mL+28uL of 1 x SDS buffer. 
• Ladder – 8uL + 40uL of 1x SDS buffer – working solution 
• In all plus 2uL of reducing agent 
Boil all 95C 10 min, briefly pellet, use supernatant for gel 
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SDS PAGE is performed on NuPage 4-12% BT gels and eluted eith MOPS 
buffer, the gel is developed at 150V for approx 90 minutes. Membrane is 
blocked with 20mL of 3% BSA in PBS for 1.5 hours, followed by incubation 
with 2.5uL of high-sensitivity Strep-HRP conjugate in 20mL of 3% BSA/PBS 
(1:8000) for 1.5 hours. Membrane is washed with PBS (2x2min) then TBS-T 
(5x5min) solutions.  Membrane is drained, 2mL of 1:1 mixture of super signal 
west femto maximum sensitivity substrate is added and incubated for 5 
minutes.  
A1 
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NMR, LCMS. 
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 Experimental Summary 
         The single crystal X-ray diffraction studies were carried out on a Bruker D8 Platinum135 CCD 
diffractometer equipped with Cu K
α
 radiation (λ = 1.5478).  A 0.217 x 0.053 x 0.051 mm piece of a 
colorless rod was mounted on a Cryoloop with Paratone oil.  Data were collected in a nitrogen gas stream 
at 125(2) K using φ and ϖ scans.  Crystal-to-detector distance was 45 mm using variable exposure time 
(2s-5s) depending on θ with a scan width of 2.0°.  Data collection was 98.4% complete to 68.00° in θ.  A 
total of 33864 reflections were collected covering the indices, -11<=h<=10, -12<=k<=14, -19<=l<=19.  
3547 reflections were found to be symmetry independent, with a R
int
 of 0.0549.  Indexing and unit cell 
refinement indicated a primitive, orthorhombic lattice.  The space group was found to be P212121.  The 
data were integrated using the Bruker SAINT software program and scaled using the SADABS software 
program.  Solution by direct methods (SHELXT) produced a complete phasing model consistent with the 
proposed structure.   
All nonhydrogen atoms were refined anisotropically by full-matrix least-squares (SHELXL-
2014).  All carbon bonded hydrogen atoms were placed using a riding model.  Their positions were 
constrained relative to their parent atom using the appropriate HFIX command in SHELXL-2014.  All 
other hydrogen atoms (H-bonding) were located in the difference map.  Their relative positions were 
restrained using DFIX commands and their thermals freely refined.   The absolute stereochemistry of the 
molecule was established by anomalous dispersion using the Parson’s method with a Flack parameter of 
0.050(34).  Crystallographic data are summarized in Table 1. 
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  Table 1.  Crystal data and structure refinement for NIH18. 
Report date  2016-08-15 
Identification code  NIH18 
Empirical formula  C21 H26 N2 O4 
Molecular formula  C21 H26 N2 O4 
Formula weight  370.44 
Temperature  125 K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P212121 
Unit cell dimensions a = 10.2972(4) Å α= 90°. 
 b = 11.7362(4) Å β= 90°. 
 c = 16.2355(6) Å γ = 90°. 
Volume 1962.06(12) Å3 
Z 4 
Density (calculated) 1.254 Mg/m3 
Absorption coefficient 0.707 mm-1 
F(000) 792 
Crystal size 0.217 x 0.053 x 0.051 mm3 
Crystal color, habit Colorless Rod 
Theta range for data collection 4.649 to 68.273°. 
Index ranges -11<=h<=10, -12<=k<=14, -19<=l<=19 
Reflections collected 33864 
Independent reflections 3547 [R(int) = 0.0549, R(sigma) = 0.0205] 
Completeness to theta = 68.000° 98.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.3201 and 0.2018 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3547 / 2 / 255 
Goodness-of-fit on F2 1.086 
Final R indices [I>2sigma(I)] R1 = 0.0252, wR2 = 0.0636 
R indices (all data) R1 = 0.0256, wR2 = 0.0639 
Absolute structure parameter 0.05(3) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.113 and -0.179 e.Å-3 
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 Table 2.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) 
for NIH18.  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
O(1) 5258(1) 4409(1) 4552(1) 27(1) 
O(2) 3340(1) 7221(1) 5607(1) 27(1) 
O(3) 5869(1) 8264(1) 3925(1) 27(1) 
O(4) 4199(1) 8020(1) 3038(1) 27(1) 
N(1) 7149(1) 5422(1) 4660(1) 21(1) 
N(2) 4456(1) 6774(1) 4066(1) 22(1) 
C(1) 5841(2) 5306(1) 4671(1) 20(1) 
C(2) 5073(2) 6405(1) 4837(1) 20(1) 
C(3) 4073(2) 6193(1) 5520(1) 22(1) 
C(4) 4726(2) 5832(2) 6332(1) 26(1) 
C(5) 3694(2) 5499(2) 6967(1) 32(1) 
C(6) 5636(2) 6748(2) 6674(1) 35(1) 
C(7) 3349(2) 6134(2) 3740(1) 29(1) 
C(8) 4918(2) 7723(1) 3696(1) 21(1) 
C(9) 8088(2) 4562(1) 4501(1) 21(1) 
C(10) 7768(2) 3418(2) 4387(1) 26(1) 
C(11) 8756(2) 2631(2) 4245(1) 30(1) 
C(12) 10040(2) 2962(2) 4217(1) 32(1) 
C(13) 10350(2) 4102(2) 4330(1) 33(1) 
C(14) 9380(2) 4902(2) 4472(1) 27(1) 
C(15) 4685(2) 8978(2) 2553(1) 30(1) 
C(16) 4124(2) 10092(1) 2842(1) 24(1) 
C(17) 2932(2) 10458(2) 2541(1) 30(1) 
C(18) 2419(2) 11493(2) 2790(1) 33(1) 
C(19) 3097(2) 12171(2) 3340(1) 31(1) 
C(20) 4278(2) 11812(2) 3647(1) 28(1) 
C(21) 4791(2) 10775(2) 3398(1) 26(1) 
________________________________________________________________________________  
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O(1)-C(1)  1.227(2) 
O(2)-H(2)  0.890(19) 
O(2)-C(3)  1.4299(18) 
O(3)-C(8)  1.225(2) 
O(4)-C(8)  1.345(2) 
O(4)-C(15)  1.462(2) 
N(1)-H(1)  0.906(17) 
N(1)-C(1)  1.354(2) 
N(1)-C(9)  1.421(2) 
N(2)-C(2)  1.469(2) 
N(2)-C(7)  1.464(2) 
N(2)-C(8)  1.352(2) 
C(1)-C(2)  1.536(2) 
C(2)-H(2A)  1.0000 
C(2)-C(3)  1.535(2) 
C(3)-H(3)  1.0000 
C(3)-C(4)  1.540(2) 
C(4)-H(4)  1.0000 
C(4)-C(5)  1.531(2) 
C(4)-C(6)  1.530(3) 
C(5)-H(5A)  0.9800 
C(5)-H(5B)  0.9800 
C(5)-H(5C)  0.9800 
C(6)-H(6A)  0.9800 
C(6)-H(6B)  0.9800 
C(6)-H(6C)  0.9800 
C(7)-H(7A)  0.9800 
C(7)-H(7B)  0.9800 
C(7)-H(7C)  0.9800 
C(9)-C(10)  1.395(2) 
C(9)-C(14)  1.390(2) 
C(10)-H(10)  0.9500 
C(10)-C(11)  1.393(2) 
C(11)-H(11)  0.9500 
C(11)-C(12)  1.379(3) 
C(12)-H(12)  0.9500 
C(12)-C(13)  1.387(3) 
C(13)-H(13)  0.9500 
C(13)-C(14)  1.391(2) 
C(14)-H(14)  0.9500 
C(15)-H(15A)  0.9900 
C(15)-H(15B)  0.9900 
C(15)-C(16)  1.504(2) 
C(16)-C(17)  1.389(3) 
C(16)-C(21)  1.390(2) 
C(17)-H(17)  0.9500 
C(17)-C(18)  1.385(3) 
C(18)-H(18)  0.9500 
C(18)-C(19)  1.385(3) 
C(19)-H(19)  0.9500 
C(19)-C(20)  1.380(3) 
C(20)-H(20)  0.9500 
C(20)-C(21)  1.387(3) 
C(21)-H(21)  0.9500 
 
C(3)-O(2)-H(2) 110.1(15) 
C(8)-O(4)-C(15) 115.95(13) 
C(1)-N(1)-H(1) 117.6(14) 
C(1)-N(1)-C(9) 127.42(14) 
C(9)-N(1)-H(1) 114.8(14) 
C(7)-N(2)-C(2) 119.49(13) 
C(8)-N(2)-C(2) 118.01(13) 
C(8)-N(2)-C(7) 122.46(14) 
O(1)-C(1)-N(1) 124.81(15) 
O(1)-C(1)-C(2) 119.73(14) 
N(1)-C(1)-C(2) 115.46(14) 
N(2)-C(2)-C(1) 108.72(12) 
N(2)-C(2)-H(2A) 108.8 
N(2)-C(2)-C(3) 111.94(13) 
C(1)-C(2)-H(2A) 108.8 
C(3)-C(2)-C(1) 109.66(12) 
C(3)-C(2)-H(2A) 108.8 
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O(2)-C(3)-C(2) 106.79(12) 
O(2)-C(3)-H(3) 108.7 
O(2)-C(3)-C(4) 112.23(13) 
C(2)-C(3)-H(3) 108.7 
C(2)-C(3)-C(4) 111.75(13) 
C(4)-C(3)-H(3) 108.7 
C(3)-C(4)-H(4) 107.6 
C(5)-C(4)-C(3) 110.08(14) 
C(5)-C(4)-H(4) 107.6 
C(6)-C(4)-C(3) 112.64(14) 
C(6)-C(4)-H(4) 107.6 
C(6)-C(4)-C(5) 111.11(15) 
C(4)-C(5)-H(5A) 109.5 
C(4)-C(5)-H(5B) 109.5 
C(4)-C(5)-H(5C) 109.5 
H(5A)-C(5)-H(5B) 109.5 
H(5A)-C(5)-H(5C) 109.5 
H(5B)-C(5)-H(5C) 109.5 
C(4)-C(6)-H(6A) 109.5 
C(4)-C(6)-H(6B) 109.5 
C(4)-C(6)-H(6C) 109.5 
H(6A)-C(6)-H(6B) 109.5 
H(6A)-C(6)-H(6C) 109.5 
H(6B)-C(6)-H(6C) 109.5 
N(2)-C(7)-H(7A) 109.5 
N(2)-C(7)-H(7B) 109.5 
N(2)-C(7)-H(7C) 109.5 
H(7A)-C(7)-H(7B) 109.5 
H(7A)-C(7)-H(7C) 109.5 
H(7B)-C(7)-H(7C) 109.5 
O(3)-C(8)-O(4) 123.18(15) 
O(3)-C(8)-N(2) 124.98(15) 
O(4)-C(8)-N(2) 111.83(14) 
C(10)-C(9)-N(1) 123.19(15) 
C(14)-C(9)-N(1) 116.96(15) 
C(14)-C(9)-C(10) 119.84(16) 
C(9)-C(10)-H(10) 120.4 
C(11)-C(10)-C(9) 119.20(16) 
C(11)-C(10)-H(10) 120.4 
C(10)-C(11)-H(11) 119.4 
C(12)-C(11)-C(10) 121.25(17) 
C(12)-C(11)-H(11) 119.4 
C(11)-C(12)-H(12) 120.4 
C(11)-C(12)-C(13) 119.21(16) 
C(13)-C(12)-H(12) 120.4 
C(12)-C(13)-H(13) 119.7 
C(12)-C(13)-C(14) 120.53(17) 
C(14)-C(13)-H(13) 119.7 
C(9)-C(14)-C(13) 119.96(17) 
C(9)-C(14)-H(14) 120.0 
C(13)-C(14)-H(14) 120.0 
O(4)-C(15)-H(15A) 109.3 
O(4)-C(15)-H(15B) 109.3 
O(4)-C(15)-C(16) 111.68(13) 
H(15A)-C(15)-H(15B) 107.9 
C(16)-C(15)-H(15A) 109.3 
C(16)-C(15)-H(15B) 109.3 
C(17)-C(16)-C(15) 119.95(16) 
C(17)-C(16)-C(21) 119.15(16) 
C(21)-C(16)-C(15) 120.89(17) 
C(16)-C(17)-H(17) 119.8 
C(18)-C(17)-C(16) 120.39(17) 
C(18)-C(17)-H(17) 119.8 
C(17)-C(18)-H(18) 120.0 
C(17)-C(18)-C(19) 119.98(17) 
C(19)-C(18)-H(18) 120.0 
C(18)-C(19)-H(19) 119.9 
C(20)-C(19)-C(18) 120.14(17) 
C(20)-C(19)-H(19) 119.9 
C(19)-C(20)-H(20) 120.1 
C(19)-C(20)-C(21) 119.88(17) 
C(21)-C(20)-H(20) 120.1 
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C(9)-C(10)-H(10) 120.4 
C(11)-C(10)-C(9) 119.20(16) 
C(11)-C(10)-H(10) 120.4 
C(10)-C(11)-H(11) 119.4 
C(12)-C(11)-C(10) 121.25(17) 
C(12)-C(11)-H(11) 119.4 
C(11)-C(12)-H(12) 120.4 
C(11)-C(12)-C(13) 119.21(16) 
C(13)-C(12)-H(12) 120.4 
C(12)-C(13)-H(13) 119.7 
C(12)-C(13)-C(14) 120.53(17) 
C(14)-C(13)-H(13) 119.7 
C(9)-C(14)-C(13) 119.96(17) 
C(9)-C(14)-H(14) 120.0 
C(13)-C(14)-H(14) 120.0 
O(4)-C(15)-H(15A) 109.3 
O(4)-C(15)-H(15B) 109.3 
O(4)-C(15)-C(16) 111.68(13) 
H(15A)-C(15)-H(15B) 107.9 
C(16)-C(15)-H(15A) 109.3 
C(16)-C(15)-H(15B) 109.3 
C(17)-C(16)-C(15) 119.95(16) 
C(17)-C(16)-C(21) 119.15(16) 
C(21)-C(16)-C(15) 120.89(17) 
C(16)-C(17)-H(17) 119.8 
C(18)-C(17)-C(16) 120.39(17) 
C(18)-C(17)-H(17) 119.8 
C(17)-C(18)-H(18) 120.0 
C(17)-C(18)-C(19) 119.98(17) 
C(19)-C(18)-H(18) 120.0 
C(18)-C(19)-H(19) 119.9 
C(20)-C(19)-C(18) 120.14(17) 
C(20)-C(19)-H(19) 119.9 
C(19)-C(20)-H(20) 120.1 
C(19)-C(20)-C(21) 119.88(17) 
C(21)-C(20)-H(20) 120.1 
C(9)-C(10)-H(10) 120.4 
C(11)-C(10)-C(9) 119.20(16) 
C(11)-C(10)-H(10) 120.4 
C(10)-C(11)-H(11) 119.4 
C(12)-C(11)-C(10) 121.25(17) 
C(12)-C(11)-H(11) 119.4 
C(11)-C(12)-H(12) 120.4 
C(11)-C(12)-C(13) 119.21(16) 
C(13)-C(12)-H(12) 120.4 
C(12)-C(13)-H(13) 119.7 
C(12)-C(13)-C(14) 120.53(17) 
C(14)-C(13)-H(13) 119.7 
C(9)-C(14)-C(13) 119.96(17) 
C(9)-C(14)-H(14) 120.0 
C(13)-C(14)-H(14) 120.0 
O(4)-C(15)-H(15A) 109.3 
O(4)-C(15)-H(15B) 109.3 
O(4)-C(15)-C(16) 111.68(13) 
H(15A)-C(15)-H(15B) 107.9 
C(16)-C(15)-H(15A) 109.3 
C(16)-C(15)-H(15B) 109.3 
C(17)-C(16)-C(15) 119.95(16) 
C(17)-C(16)-C(21) 119.15(16) 
C(21)-C(16)-C(15) 120.89(17) 
C(16)-C(17)-H(17) 119.8 
C(18)-C(17)-C(16) 120.39(17) 
C(18)-C(17)-H(17) 119.8 
C(17)-C(18)-H(18) 120.0 
C(17)-C(18)-C(19) 119.98(17) 
C(19)-C(18)-H(18) 120.0 
C(18)-C(19)-H(19) 119.9 
C(20)-C(19)-C(18) 120.14(17) 
C(20)-C(19)-H(19) 119.9 
C(19)-C(20)-H(20) 120.1 
C(19)-C(20)-C(21) 119.88(17) 
C(21)-C(20)-H(20) 120.1 
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C(16)-C(21)-H(21) 119.8 
C(20)-C(21)-C(16) 120.46(17) 
C(20)-C(21)-H(21) 119.8 
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 Table 4.   Anisotropic displacement parameters  (Å2x 103) for NIH18.  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
O(1) 23(1)  20(1) 38(1)  -3(1) 2(1)  -1(1) 
O(2) 23(1)  20(1) 37(1)  2(1) 8(1)  5(1) 
O(3) 21(1)  24(1) 35(1)  6(1) 0(1)  -2(1) 
O(4) 32(1)  23(1) 26(1)  3(1) -4(1)  2(1) 
N(1) 20(1)  18(1) 26(1)  0(1) 1(1)  0(1) 
N(2) 21(1)  20(1) 25(1)  1(1) -2(1)  -1(1) 
C(1) 20(1)  20(1) 20(1)  1(1) 1(1)  0(1) 
C(2) 19(1)  18(1) 24(1)  1(1) -1(1)  -1(1) 
C(3) 20(1)  18(1) 28(1)  0(1) 3(1)  1(1) 
C(4) 26(1)  26(1) 26(1)  1(1) 3(1)  3(1) 
C(5) 38(1)  30(1) 27(1)  2(1) 7(1)  0(1) 
C(6) 32(1)  42(1) 30(1)  -1(1) -2(1)  -3(1) 
C(7) 27(1)  27(1) 34(1)  0(1) -8(1)  -4(1) 
C(8) 19(1)  21(1) 23(1)  0(1) 4(1)  5(1) 
C(9) 23(1)  22(1) 19(1)  1(1) 1(1)  3(1) 
C(10) 25(1)  23(1) 31(1)  -1(1) -3(1)  2(1) 
C(11) 34(1)  24(1) 33(1)  -1(1) -1(1)  5(1) 
C(12) 31(1)  31(1) 35(1)  3(1) 8(1)  13(1) 
C(13) 23(1)  35(1) 40(1)  5(1) 9(1)  3(1) 
C(14) 24(1)  26(1) 32(1)  2(1) 4(1)  1(1) 
C(15) 42(1)  25(1) 22(1)  5(1) 5(1)  6(1) 
C(16) 30(1)  23(1) 19(1)  4(1) 4(1)  2(1) 
C(17) 34(1)  28(1) 27(1)  2(1) -5(1)  0(1) 
C(18) 27(1)  32(1) 40(1)  6(1) -1(1)  7(1) 
C(19) 35(1)  22(1) 35(1)  2(1) 11(1)  4(1) 
C(20) 33(1)  25(1) 27(1)  0(1) 5(1)  -5(1) 
C(21) 24(1)  29(1) 26(1)  5(1) 1(1)  0(1) 
______________________________________________________________________________  
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 Table 5.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) 
for NIH18. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 2545(19) 7060(20) 5790(14) 44(6) 
H(1) 7480(20) 6132(15) 4723(12) 30(5) 
H(2A) 5690 7010 5023 24 
H(3) 3474 5571 5340 26 
H(4) 5261 5140 6216 31 
H(5A) 3160 6165 7099 48 
H(5B) 4120 5223 7469 48 
H(5C) 3143 4896 6740 48 
H(6A) 6424 6783 6337 52 
H(6B) 5869 6559 7243 52 
H(6C) 5197 7489 6662 52 
H(7A) 2558 6358 4035 44 
H(7B) 3501 5316 3817 44 
H(7C) 3247 6299 3152 44 
H(10) 6888 3178 4406 31 
H(11) 8541 1851 4167 36 
H(12) 10704 2417 4120 39 
H(13) 11232 4337 4310 39 
H(14) 9600 5681 4548 33 
H(15A) 4460 8861 1967 36 
H(15B) 5644 9008 2597 36 
H(17) 2466 9996 2162 36 
H(18) 1601 11737 2584 40 
H(19) 2748 12884 3506 37 
H(20) 4739 12275 4028 34 
H(21) 5604 10530 3610 31 
________________________________________________________________________________  
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 Table 6.  Hydrogen bonds for NIH18  [Å and °]. 
____________________________________________________________________________  
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________  
 O(2)-H(2)...O(3)#1 0.890(19) 1.828(19) 2.7157(17) 175(2) 
 N(1)-H(1)...O(2)#2 0.906(17) 2.193(18) 3.0566(18) 159.2(18) 
____________________________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
#1 x-1/2,-y+3/2,-z+1    #2 x+1/2,-y+3/2,-z+1       
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Lit. Spectra 202
5.52-5.29 (m. 2 H) δ 5.56 – 5.31 (m, 2H)
3.65 (t, 1 N-CH3) 3.68 (t, J  = 6.0 Hz, 1H)
3.50 (d, 1 H, J = 5.8 Hz) 3.54 (d, J  = 6.0 Hz, 1H)
2.61 (s, 3 H) 2.65 (s, 3H)
2.15 (br d, 1 H, 13.0 Hz) 2.19 (d, J  = 13.9 Hz, 1H)
1.82-1.70 (m, 1 H) 1.87 – 1.74 (m, 1H)
1.62-1.53 (m, 1 H) 1.61 (dtd, J  = 9.6, 6.5, 3.3 Hz, 1H)
1.52 (d, 3 H, J = 5.4) 1.56 (dd, J  = 5.9, 1.3 Hz, 3H)
 0.81 (d, 3 H, J = 6.7)  0.85 (d, J  = 6.8 Hz, 3H)
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